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WITH CANCER RISK AND REPRODUCTIVE STATE 
Sajin Bae, Ph.D. 
Cornell University 2017 
Folate, choline and vitamin B12 are essential nutrients involved in one-carbon 
metabolism (OCM), a network of interconnected pathways necessary for the de novo synthesis of 
purines and thymidylate and for the remethylation of homocysteine to methionine. Disruptions in 
OCM are associated with aberrant DNA synthesis and methylation and high risk for cancer. 
Thus, it is of particular importance to elucidate the role of these nutrients in the functioning of 
OCM. In addition, the status of these nutrients and their demand differ by reproductive and/or 
pathological state, further addressing the need to better understand the effects of these nutrients. 
This dissertation research involves both human participant studies and laboratory-based 
molecular research to advance current knowledge of the role of these nutrients. 
Study 1 examined the impact of mandatory folic acid fortification on DNA methylation 
status among postmenopausal women enrolled in the Women’s Health Initiative Observational 
Study (WHI-OS). As expected, given the role of folate in OCM, women with higher red blood 
cell (RBC) folate concentration had higher DNA methylation in the pre-fortification period. 
However, this expected result was not observed in the post-fortification period during which 
women with higher (vs. lower) RBC folate status had lower DNA methylation. Overall, these 
findings suggest an inverted U-shaped relationship between folate status and DNA methylation 
across fortification periods, and further investigation is warranted to clarify the health outcomes 
of the inverse relationship observed in the era of folic acid fortification. 
Study 2 examined associations between biomarkers of choline metabolism and colorectal 
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cancer risk in a case-control study nested within the WHI-OS. The main findings indicate 1) a 
positive association between plasma trimethylamine N-oxide (TMAO; a derivative of choline 
produced by intestinal bacteria) and rectal cancer risk; and 2) an inverse relationship between 
plasma betaine and colorectal cancer risk. These findings demonstrate that alterations in choline 
metabolism associate with higher risk of colorectal cancer, suggesting the potential utilization of 
these biomarkers as predictors of increased colorectal cancer risk.   
Study 3 assessed changes in status and functional biomarkers of vitamin B12 among 
pregnant, lactating and control (nonpregnant, nonlactating) women who consumed equivalent 
vitamin B12 intakes under controlled feeding conditions. Pregnant (vs. control) women had a 
higher ratio of plasma holotranscobalamin (bioactive form of vitamin B12) to total vitamin B12, 
indicating that greater amounts of vitamin B12 are partitioned toward the biologically active 
form in this reproductive state. Overall, the results of this study suggest that metabolic 
adaptations transpire to enhance vitamin B12 supply during pregnancy.  
Study 4 employed in vitro cell culture models to investigate the effect of folate-
independent generation of formate, a primary source of one-carbons for folate-mediated OCM, 
on the synthesis of purines and thymidylate. The study findings demonstrate that in human 
hepatocarcinoma (HepG2) cells, alcohol dehydrogenase 5 is a source of formate for de novo 
purine biosynthesis, especially during folate deficiency when folate-dependent formate 
production is limited. 
Taken together, this dissertation research spans from in vitro molecular studies to 
epidemiological studies to address the role of folate, choline and vitamin B12. The findings of 
this research will help inform the development of nutrient intake recommendations and the use of 
nutritional biomarkers for disease prediction.   
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PREFACE 
One-carbon metabolism is a metabolic network essential for the de novo synthesis of 
purines and thymidylate and for the remethylation of homocysteine to methionine. Disruptions in 
one-carbon metabolism, which can arise from insufficient intake of relevant nutrients (including 
folate, choline and vitamin B12) and/or genetic variants, have been linked to a number of human 
diseases including cancer, neurodegenerative diseases and developmental anomalies. The status 
of these nutrients and their demand are dependent on each other and can be altered by 
reproductive and/or pathological state. The overarching goal of this dissertation research was to 
investigate the associations of the intake and status of these nutrients with 1) the functioning of 
one-carbon metabolic pathways; 2) cancer risk; and 3) reproductive state. To achieve this goal, a 
multidisciplinary translational approach including both human participant studies and in vitro 
cell culture experiments was used with a focus on the following specific aims: 
Aim 1: To investigate the impact of mandatory folic acid fortification on DNA methylation 
status and the relationship between DNA methylation and one-carbon metabolic biomarkers. 
This aim was achieved by using samples from postmenopausal women of the Women’s 
Health Initiative Observational Study (WHI-OS) cohort collected before and after folic acid 
fortification. Study findings are presented in chapter 1.  
Aim 2: To investigate associations between plasma biomarkers of choline metabolism and 
colorectal cancer risk among postmenopausal women in a case-control study nested within 
the WHI-OS. Results are presented in chapter 2. 
Aim 3: To investigate changes in vitamin B12 status during pregnancy and lactation under 
controlled feeding conditions. This aim was achieved by assessing and comparing vitamin 
B12 status and functional biomarkers among pregnant, lactating and control (nonpregnant, 
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nonlactating) women who consumed equivalent vitamin B12 intakes under controlled 
feeding conditions. Study findings are presented in chapter 3.  
Aim 4: To investigate the contribution of folate-independent generation of formate, a primary 
source of one-carbons for folate-mediated one-carbon metabolism, to the de novo synthesis 
of purines and thymidylate. This aim was achieved by using in vitro cell culture models that 
employed a gene knockout system and radioactive isotope tracers. Results are presented in 
chapter 4. 
Aim 5: To evaluate and summarize scientific evidence on the effects of provision of folic acid 
for reducing arsenic toxicity in arsenic-exposed children and adults. This is an ongoing 
systematic review being done with the Cochrane Developmental, Psychosocial and Learning 
Problems Group. The results of this review will serve to inform evidence-based public health 
guidelines on folic acid interventions in arsenic-exposed populations including all ages and 
gender groups. The Cochrane protocol, which prespecifies a detailed plan for the review and 
is required to be published prior to conducting a Cochrane review, has been developed and is 
presented in Appendix A.   
This dissertation research yielded four published primary research manuscripts in peer-reviewed 
journals (Chapters 1-4) and one Cochrane Systematic Protocol, which has been published in the 
Cochrane Database of Systematic Reviews (Appendix A).  
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CHAPTER 1 
Impact of folic acid fortification on global DNA methylation and one-carbon biomarkers in the 
Women’s Health Initiative Observational Study cohort* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Bae S, Ulrich CM, Bailey LB, Malysheva O, Brown EC, Maneval DR, Neuhouser ML, Cheng 
TY, Miller JW, Zheng Y, Xiao L, Hou L, Song X, Buck K, Beresford SA, Caudill MA. Impact 
of folic acid fortification on global DNA methylation and one-carbon biomarkers in the 
Women’s Health Initiative Observational Study cohort. Epigenetics 2014;9(3):396-403. 
Copyright approval has been obtained from Taylor & Francis LLC (Appendix B). 
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ABSTRACT 
DNA methylation is an epigenetic mechanism that regulates gene expression and can be 
Modified by one-carbon nutrients. The objective of this study was to investigate the impact of 
folic acid (FA) fortification of the US food supply on leukocyte global DNA methylation and the 
relationship between DNA methylation, red blood cell (RBC) folate, and other one-carbon 
biomarkers among postmenopausal women enrolled in the Women’s Health Initiative 
Observational Study. We selected 408 women from the highest and lowest tertiles of RBC folate 
distribution matching on age and timing of the baseline blood draw, which spanned the pre- 
(1994–1995), peri- (1996–1997), or post-fortification (1998) periods. Global DNA methylation 
was assessed by liquid chromatography-tandem mass spectrometry and expressed as a 
percentage of total cytosine. We observed an interaction (P = 0.02) between fortification period 
and RBC folate in relation to DNA methylation. Women with higher (vs. lower) RBC folate had 
higher mean DNA methylation (5.12 vs. 4.99%; P = 0.05) in the pre-fortification period, but 
lower (4.95 vs. 5.16%; P = 0.03) DNA methylation in the post-fortification period. We also 
observed significant correlations between one-carbon biomarkers and DNA methylation in the 
pre-fortification period, but not in the peri- or post-fortification period. The correlation between 
plasma homocysteine and DNA methylation was reversed from an inverse relationship during 
the pre-fortification period to a positive relationship during the post-fortification period. Our data 
suggest that (1) during FA fortification, higher RBC folate status is associated with a reduction in 
leukocyte global DNA methylation among postmenopausal women and; (2) the relationship 
between one-carbon biomarkers and global DNA methylation is dependent on folate availability. 
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INTRODUCTION 
DNA methylation is an epigenetic modification of the genome, which influences gene 
expression and genome integrity.1 DNA methylation can be modified by nutrients involved in 
one-carbon metabolism (e.g., folate, choline, vitamin B12, and vitamin B6), and disturbances in 
methylation reactions caused by abnormal status of these nutrients have been implicated in a 
number of human diseases including cancer.2-6 Folate, in the form of 5-methyltetrahydrofolate 
(5-methyl-THF), participates in cellular methylation reactions (including DNA methylation) by 
donating a methyl group for the vitamin B12-dependent re-methylation of homocysteine to 
methionine (Supplementary Figure S1.1). Folic acid (FA), the synthetic form of folate, can also 
participate in DNA methylation after its reduction to THF and conversion to 5-methyl-THF.7 
Homocysteine re-methylation to methionine can also proceed via a folate and B12-independent 
route in which betaine (a derivative of choline) serves as the methyl donor.8 
In January of 1998, the US Food and Drug Administration mandated FA fortification of 
enriched cereal-grain products (i.e., addition of 140 μg of FA/100 g of grain) in an effort to 
reduce the occurrence of neural tube defects, a mandate that some food companies initiated in 
1996 and 1997.9 FA fortification of the US food supply has led to significant increases in serum 
and red blood cell (RBC) folate concentrations as well as decreases in plasma total 
homocysteine;10,11 however, less is known about the impact of FA fortification on DNA 
methylation.  
In this report, we investigated the association between mandatory FA fortification and 
leukocyte global DNA methylation, as well as the relationship between global DNA methylation, 
RBC folate, plasma choline, and other biomarkers of one-carbon metabolism among 
postmenopausal women enrolled in the Women’s Health Initiative Observational Study (WHI-
 4 
OS). 
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RESULTS 
Characteristics of the study population 
The participants of this study were a subset of the control group from a nested case-
control study investigating colorectal cancer risk in the WHI-OS.12,13 Baseline demographic and 
biochemical characteristics of the participants, which corresponded to FA fortification periods 
[pre (1994–1995), peri (1996–1997), or post (1998)], are shown in Table 1.1. BMI differed 
among FA fortification periods (P = 0.01) with a higher mean BMI (28.3 kg/m2) in the post-
fortification period than in the pre- (26.5 kg/m2; P = 0.02) and peri-fortification (26.4 kg/m2; P = 
0.01) periods. The ethnic distribution also differed among fortification periods (P = 0.03).  
Plasma folate differed among FA fortification periods (P = 0.002) with higher median 
plasma folate (20 ng/mL) in the post-fortification period than in the pre- (14 ng/mL; P = 0.001) 
and peri-fortification (16 ng/mL; P = 0.002) periods. Similarly, RBC folate differed among FA 
fortification periods (P = 0.002) with higher median RBC folate in the peri- (572 ng/mL; P = 
0.02) and post-fortification (726 ng/mL; P < 0.001) periods compared with the pre-fortification 
(424 ng/mL) period. 
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Table 1.1. Baseline characteristics of the study participants (n = 408) according to folic acid 
(FA) fortification period1-3 
Characteristic 
FA fortification period 
P value 
Pre 
(1994–1995) 
Peri 
(1996–1997) 
Post 
(1998) 
Age (years)4 67 ± 7 67 ± 7 67 ± 6 0.87 
BMI (kg/m2)4 26.5 ± 5a 26.4 ± 5a 28.3 ± 6b 0.01 
Race/ethnicity5    0.03 
Non-Hispanic White 86 88 76  
Other7 14 12 24  
Education5 
≤ High school 
≥ College 
   0.69 
21 24 20  
79 76 80  
Pack-years of smoking6 0 (0–10) 0 (0–15) 0.3 (0–12.5) 0.49 
Leisure physical activity6 
(minutes/week) 
60 (0–210) 40 (0–180) 30 (0–150) 0.70 
Plasma folate (ng/mL)6 14 (8–27)a 16 (8–25)a 20 (14–31)b 0.002 
RBC folate (ng/mL)6 424 (321–771)a 572 (361–852)b 
726 (431–
863)b 
0.002 
Plasma Hcy (µmol/L)6 8.6 (6.9–10.8) 8.5 (6.8–9.7) 7.9 (6.8–9.7) 0.13 
Plasma MMA (nmol/L)6 158 (113–204) 146 (120–179) 168 (136–211) 0.17 
Plasma vitamin B12 (pg/mL)6 523 (354–703) 481 (352–650) 489 (371–685) 0.43 
Plasma PLP (nmol/L)6 62 (43–109) 70 (46–114) 68 (41–132) 0.83 
Plasma choline (µmol/L)4 9.2 ± 2.0 9.3 ± 2.2 9.4 ± 1.7 0.79 
Plasma betaine (µmol/L)4 28 ± 10 28 ± 10 25 ± 10 0.16 
Plasma DMG (µmol/L)6 2.5 (2.1–2.9) 2.3 (1.9–2.9) 2.4 (1.9–2.7) 0.07 
Plasma TMAO (µmol/L)6 3.8 (2.5–6.1) 3.7 (2.6–5.4) 4.1 (2.9–6.1) 0.33 
Plasma creatinine (mg/dL)4 0.72 ± 0.13 0.70 ± 0.11 0.73 ± 0.11 0.12 
DFE (µg/d)6 409 (304–537) 411 (319–537) 441 (306–595) 0.51 
Dietary vitamin B6 intake (mg/d)6 1.4 (1.1–1.9) 1.4 (1.0–1.8) 1.5 (1.0–1.9) 0.43 
Dietary vitamin B12 intake (µg/d)6 5.1 (3.3–7.3)a 4.1 (2.7–6.5)b 5.3 (3.5–7.4)a 0.01 
Supplemental vitamin B2 intake 
(mg/d)6 
0.0 (0–1.7) 0.1 (0–1.7) 0.0 (0–1.7) 0.84 
Supplemental vitamin B6 intake 
(mg/d)6 
0.0 (0–2.0) 1.0 (0–2.0) 0.0 (0–2.0) 0.32 
Supplemental vitamin B12 intake 
(µg/d)6 
0.0 (0–6.0) 2.3 (0–6.0) 0.0 (0–6.0) 0.89 
1The study participants were a subset of the control group from a nested case-control study investigating 
colorectal cancer risk in the Women's Health Initiative-Observational Study.  
2Differences between FA fortification periods were analyzed by chi-square tests (categorical variables), 
one-way ANOVA (normally distributed continuous variables), or non-parametric Kruskal-Wallis tests 
(non-normally distributed continuous variables); different superscript letters within a row indicate a 
difference between FA fortification periods at P < 0.05. 
3n = 122 in the pre-fortification period; n = 204 in the peri-fortification period; n = 82 in the post-
fortification period.  
4Values are mean ± SD for normally distributed continuous variables.  
5Values are percentage for categorical variables.  
6Values are median (interquartile range) for non-normally distributed continuous variables.  
 7 
7African American, Hispanic, Asian or Pacific Islander, American Indian or Alaskan Native. Abbreviations 
used: BMI, body mass index; RBC, red blood cell; Hcy, homocysteine; MMA, methylmalonic acid; PLP, 
pyridoxal-5’-phosphate; DMG, dimethylglycine; TMAO, trimethylamine N-oxide; DFE, dietary folate 
equivalent. 
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Effect of FA fortification period on baseline leukocyte global DNA methylation 
Leukocyte global DNA methylation did not differ (P = 0.86, unadjusted; P = 0.38, 
multivariate-adjusted) among FA fortification periods (Table 1.2). However, we observed an 
interaction (P = 0.02) between fortification period and RBC folate status in relation to DNA 
methylation. Specifically, the highest (vs. lowest) RBC folate group had higher marginal mean 
DNA methylation (5.12 vs. 4.99%; P = 0.05) in the pre-fortification period, but lower DNA 
methylation (4.95 vs. 5.16%; P = 0.03) in the post-fortification period (Table 1.3). In addition, 
leukocyte global DNA methylation tended to differ (P = 0.08; multivariate-adjusted) among 
fortification periods (post < peri < pre) within the highest RBC folate group, but not within the 
lowest RBC folate group (P = 0.20; multivariate-adjusted) (Table 1.3). 
 
Table 1.2. Baseline leukocyte global DNA methylation levels (%) according to folic acid (FA) 
fortification period1 
 
FA fortification period 
P value 
Pre (1994–1995) Peri (1996–1997) Post (1998) 
Global DNA 
methylation (%) 
n Value n Value n Value 
Unadjusted2 122 5.04 ± 0.35 204 5.05 ± 0.37 82 5.03 ± 0.38 0.86 
Multivariate-adjusted3 118 5.04 ± 0.03 199 5.06 ± 0.03 77 5.00 ± 0.04 0.38 
1Linear regression models were used to compare mean DNA methylation across fortification periods. 
2Values are mean ± SD for unadjusted analyses.  
3Multivariate analyses were adjusted for age, BMI, ethnicity, creatinine, and MTHFR C677T genotype; 
values are marginal mean ± SE. 
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Table 1.3. Baseline leukocyte global DNA methylation levels (%) within the lowest and highest 
RBC folate groups according to folic acid (FA) fortification period1,2 
 
Lowest RBC Folate group Highest RBC Folate group 
P value n Value n Value 
Pre-fortification (1994–1995)      
Unadjusted3 71 5.01 ± 0.37 51 5.08 ± 0.32 0.29 
Multivariate-adjusted4 69 4.99 ± 0.04 49 5.12 ± 0.05 0.05 
Peri-fortification (1996–1997)      
Unadjusted3 102 5.09 ± 0.38 102 5.02 ± 0.36 0.21 
Multivariate-adjusted4 101 5.08 ± 0.04 98 5.03 ± 0.04 0.37 
Post-fortification (1998)      
Unadjusted3 29 5.18 ± 0.39 53 4.94 ± 0.34 0.01 
Multivariate-adjusted4 25 5.16 ± 0.07 52 4.95 ± 0.05 0.03 
1Participants were divided into tertiles of RBC folate, and lowest (<471 ng/mL) and highest (>672 ng/mL) 
RBC folate groups were further stratified by FA fortification period. 
2Linear regression models were used to compare differences between RBC folate groups.  
3Values are mean ± SD for unadjusted analyses.  
4Multivariate analyses were adjusted for age, BMI, ethnicity, creatinine, and MTHFR C677T genotype; 
values are marginal mean ± SE. 
 
Correlations between baseline leukocyte global DNA methylation and one-carbon biomarkers 
according to FA fortification period 
The univariate Spearman correlations between one-carbon biomarkers and leukocyte 
global DNA methylation are shown in Table 1.4. Prior to fortification, there were significant, but 
modest, positive associations of global DNA methylation with plasma folate (r = 0.20, P = 0.04) 
and RBC folate (r = 0.24, P = 0.01) as well as a borderline significant positive association 
with plasma vitamin B12 (r = 0.18, P = 0.06). Global DNA methylation was also inversely 
correlated with plasma methylmalonic acid (MMA; r = -0.26, P = 0.03), choline (r = -0.31, P = 
0.002) and homocysteine (r = -0.26, P = 0.007). In the peri-fortification period, no significant 
relationships were observed between one-carbon biomarkers and global DNA methylation. 
Finally, in the post-fortification period, global DNA methylation was positively correlated with 
plasma homocysteine (r = 0.28, P = 0.02). 
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Table 1.4. Spearman rank correlation coefficients (r) between baseline leukocyte global DNA 
methylation and one-carbon biomarkers according to folic acid (FA) fortification period1 
 
FA fortification period 
Pre (1994–1995) Peri (1996–1997) Post (1998) 
 n r P value n r P value n r P value 
Plasma folate (ng/mL) 115 0.20 0.04 195 0.05 0.52 75 0.07 0.56 
RBC folate (ng/mL) 118 0.24 0.01 199 0.01 0.88 77 0.09 0.47 
Plasma vitamin B12 
(pg/mL) 
115 0.18 0.06 195 0.08 0.26 75 0.17 0.16 
Plasma MMA (nmol/L) 74 0.26 0.03 130 0.12 0.19 46 0.02 0.90 
Plasma choline 
(µmol/L) 
102 0.31 0.002 181 0.07 0.37 73 0.001 0.99 
Plasma betaine 
(µmol/L) 
102 0.09 0.39 181 0.06 0.46 73 0.05 0.69 
Plasma DMG (µmol/L) 102 0.15 0.14 181 0.007 0.92 73 0.05 0.67 
Plasma TMAO 
(µmol/L) 
102 0.001 0.99 181 0.01 0.90 73 0.18 0.13 
Plasma Hcy (µmol/L) 115 0.26 0.007 197 0.03 0.71 77 0.28 0.02 
Plasma cysteine 
(µmol/L) 
115 –0.10 0.28 197 0.04 0.54 77 0.01 0.90 
1Analyses were adjusted for age, BMI, ethnicity, creatinine, and MTHFR C677T genotype. Abbreviations 
used: RBC, red blood cell; MMA, methylmalonic acid; DMG, dimethylglycine; TMAO, trimethylamine 
N-oxide; Hcy, homocysteine. 
 
Main predictors of baseline leukocyte global DNA methylation according to FA fortification 
period 
One-carbon biomarkers that predicted global DNA methylation were identified according 
to FA fortification period, testing them individually in multivariate-adjusted models (Table 1.5). 
Prior to fortification, RBC folate positively predicted global DNA methylation (β = 0.25, P = 
0.02) explaining 5% of the residual variation (partial R2 = 0.05). Plasma vitamin B12 also tended 
to positively predict DNA methylation (β = 0.20, P = 0.08) explaining 3% of the residual 
variation (partial R2 = 0.03); however, plasma homocysteine (β = -21.23, P = 0.03), MMA (β = -
1.18, P = 0.05), and choline (β = -57.82, P = 0.002) negatively predicted global DNA 
methylation explaining 4% (partial R2 = 0.04), 6% (partial R2 = 0.06) and 10% (partial R2 = 0.10) 
of the residual variation, respectively. In the peri-fortification period, no significant predictors of 
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DNA methylation were detected. Finally, in the post-fortification period, plasma homocysteine 
tended to positively predict global DNA methylation (β = 29.37, P = 0.07) explaining 4% of the 
residual variation (partial R2 = 0.04). The overall R2 explained by one-carbon biomarkers, tested 
in an unadjusted linear regression model in which all variables were included simultaneously, 
was 0.12 in the pre- and peri-fortification periods and 0.19 in the post-fortification period 
(Supplementary Table S1.1) with plasma choline, plasma dimethylglycine (DMG), and plasma 
homocysteine being the strongest predictors in each period, respectively (Supplementary Table 
S1.2). 
 
Table 1.5. Predictors of baseline leukocyte global DNA methylation according to folic acid (FA) 
fortification period1,2 
 
FA fortification period 
Pre (1994–1995) Peri (1996–1997) Post (1998) 
n 
β 
Coefficient 
P 
value 
n 
β 
Coefficient 
P 
value 
n 
β 
Coefficient 
P 
value 
Plasma folate 
(ng/mL) 
115 3.98 0.31 195 0.17 0.92 75 2.33 0.54 
RBC folate (ng/mL) 118 0.25 0.02 199 0.03 0.73 77 0.24 0.14 
Plasma vitamin B12 
(pg/mL) 
115 0.20 0.08 195 0.14 0.20 75 0.25 0.18 
Plasma MMA 
(nmol/L) 
74 1.18 0.05 130 0.67 0.11 46 0.34 0.56 
Plasma choline 
(µmol/L) 
102 57.82 0.002 181 7.10 0.57 73 7.65 0.79 
Plasma betaine 
(µmol/L) 
102 2.91 0.41 181 1.21 0.64 73 1.58 0.74 
Plasma DMG 
(µmol/L) 
102 31.11 0.43 181 6.28 0.79 73 3.25 0.96 
Plasma TMAO 
(µmol/L) 
102 6.10 0.12 181 0.17 0.97 73 1.45 0.83 
Plasma Hcy 
(µmol/L) 
115 21.23 0.03 197 1.38 0.91 77 29.37 0.07 
Plasma cysteine 
(µmol/L) 
115 –1.23 0.19 197 0.48 0.53 77 –0.26 0.86 
1Linear regression models were used, adjusting for age, BMI, ethnicity, creatinine, and MTHFR C677T 
genotype.  
2Beta (β) coefficient indicates mean increase in DNA methylation per 1000-unit increase in one-carbon 
biomarker. Abbreviations used: RBC, red blood cell; MMA, methylmalonic acid; DMG, dimethylglycine; 
TMAO, trimethylamine N-oxide; Hcy, homocysteine. 
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DISCUSSION 
The present study investigated the association between mandatory FA fortification and 
leukocyte global DNA methylation, as well as the relationship between global DNA methylation, 
RBC folate, and other biomarkers of one-carbon metabolism in postmenopausal women. The 
following two main findings emerged: (1) FA fortification period and RBC folate status 
interacted to influence global DNA methylation and; (2) associations between one-carbon 
biomarkers and global DNA methylation differed between FA fortification periods. 
 
FA fortification period interacted with RBC folate status to influence global DNA methylation 
Previous studies have found that global DNA methylation can be altered by folate 
depletion or repletion in healthy adults.14-17 In postmenopausal women, global DNA methylation 
significantly decreased under folate depletion14,15 and increased upon folate repletion.14 Based on 
these findings and the role of folate as a methyl donor, we anticipated that global DNA 
methylation would be higher among postmenopausal women with higher (vs. lower) RBC folate 
status. This expected result was observed in the pre-fortification period, but not in the post-
fortification period during which women with higher (vs. lower) RBC folate status had lower 
DNA methylation.  
Excess FA intake through fortified foods and supplements can lead to the accumulation 
of unmetabolized FA,18 which may interfere with normal folate metabolism19-22 and lower global 
DNA methylation.23 Although supraphysiologic folate status (i.e., total plasma folate 
concentrations > 19.8 ng/mL)24 was observed among postmenopausal women with higher RBC 
folate in the post-fortification period (25.3 ng/mL; Supplementary Table S1.3), it was similarly 
observed among women with higher RBC folate in the pre-fortification period (25.1 ng/mL) and 
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appeared to be mostly attributable to FA supplement use in both periods. Specifically, a higher 
percentage of FA supplement users was observed among participants with higher (vs. lower) 
RBC concentrations (76% vs. 20%; Supplementary Table S1.4), and higher RBC folate 
concentrations were observed among FA supplement users (vs. non-users) across fortification 
periods (Supplementary Table S1.5). Nonetheless, a previous study conducted in the US reported 
the highest concentration of plasma unmetabolized FA in subjects exposed to both FA fortified 
foods and supplements as compared to those exposed only to FA fortified foods, or only to 
supplements.25 Thus, it is possible that unmetabolized FA was elevated to a greater extent in the 
post- (vs. pre-) fortification period among women with higher RBC folate status. Measurements 
of unmetabolized FA in our cohort are needed to further explore this possibility, and additional 
studies are required to clarify the health outcomes, if any, of the inverse relationship between 
leukocyte global DNA methylation and high RBC folate in the era of FA fortification. 
 
Associations between one-carbon biomarkers and global DNA methylation differed among FA 
fortification periods 
Previous human studies have reported conflicting results with positive14,16,26 or no27,28 
relationships between circulating folate (i.e., plasma and RBC folate) and global DNA 
methylation.29 In the present study, plasma and RBC folate were positively correlated with DNA 
methylation in the pre-fortification period, but not in the peri- or post-fortification period. These 
findings suggest that the relationship between folate status and global DNA methylation is 
nonlinear and that folate status is likely to be a stronger predictor of global DNA methylation 
when folate availability is lower (i.e., prior to FA fortification). However, as alluded to above, it 
is possible that the differences in the relationship between circulating folate and DNA 
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methylation across fortification periods arose from differences in the amounts of metabolized 
and unmetabolized folate. For example, metabolized folate present in the pre-fortification period 
may positively associate with global DNA methylation, while unmetabolized FA more likely to 
be present in the peri- and post-fortification periods24 may attenuate the positive relationship 
between folate status and global DNA methylation. Taken together, when total folate status 
(metabolized plus unmetabolized) is considered across the full spectrum from deficiency to very 
high, the overall association between folate and global DNA methylation may approximate a 
reverse U-shaped curve rather than a linear relationship. 
Folate intake/status may also modify the relationship between DNA methylation and 
other nutrients involved in one-carbon metabolism. Indeed, biomarkers of vitamin B12 status 
(i.e., plasma vitamin B12 and MMA) were associated with leukocyte global DNA methylation in 
the pre-fortification period, but not in the peri- or post-fortification period. Both folate and 
vitamin B12 are required for the provision of methyl groups through the methionine synthase 
reaction (Supplementary Figure S1.1). However, folate is suggested to be a stronger determinant 
of biomarkers of the methylation cycle (e.g., plasma homocysteine) than vitamin B12,30,31 which 
may explain the lack of association between vitamin B12 status and global DNA methylation in 
the peri- and post-fortification periods. 
The relationship between plasma choline and global DNA methylation was also modified 
by FA exposure with an inverse relationship observed in the pre-fortification period, but not in 
the peri- or post-fortification period. The inverse relationship between choline (a methyl donor) 
and DNA methylation in the pre-fortification period is unexpected and requires confirmation in 
other studies. However, when folate is less abundant (i.e., prior to FA fortification), supply of S-
adenosylmethionine (SAM) for methylation reactions may be reduced thereby creating a 
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competition among the various methyltransferases. As the affinity of DNA methyltransferase for 
SAM is ~18 times higher than phosphatidylethanolamine N-methyltransferase,32 the enzyme that 
produces choline endogenously, SAM may be preferentially partitioned toward DNA 
methylation thus reducing endogenous choline production. In turn, this could lead to the inverse 
relationship observed in the pre-fortification period between DNA methylation and plasma 
choline. 
Prior to FA fortification, we observed an inverse relationship between plasma 
homocysteine and global DNA methylation, which is consistent with previous reports.26,33 
Interestingly, however, plasma homocysteine was positively correlated with DNA methylation in 
the post-fortification period. The divergent relationships between homocysteine and DNA 
methylation across fortification periods may arise from the fact that homocysteine is both a 
precursor and product of cellular methylation reactions. These data collectively suggest that the 
relationship between homocysteine and DNA methylation is dynamic and likely to be dependent 
on folate availability. 
 
Strengths and limitations 
The present study had several strengths including: (1) a unique opportunity to investigate 
the impact of mandatory FA fortification on global DNA methylation by stratifying into three 
fortification periods (pre-, peri-, and post-) and; (2) examination of a wide range of biomarkers 
involved in one-carbon metabolism as potential predictors of global DNA methylation according 
to FA fortification period. Several limitations should also be noted: (1) relatively small sample 
size; (2) potential for residual confounding by factors that were either not collected in the WHI-
OS or not measured with sufficient precision and; (3) single measures of one-carbon biomarkers 
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and global DNA methylation within each FA fortification period, which may not fully reflect the 
true complexity of DNA methylation reactions. 
 
Conclusion 
These data suggest that during FA fortification, higher RBC folate status is associated 
with a reduction in leukocyte global DNA methylation among postmenopausal women. If 
reductions in leukocyte global DNA methylation are shown to have adverse health outcomes in 
future studies, FA supplement use may not be advisable among postmenopausal women residing 
in the US or other countries with mandated FA fortification programs. The present study also 
suggests that FA intake via fortification modifies the relationship between one-carbon 
biomarkers and global DNA methylation, but potential biologic mechanisms need discerning. 
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MATERIALS AND METHODS 
Subjects and study design 
The WHI-OS is a prospective cohort study that was established to investigate the 
predictors and causes of morbidity and mortality in postmenopausal women.34,35 The study 
enrolled 93676 postmenopausal women, aged 50–79 y, at 40 clinical Centers throughout the US 
between 1993 and 1998. These years of enrollment spanned the pre- (prior to January 1, 1996), 
peri- (1996–1997), and post- (after January 1, 1998) FA fortification periods in the US.9 Women 
were excluded from the study if they had medical conditions with a predicted survival of less 
than 3 y; if they had adherence/retention issues (alcoholism, drug dependency, mental illness, or 
dementia); or if they were participating in another clinical trial. The study was approved by the 
human subject review boards at the Fred Hutchinson Cancer Research Center where the WHI 
Clinical Coordinating Center is located and at all 40 clinical centers. Written informed consent 
was obtained from all participants.34,35 
In the present study, participants were a subset of those from a nested case-control study 
investigating colorectal cancer risk in the WHI-OS.12,13 From the controls of the study, we 
selected 408 women from the lowest (n = 202) and highest (n = 206) tertiles of baseline RBC 
folate concentrations, matching on age and timing of the baseline blood draw, which spanned the 
following FA fortification periods: pre-fortification (1994–1995; n = 71 low tertile, 51 high 
tertile), peri-fortification (1996–1997; n = 102 low tertile, 102 high tertile), and post-fortification 
(1998; n = 29 low tertile, 53 high tertile). The proportions in the fortification periods correspond 
approximately to the recruitment of the WHI-OS. However, because the nested case-control 
study from which we were sampling did not contain at least 50 participants in the post-
fortification period, low RBC folate group, we selected additional participants from the pre-
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fortification, low RBC folate group in order to maintain approximately the same number of 
participants in each of the low and high RBC folate tertiles. 
 
Data collection 
Baseline demographic and health-related characteristics (i.e., age, race/ethnicity, 
education, smoking status, and physical activity) were collected using standardized 
questionnaires.34 Height and weight were measured using a standardized protocol, and BMI was 
calculated as weight (kg)/height (m2). Dietary intake of folate, vitamin B6 and vitamin B12 was 
based on data derived from the WHI food-frequency questionnaire as previously described.36 
Supplemental vitamin intakes of B2, B6, and B12 were assessed by an inventory in which 
nutrients were recorded based on participants’ current dietary supplement bottles, which they 
brought to the clinic visits. To account for differences in bioavailability between synthetic FA 
and natural food folate, dietary folate equivalent (DFE) was used as the unit for total folate 
intake.37 
 
Analytic measurements 
Blood samples were drawn at baseline after at least 12 h of fasting. Samples were kept at 
4 °C for up to 1 h prior to centrifugation. Plasma and serum were collected and stored at -70 °C 
until analysis.13 Leukocyte global DNA methylation was measured in de-identified samples 
using liquid chromatographytandem mass spectrometry (LC-MS/MS) as described by Song 
et al.38 with modifications based on our instrumentation.39 A total of 11 batches (40 samples per 
batch) were run in duplicate. For each batch, all samples from both comparisons (i.e., high and 
low RBC folate) were randomly ordered and equally represented and matched on period of blood 
 19 
draw by pre-, peri- and post-fortification and on age. Both internal laboratory controls and 10% 
blind duplicate samples were used to determine assay precision and monitor assay performance. 
Internal laboratory controls included: (1) unmethylated lambda DNA (Promega); (2) methylated 
lambda DNA (~30% of DNA methylated); (3) four in-house human biological control samples 
and; (4) a negative control (water). All quality control samples were prepared in duplicate and 
interspersed among the samples. DNA methylation is expressed as a percentage of total cytosine: 
[methylated cytosine / (methylated + unmethylated cytosine)] × 100%. 
Plasma concentrations of choline and its metabolites (i.e., betaine, DMG, trimethylamine 
N-oxide [TMAO]) were measured using stable isotope dilution LC-MS/MS methodology.40 
Plasma total homocysteine and cysteine were determined by high-pressure liquid 
chromatography (HPLC) with post-column fluorescence detection41; plasma and RBC folate as 
well as plasma vitamin B12 were measured by radioassay (SimulTRAC; MP Biomedicals); 
plasma pyridoxal-5′-phosphate (PLP) was analyzed by HPLC with fluorescence detection42; 
plasma MMA was measured by LC-MS/MS43; plasma creatinine was quantified by the Jaffe rate 
reaction method (DxC Instrument; Beckman Coulter); and methylenetetrahydrofolate reductase 
(MTHFR) C677T genotype (rs 1801133) was determined by the Illumina 384-plex BeadXpress 
genotyping platform (Illumina Inc.). 
Inter-assay coefficients of variance of the blind duplicate control samples for each of the 
assays were as follows: global DNA methylation, 5.5%; choline, 5.6%; betaine, 4.6%; DMG, 
11.9%; TMAO, 5.8%; homocysteine, 6.5%; cysteine, 7.1%; RBC folate, 10.2%; plasma folate, 
4.8%; vitamin B12, 6.2%; PLP, 5.9%; MMA, 15.0%; and creatinine, 4.1%. 
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Statistical analysis 
Differences in baseline characteristics of the study population between FA fortification 
periods were analyzed by: (1) one-way analysis of variance (ANOVA) for normally distributed 
continuous variables; (2) non-parametric Kruskal-Wallis tests for non-normally distributed 
continuous variables or; (3) chi-square tests for categorical variables. Linear regression models 
were used to: (1) examine the influence of FA fortification and RBC folate (and their interaction 
term) on baseline leukcoyte global DNA methylation and; (2) identify the one-carbon biomarkers 
that predicted leukocyte global DNA methylation. The partial R2 for each predictor variable was 
determined to estimate the contribution of each predictor to the total variability in DNA 
methylation. Spearman rank correlation coefficients (r) were also computed to examine 
associations between leukocyte global DNA methylation and one-carbon biomarkers. In the 
multivariate-adjusted analyses, we controlled for age and BMI along with plasma creatinine, 
ethnicity (white/not white) and MTHFR C677T genotype as these three variables were shown to 
be influential in a univariate model assessing possible confounders on DNA methylation. 
MTHFR C677T genotype was treated as an additive variable (i.e., minor allele count) in our 
statistical models because of reduced variation; parameter estimates were not changed 
substantially when MTHFR C677T genotype was treated as a categorical variable. Because 
approximately 25% of plasma creatinine values were missing among the sample due to 
insufficient sample availability, simple mean imputation was used for the missing creatinine 
values. Model results using multiple imputation and simple mean imputation were similar. 
Significance was defined as P < 0.05, and all statistical tests were 2-sided. The data were 
analyzed by SAS version 9.3 (SAS Institute Inc.). 
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Supplementary Figure S1.1 Simplified diagram of folate- and choline-mediated DNA methylation 
reactions. Relevant enzymes are highlighted in gray. Abbreviations: BHMT, betaine homocysteine 
methyltransferase; DHF, dihydrofolate; DHFR, dihydrofolate reductase; DMG, dimethylglycine; DNMT, 
DNA methyltransferase; MS, methionine synthase; MTHFR, methylenetetrahydrofolate reductase; SAH, 
S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate. 
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Supplementary Table S1.1 Overall R2 explained by all one-carbon biomarkers according to 
folic acid (FA) fortification period1, 2 
 Overall unadjusted R
2 
Pre-fortification (1994-1995) 0.12 
Peri-fortification (1996-1997) 0.12 
Post-fortification (1998) 0.19 
1Unadjusted linear regression models were used by including all variables simultaneously.  
2n=73 in the pre-fortification period; n=123 in the peri-fortification period; n=45 in the post-fortification 
period. 
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Supplementary Table S1.2. Predictors of baseline leukocyte global DNA methylation according to folic acid (FA) fortification 
period with all variables included in the statistical model1, 2, 3  
1Unadjusted linear regression models were used by including all variables simultaneously.  
2Beta (β) coefficient indicates mean increase in DNA methylation per 1000-unit increase in one-carbon biomarker. 
3n=73 in the pre-fortification period; n=123 in the peri-fortification period; n=45 in the post-fortification period. 
Abbreviations used: RBC, red blood cell; MMA, methylmalonic acid; DMG, dimethylglycine; TMAO, trimethylamine N-oxide; Hcy, 
homocysteine.
 
FA fortification period 
Pre- (1994-1995) Peri- (1996-1997) Post- (1998) 
β  
Coefficient 
P 
value 
Partial 
R2 
β  
Coefficient 
P 
value 
Partial 
R2 
β  
Coefficient 
P 
value 
Partial 
R2 
Plasma folate (ng/mL) -1.16 0.79 0.001 -3.20 0.19 0.015 9.42 0.13 0.066 
RBC folate (ng/mL) 0.11 0.53 0.006 -0.13 0.24 0.012 -0.18 0.52 0.012 
Plasma vitamin B12 (pg/mL) 0.04 0.84 0.001 -0.08 0.65 0.002 0.00 0.99 0.000 
Plasma MMA (nmol/L) -0.49 0.38 0.012 0.26 0.55 0.003 -0.36 0.64 0.007 
Plasma choline (µmol/L) -44.37 0.06 0.057 -10.37 0.50 0.004 -37.03 0.42 0.019 
Plasma betaine (µmol/L) -1.78 0.75 0.002 -1.83 0.61 0.002 8.60 0.39 0.022 
Plasma DMG (µmol/L) -0.85 0.99 0.000 61.89 0.07 0.029 -89.57 0.46 0.016 
Plasma TMAO (µmol/L) 7.10 0.31 0.016 0.72 0.86 0.000 -7.05 0.53 0.012 
Plasma Hcy (µmol/L) 16.22 0.51 0.007 11.84 0.52 0.004 72.77 0.08 0.088 
Plasma cysteine (µmol/L) 0.08 0.96 0.000 0.06 0.95 0.000 -2.10 0.36 0.025 
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Supplementary Table S1.3. Plasma folate concentrations (ng/mL) within the lowest and highest 
RBC folate groups according to folic acid (FA) fortification period1 
  
Lowest RBC Folate group Highest RBC Folate group 
P value n Median (IQR) n Median (IQR) 
Pre-fortification (1994-1995) 70 8.5 (5.8-14.6) 49 25.1 (17.3-37.5) < 0.001 
Peri-fortification (1996-1997) 100 9.2 (5.8-13.7) 100 23.0 (17.2-30.3) < 0.001 
Post-fortification (1998) 28 12.8 (9.7-20.0) 51 25.3 (17.5-34.7) < 0.001 
1Linear regression models were used to compare median plasma folate concentrations between RBC folate 
groups and were adjusted for age, BMI, ethnicity, creatinine, and MTHFR C677T genotype. 
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Supplementary Table S1.4. Folic acid (FA) supplement use (%) within the lowest (n=202) and 
highest (n=206) RBC folate groups. 
FA supplement use Lowest RBC folate group Highest RBC folate group 
Yes 19.8% (40/202) 75.7% (156/206) 
No 80.2% (162/202) 24.3% (50/206) 
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Supplementary Table S1.5. RBC folate concentrations (ng/mL) within folic acid (FA) 
supplement users and non-supplement users according to FA fortification period1 
 
FA supplement users Non-FA supplement users 
P value n Mean ± SD n Mean ± SD 
Pre-fortification (1994-1995) 56 761 ± 282 66 386 ± 173 < 0.001 
Peri-fortification (1996-1997) 103 820 ± 317 101 450 ± 220 < 0.001 
Post-fortification (1998) 37 814 ± 276 45 582 ± 247 0.0495 
1Linear regression models were used to compare mean RBC folate concentrations between FA 
supplement users and non-supplement users and were adjusted for age, BMI, ethnicity, creatinine, 
and MTHFR C677T genotype. 
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CHAPTER 2 
Plasma Choline Metabolites and Colorectal Cancer Risk in the Women's Health Initiative 
Observational Study* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Bae S, Ulrich CM, Neuhouser ML, Malysheva O, Bailey LB, Xiao L, Brown EC, Cushing-
Haugen KL, Zheng Y, Cheng TY, Miller JW, Green R, Lane DS, Beresford SA, Caudill MA. 
Plasma Choline Metabolites and Colorectal Cancer Risk in the Women's Health Initiative 
Observational Study. Cancer Res 2014;74(24):7442-52.  
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ABSTRACT 
Few studies have examined associations between plasma choline metabolites and risk of 
colorectal cancer. Therefore, we investigated associations between plasma biomarkers of choline 
metabolism [choline, betaine, dimethylglycine, and trimethylamine N-oxide (TMAO)] and 
colorectal cancer risk among postmenopausal women in a case–control study nested within the 
Women's Health Initiative Observational Study. We selected 835 matched case–control pairs, 
and cases were further stratified by tumor site (proximal, distal, or rectal) and stage 
(local/regional or metastatic). Colorectal cancer was assessed by self-report and confirmed by 
medical records over the mean of 5.2 years of follow-up. Baseline plasma choline metabolites 
were measured by LC/MS-MS. In multivariable-adjusted conditional logistic regression models, 
plasma choline tended to be positively associated with rectal cancer risk [OR (95% confidence 
interval, CI)highest vs. lowest quartile = 2.44 (0.93–6.40); P trend = 0.08], whereas plasma betaine was 
inversely associated with colorectal cancer overall [0.68 (0.47–0.99); P trend = 0.01] and with 
local/regional tumors [0.64 (0.42–0.99); P trend = 0.009]. Notably, the plasma betaine:choline 
ratio was inversely associated with colorectal cancer overall [0.56 (0.39–0.82); P trend = 0.004] 
as well as with proximal [0.66 (0.41–1.06); P trend = 0.049], rectal [0.27 (0.10–0.78); P trend = 
0.02], and local/regional [0.50 (0.33–0.76); P trend = 0.001] tumors. Finally, plasma TMAO, an 
oxidative derivative of choline produced by intestinal bacteria, was positively associated with 
rectal cancer [3.38 (1.25–9.16); P trend = 0.02] and with overall colorectal cancer risk among 
women with lower (vs. higher) plasma vitamin B12 levels (P interaction = 0.003). Collectively, 
these data suggest that alterations in choline metabolism, which may arise early in disease 
development, may be associated with higher risk of colorectal cancer. The positive association 
between plasma TMAO and colorectal cancer risk is consistent with an involvement of the gut 
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microbiome in colorectal cancer pathogenesis. 
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INTRODUCTION 
Colorectal cancer is the third most commonly diagnosed cancer in both men and women 
and a major cause of cancer deaths in the United States (1). Disturbances in one-carbon 
metabolism, which lead to genomic instability (e.g., aberrant DNA methylation and DNA 
damage), may contribute to colorectal cancer development (2, 3). Choline and folate are methyl 
nutrients involved in one-carbon metabolism and play a critical role in methylation reactions, 
including DNA methylation, as well as DNA stability and repair (4–6). Although low folate 
intake and low circulating levels of folate are associated with high risk of colorectal cancer (2, 7–
9), less is known about the association between choline and colorectal cancer risk.  
Choline participates in methylation reactions following its oxidation to betaine, which 
donates a methyl group for homocysteine remethylation, forming methionine and 
dimethylglycine (DMG). Betaine also serves as an osmolyte and plays a major role in protecting 
cells from hyperosmotic stress that can lead to chronic inflammation, a risk factor for colorectal 
cancer (1, 10, 11). To date, only a few studies have examined the association between plasma 
betaine and colorectal carcinogenesis. In a Norwegian population, plasma betaine was inversely 
associated with the occurrence of distal colorectal adenomas (12). A recent case–control study 
nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) also 
reported an inverse association between plasma betaine and colorectal cancer risk among 
participants with low plasma folate concentrations (13). 
Choline can also undergo catabolism by the intestinal bacteria to form trimethylamine 
(TMA), which is further converted to trimethylamine N-oxide (TMAO) by the liver enzyme 
flavin monooxygenase (FMO; refs. 14, 15). Although intestinal microbiota have been implicated 
in the development of colorectal cancer (16–18), the association between gut microbiota–
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dependent choline metabolites and colorectal cancer risk is unknown. 
In this report, we investigated the associations between plasma biomarkers of choline 
metabolism (choline, betaine, DMG, and TMAO) and colorectal cancer risk in a case–control 
study nested within the Women's Health Initiative Observational Study (WHI-OS) cohort. 
Because of the interdependence of choline and folate as well as other B vitamins (vitamin B6 and 
B12) in one-carbon metabolism (4, 5), we further explored their influence and that of folic acid 
(FA) fortification (19) on the associations between plasma choline metabolites and colorectal 
cancer risk. 
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Patients and Methods 
Study population 
The WHI-OS is a prospective cohort study designed to investigate the predictors and 
causes of morbidity and mortality in postmenopausal women (20, 21). The study enrolled 93,676 
postmenopausal women, ages 50 to 79 years, at 40 centers throughout the United States between 
1993 and 1998. Women were excluded if they had medical conditions with a predicted survival 
of <3 years; if they had adherence/retention issues; or if they were participating in another 
clinical trial. 
For the present study, incident colorectal cancer cases were selected as of April 24, 2008, 
and the average time from baseline to colorectal cancer diagnosis was 5.2 ± 3.1 years (mean ± 
SD; refs. 11, 22). Women were excluded if they had a history of colorectal cancer or in situ 
colorectal cancer; if they had no available biospecimens; or if a death certificate provided the 
only report of colorectal cancer. Controls who were free of cancer at the time of case diagnosis 
were selected from the WHI-OS by using risk-set sampling. Cases and controls were matched on 
age (± 3 years), race/ethnicity, timing of baseline blood draw (± 6 months), enrollment date (± 1 
year), and baseline hysterectomy status (11, 22). Thus, the present study included 835 incident 
colorectal cancer cases and 835 matched controls. Approval for conducting the study was 
obtained from human subject review committees at the Fred Hutchinson Cancer Research Center 
(WHI Clinical Coordinating Center), as well as at all 40 clinical centers. Written informed 
consent was obtained from all participants. 
 
Data collection 
Demographic and health-related characteristics were collected at baseline using 
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standardized questionnaires (20). Height and weight were measured using a standardized 
protocol, and body mass index (BMI) was calculated as weight (kg)/height (m2). Colorectal 
cancer was annually assessed using self-administered questionnaires collected from each 
participant by mail and during an in-person clinical follow-up visit at year 3 (23). All colorectal 
cancer cases were confirmed by physician adjudicators. The International Classification of 
Diseases for Oncology, second edition codes were used to identify colorectal cancer cases based 
on tumor site as previously described (11). The Surveillance Epidemiology and End Results 
(SEER) program guidelines of the NCI were used for classifications of cancer cases (23). 
 
Analytic measurements 
Blood samples were drawn at study baseline after at least 12 hours of fasting. Samples 
were kept at 4°C for up to 1 hour before centrifugation. Plasma and serum were collected and 
stored at -70°C until analysis (22). Plasma concentrations of choline and its metabolites (betaine, 
DMG, and TMAO) were measured in de-identified samples using LC/MS-MS methodology 
with modifications based on our instrumentation (24). Plasma and red blood cell (RBC) folate as 
well as plasma vitamin B12 were measured by radioassays (SimulTRAC; MP Biomedicals); 
plasma pyridoxal-5’-phosphate (PLP) was analyzed by high-pressure liquid chromatography 
(HPLC) with fluorescence detection (25); and total plasma homocysteine was determined by 
HPLC with postcolumn fluorescence detection (26). Interassay coefficients of variance of the 
blind duplicate control samples for each of the assays were as follows: choline, 7%; betaine, 5%; 
DMG, 9%; TMAO, 6%; plasma folate, 5%; RBC folate, 10%; vitamin B12, 6%; PLP, 6%; and 
homocysteine, 7%.  
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Statistical analysis 
Baseline characteristics of colorectal cancer cases and controls were compared using (i) t 
tests for normally distributed continuous variables; (ii) Wilcoxon tests for non-normally 
distributed continuous variables; and (iii) χ2 tests for categorical variables. Associations among 
plasma concentrations of choline metabolites were assessed using Spearman correlation analysis. 
Plasma choline metabolites were divided into quartiles based on the distribution of the controls. 
Conditional logistic regression models were used to estimate ORs and 95% confidence intervals 
(CI) of colorectal cancer risk among quartiles of choline metabolites, using the lowest quartiles 
as reference groups. Because risk-set sampling was used for selecting matched controls, the 
conditional ORs yielded estimates of the incidence rate ratio in a full cohort study. We further 
explored the associations between the ratios of choline metabolites (i.e., betaine:choline, 
DMG:choline, and DMG: betaine) and colorectal cancer risk, because the ratios of these 
metabolites (vs. individual metabolite alone) are suggested to be stronger predictors of metabolic 
disturbances (27). The models were first adjusted only for age (continuous) and then further 
adjusted for baseline confounding factors selected a priori: BMI, pack-years of smoking, 
physical activity, use of postmenopausal hormone therapy, history of colonoscopy, RBC folate, 
plasma vitamin B12, PLP, and homocysteine. All of these factors were added in the model as 
continuous variables except for postmenopausal hormone therapy use (categorical: never, past, 
or current). Tests of linear trend across increasing quartiles of choline metabolites were 
conducted by the Wald test, using the median value for each quartile as a single continuous 
variable.  
To explore whether the associations between choline metabolites and colorectal cancer 
risk were modified by B vitamins involved in one-carbon metabolism, we conducted analyses 
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stratified into high/low plasma concentrations of folate, PLP, and vitamin B12 based on median 
values among controls. We also examined the influence of FA fortification by stratifying into the 
following FA fortification periods based on the timing of baseline blood draw: prefortification 
(1994–1995), perifortification (1996–1997; when initial fortification began, but was not yet 
mandated), and postfortification (1998; ref. 28). The Wald test was used to evaluate the effect 
modification including a two-way interaction term between the ordinal trend variables (choline 
metabolites) and effect modifiers (B vitamins or FA fortification period). Because the matching 
was broken, unconditional multiple logistic regression models were used in these stratified 
analyses, further adjusting for days to colorectal cancer diagnosis and ethnicity. Significance was 
defined as P < 0.05, and all statistical tests were two-sided. Analyses were conducted by SAS 
version 9.3 (SAS Institute Inc.). 
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Results 
Characteristics of the study population 
Baseline characteristics of the colorectal cancer cases and controls are shown in Table 
2.1. Compared with the controls, the cases had a higher BMI, a greater number of cigarettes 
smoked among current smokers, fewer weekly minutes of moderate or strenuous physical 
activity, and had a different distribution pattern of postmenopausal hormone therapy use. The 
colorectal cancer group also had a lower percentage of previous colonoscopy, but a higher 
percentage of having history of a colon polyp removed.  
Plasma choline, betaine, and DMG concentrations did not differ between cases and 
controls (Table 2.1). However, the cases (vs. controls) had higher (P = 0.005) median plasma 
concentrations of TMAO (4.0 vs. 3.8 µmol/L) and tended to have a lower (P = 0.07) mean 
plasma betaine:choline ratio (2.9 vs. 3.0). In addition, the cases had lower median plasma folate, 
PLP, and vitamin B12 as well as higher median plasma homocysteine. 
Among the cases, tumors were classified by tumor site (proximal, distal, or rectal) and 
stage (local/regional or metastatic). More than half (59%; n = 489) of the tumors were proximal 
followed by distal (21%; n = 177) and rectal (19%; n = 155). Two percent (n = 14) of the tumors 
were not classified by tumor site because they were unknown or had overlapping lesions. In 
addition, when stratified by tumor stage, the majority of the cases (85%; n = 712) had localized or 
regional tumors, whereas 12% of the cases (n = 104) had distant metastases. Two percent (n = 18) 
of the tumors were not stratified by tumor stage because their stages were unknown or not 
determined. 
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Table 2.1. Characteristics of CRC cases and controlsa  
Characteristics 
Cases Controls 
P value n Value n Value 
Age (years)b 835 66 ± 7 835 67 ± 7 0.52 
BMI (kg/m2)b 824 28.2 ± 6.1 827 27.1 ± 5.9 0.004 
Race/ethnicityc 835 100 835 100 1.0 
White 711 85 711 85  
Othere 124 15 124 15  
Family income ($)c 801 100 793 100 0.30 
< 34,999 374 47 351 44  
35,000–74,999 294 37 282 36  
≥ 75,000 111 14 137 17  
Do not know 22 3 23 3  
Education (high school or less)c 160 19 186 22 0.11 
Residence location (US region)c 835 100 835 100 0.57 
Northeast 210 25 189 23  
South 188 23 203 24  
Midwest 196 23 191 23  
West 241 29 252 30  
Pack-years smokingb 802 13 ± 22 799 9 ± 17 <0.001 
Moderate or strenuous activity (min/wk)b 824 98 ± 136 827 111 ± 145 0.05 
Use of postmenopausal hormone therapyc 834 100 835 100 <0.001 
Never 415 50 346 41  
Past 138 17 135 16  
Current 281 34 354 42  
Family history of CRC (yes)c 167 22 143 19 0.17 
History of colonoscopy or sigmoidoscopy (yes)c 431 53 500 61 <0.001 
History of colon polyp removal (yes)c 102 24 90 18 0.03 
Plasma choline (µmol/L)b 835 9.5 ± 2.3 835 9.4 ± 2.2 0.25 
Plasma betaine (µmol/L)b 835 26.6 ± 10.8 835 27.1 ± 10.7 0.31 
Plasma DMG (µmol/L)d 835 2.3 (1.9-2.9) 834 2.3 (1.9-2.9) 0.89 
Plasma TMAO (µmol/L)d 835 4.0 (2.9-6.0) 835 3.8 (2.6-5.7) 0.005 
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Plasma betaine:choline ratiob 835 2.9 ± 1.2 835 3.0 ± 1.3 0.07 
Plasma DMG:choline ratiob 835 0.27 ± 0.12 834 0.28 ± 0.11 0.52 
Plasma DMG:betaine ratiob 835 0.10 ± 0.05 834 0.10 ± 0.05 0.51 
Plasma folate (ng/mL)d 835 15.6 (8.9-25.3) 835 17.2 (9.9-27.1) 0.02 
RBC folate (ng/mL)d 832 564 (410-742) 835 591 (431-751) 0.16 
Plasma PLP (nmol/L)d 821 60 (39-101) 817 67 (44-113) 0.002 
Plasma vitamin B12 (pg/mL)d 833 477 (336-661) 835 505 (376-691) 0.02 
Plasma homocysteine (µmol/L)d 835 8.1 (6.8-9.9) 835 7.7 (6.7-9.4) 0.002 
    aDifferences between cases and controls were analyzed by t tests (normally distributed continuous variables); Wilcoxon tests (non-normally 
distributed continuous variables); and chi-square tests (categorical variables).  
        bValues are mean ± SD for normally distributed continuous variables. 
        cValues are percentage for categorical variables. 
        dValues are median (interquartile range) for non-normally distributed continuous variables.  
        eBlack or African-American, Hispanic, Asian or Pacific Islander, American Indian or Alaskan Native, or missing. 
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Correlations among plasma concentrations of choline metabolites 
Spearman correlation coefficients (r) were computed to examine associations among 
plasma choline metabolites. There were statistically significant, but modest, positive associations 
of plasma choline with plasma betaine (r = 0.22; P < 0.001), DMG(r = 0.21; P < 0.001) and 
TMAO(r = 0.18; P < 0.001). Plasma betaine was also positively correlated with plasma DMG (r 
= 0.39; P < 0.001). 
 
Associations between plasma choline metabolites and colorectal cancer risk 
In multivariable-adjusted analyses, women in the highest (vs. lowest) choline quartile 
were at an estimated 2.4 times greater risk of rectal cancer (P trend = 0.08; Table 2.2). 
Conversely, women in the highest (vs. lowest) betaine quartile were at 32% lower colorectal 
cancer risk overall [OR (95% CI)highest vs. lowest quartile = 0.68 (0.47–0.99); P trend = 0.01], 36% 
lower risk of local/regional tumors [0.64 (0.42–0.99); P trend = 0.009], and 31% lower risk of 
proximal tumors [0.69 (0.43–1.10); P trend = 0.05; Table 2.3]. No association between 
DMG quartiles and colorectal cancer risk was observed (Supplementary Table S2.1). 
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Table 2.2. ORs (95% CIs) of CRC by quartile of plasma cholinea 
 Quartiles of choline (µmol/L) 
P-trendb 1 (≤7.9) 2 (>7.9-9.2) 3 (>9.2-10.6) 4 (>10.6) 
n 412 403 408 447  
All participants       
  Age-adjusted  1 1.06 (0.80, 1.40) 0.96 (0.71, 1.29) 1.30 (0.97, 1.74) 0.09 
  Multivariablec  1 1.01 (0.74, 1.39) 0.95 (0.68, 1.31) 1.22 (0.88, 1.70) 0.26 
By tumor site      
  Proximal       
     Age-adjusted  1 1.16 (0.80, 1.70) 1.11 (0.75, 1.62) 1.33 (0.91, 1.95) 0.17 
     Multivariablec  1 1.06 (0.68, 1.66) 1.07 (0.69, 1.65) 1.21 (0.78, 1.87) 0.39 
  Distal       
     Age-adjusted  1 1.02 (0.58, 1.82) 0.69 (0.34, 1.39) 1.12 (0.61, 2.05) 0.73 
     Multivariablec 1 0.92 (0.48, 1.77) 0.68 (0.31, 1.49) 1.07 (0.51, 2.23) 0.91 
Rectal      
     Age-adjusted  1 1.08 (0.56, 2.08) 1.00 (0.51, 1.95) 1.79 (0.88, 3.64) 0.13 
     Multivariablec  1 1.38 (0.59, 3.22) 1.37 (0.56, 3.34) 2.44 (0.93, 6.40) 0.08 
By stage      
  Local/regional       
     Age-adjusted  1 1.11 (0.82, 1.51) 1.07 (0.78, 1.48) 1.33 (0.97, 1.81) 0.08 
     Multivariablec  1 1.01 (0.71, 1.44) 1.01 (0.70, 1.45) 1.23 (0.86, 1.76) 0.24 
    Metastatic       
     Age-adjusted  1 0.84 (0.37, 1.90) 0.41 (0.16, 1.04) 1.12 (0.46, 2.73) 0.82 
     Multivariablec  1 1.66 (0.56, 4.92) 0.55 (0.18, 1.73) 2.32 (0.69, 7.83) 0.30 
aORs (95% CIs) of CRC were determined by conditional logistic regression.  
bMedians for each quartile used in trend test: quartile 1 = 7.0 µmol/L, quartile 2 = 8.6 µmol/L, quartile 3 = 9.8 µmol/L, and quartile 4 = 11.8 
µmol/L.  
cMultivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of 
postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.  
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Table 2.3. ORs (95% CIs) of CRC by quartile of plasma betainea 
 Quartiles of betaine (µmol/L) 
P-trendb 1 (≤18.8) 2 (>18.8-26.6) 3 (>26.6-34.0) 4 (>34.0) 
n 413 464 417 376  
All participants       
       Age-adjusted  1 1.32 (1.01, 1.73) 1.02 (0.77, 1.36) 0.93 (0.70, 1.24) 0.29 
       Multivariablec  1 1.03 (0.75, 1.43) 0.74 (0.52, 1.06) 0.68 (0.47, 0.99) 0.01 
By tumor site      
Proximal       
       Age-adjusted  1 1.33 (0.95, 1.87) 1.07 (0.74, 1.54) 0.80 (0.55, 1.17) 0.16 
       Multivariablec  1 1.26 (0.84, 1.89) 0.87 (0.55, 1.38) 0.69 (0.43, 1.10) 0.05 
Distal       
       Age-adjusted  1 1.51 (0.81, 2.81) 1.25 (0.67, 2.36) 1.12 (0.58, 2.16) 0.95 
       Multivariablec  1 0.89 (0.37, 2.11) 0.82 (0.33, 2.02) 0.63 (0.23, 1.73) 0.32 
Rectal      
       Age-adjusted  1 1.44 (0.74, 2.80) 0.65 (0.33, 1.27) 1.13 (0.60, 2.14) 0.71 
       Multivariablec  1 1.02 (0.43, 2.42) 0.35 (0.13, 0.96) 0.61 (0.22, 1.70) 0.16 
By stage      
Local/regional       
       Age-adjusted  1 1.31 (0.98, 1.74) 0.91 (0.67, 1.23) 0.93 (0.67, 1.28) 0.23 
       Multivariablec  1 1.01 (0.71, 1.44) 0.64 (0.43, 0.96) 0.64 (0.42, 0.99) 0.009 
   Metastatic       
       Age-adjusted  1 1.34 (0.57, 3.15) 2.13 (0.87, 5.25) 0.91 (0.45, 1.85) 0.55 
       Multivariablec  1 0.97 (0.33, 2.82) 1.91 (0.61, 5.95) 0.85 (0.31, 2.37) 0.70 
aORs (95% CIs) of CRC were determined by conditional logistic regression.  
bMedians for each quartile used in trend test: quartile 1 = 14.4 µmol/L, quartile 2 = 22.8 µmol/L, quartile 3 = 29.9 µmol/L, and quartile 4 = 39.1 
µmol/L.  
cMultivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of 
postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.
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Notably, after controlling for covariates, women in the highest (vs. lowest) quartile of the 
plasma betaine:choline ratio were at an estimated 44% lower colorectal cancer risk overall [0.56 
(0.39–0.82); P trend = 0.004] as well as 34% lower risk of proximal tumors [0.66 (0.41–1.06); P 
trend = 0.049], 73% lower risk of rectal tumors [0.27 (0.10–0.78); P trend = 0.02], and 50% 
lower risk of local/regional tumors [0.50 (0.33–0.76); P trend = 0.001; Table 2.4]. The plasma 
DMG:choline ratio tended to be inversely associated with colorectal cancer risk overall [0.69 
(0.48–0.98); P trend = 0.06; Supplementary Table S2.2]. The inverse association was statistically 
significant for local/regional tumors [0.62 (0.42–0.91); P trend = 0.04] and borderline significant 
for proximal tumors [0.57 (0.36–0.93); P trend = 0.07]. Last, the DMG:betaine ratio tended to be 
positively associated with rectal cancer risk [2.56 (0.98–6.64); P trend = 0.09; Supplementary 
Table S2.3]. 
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Table 2.4. ORs (95% CIs) of CRC by quartile of plasma betaine:choline ratioa 
 Quartiles of betaine:choline ratio 
P-trendb 1 (≤2.0) 2 (>2.0-2.8) 3 (>2.8-3.8) 4 (>3.8) 
n 416 446 436 372  
All participants       
       Age-adjusted  1 1.12 (0.85, 1.48) 1.08 (0.83, 1.41) 0.79 (0.59, 1.05) 0.08 
       Multivariablec  1 0.83 (0.60, 1.15) 0.87 (0.62, 1.22) 0.56 (0.39, 0.82) 0.004 
By tumor site      
Proximal       
       Age-adjusted  1 1.26 (0.88, 1.79) 1.09 (0.77, 1.55) 0.74 (0.51, 1.09) 0.08 
       Multivariablec  1 1.12 (0.73, 1.70) 0.98 (0.63, 1.53) 0.66 (0.41, 1.06) 0.049 
Distal       
       Age-adjusted  1 0.90 (0.48, 1.69) 1.07 (0.61, 1.87) 0.83 (0.43, 1.60) 0.76 
       Multivariablec  1 0.53 (0.24, 1.18) 0.86 (0.40, 1.84) 0.45 (0.19, 1.10) 0.24 
Rectal      
       Age-adjusted  1 1.06 (0.55, 2.06) 0.94 (0.51, 1.73) 0.75 (0.39, 1.41) 0.32 
       Multivariablec  1 0.56 (0.22, 1.43) 0.45 (0.18, 1.13) 0.27 (0.10, 0.78) 0.02 
By stage      
Local/regional       
       Age-adjusted  1 1.17 (0.86, 1.58) 1.04 (0.78, 1.38) 0.74 (0.54, 1.02) 0.04 
       Multivariablec  1 0.88 (0.61, 1.27) 0.81 (0.56, 1.18) 0.50 (0.33, 0.76) 0.001 
   Metastatic       
       Age-adjusted  1 0.81 (0.38, 1.75) 1.05 (0.49, 2.24) 0.95 (0.43, 2.10) 0.95 
       Multivariablec  1 0.55 (0.20, 1.54) 0.80 (0.27, 2.32) 0.79 (0.25, 2.50) 0.98 
aORs (95% CIs) of CRC were determined by conditional logistic regression.  
bMedians for each quartile used in trend test: quartile 1 = 1.6, quartile 2 = 2.4, quartile 3 = 3.2 and quartile 4 = 4.4.  
cMultivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of 
postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine. 
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Plasma TMAO, an oxidative derivative of choline produced by intestinal bacteria, was 
positively associated with colorectal cancer risk in age-adjusted analyses [1.78 (1.32–2.40); P 
trend = 0.005; Table 2.5]. Women in the highest (vs. lowest) TMAO quartile were at 
approximately 1.9 times greater risk of proximal tumors (P trend = 0.04), 2.3 times greater risk 
of rectal tumors (P trend = 0.02), and 1.8 times greater risk of local/regional tumors (P trend = 
0.008). After controlling for covariates, the positive association remained strong and statistically 
significant for rectal cancer with approximately 3.4 times greater risk among women in the 
highest (vs. lowest) TMAO quartile (P trend = 0.02). A borderline significant positive 
association was also observed for local/regional tumors with approximately 1.8 times greater risk 
in the highest (vs. lowest) TMAO quartile (P trend = 0.08). Notably, although the linear trend 
across TMAO quartiles was not statistically significant, higher risk was observed from the 
second (vs. lowest) quartile of TMAO for colorectal cancer overall [1.90 (1.36–2.64)] and for 
proximal tumors [2.37 (1.52–3.70)]. Similarly, women in the second (vs. lowest) quartile of 
TMAO were at an estimated 1.9 times higher risk for local/regional tumors and 3.6 times higher 
risk for metastatic tumors, but this was not consistently observed in the other quartiles. 
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Table 2.5. ORs (95% CIs) of CRC by quartile of plasma TMAOa 
 Quartiles of TMAO (µmol/L) 
P-trendb 1 (≤2.6) 2 (>2.6-3.7) 3 (>3.7-5.6) 4 (>5.6) 
n 358 435 426 451  
All participants       
       Age-adjusted  1 1.67 (1.25, 2.23) 1.55 (1.16, 2.07) 1.78 (1.32, 2.40) 0.005 
       Multivariablec  1 1.90 (1.36, 2.64) 1.47 (1.06, 2.05) 1.65 (1.17, 2.34) 0.13 
By tumor site      
Proximal      
       Age-adjusted  1 2.06 (1.40, 3.03) 2.06 (1.39, 3.04) 1.93 (1.31, 2.83) 0.04 
       Multivariablec  1 2.37 (1.52, 3.70) 1.92 (1.23, 3.00) 1.69 (1.09, 2.63) 0.42 
Distal       
       Age-adjusted  1 1.50 (0.77, 2.92) 1.20 (0.63, 2.27) 1.54 (0.78, 3.06) 0.41 
       Multivariablec 1 1.96 (0.86, 4.48) 1.19 (0.56, 2.53) 1.69 (0.73, 3.90) 0.59 
Rectal      
       Age-adjusted  1 1.03 (0.53, 1.98) 0.99 (0.52, 1.89) 2.26 (1.06, 4.79) 0.02 
       Multivariablec  1 1.42 (0.62, 3.28) 1.20 (0.53, 2.72) 3.38 (1.25, 9.16) 0.02 
By stage      
Local/regional       
       Age-adjusted  1 1.59 (1.16, 2.19) 1.56 (1.13, 2.14) 1.78 (1.28, 2.46) 0.008 
       Multivariablec  1 1.90 (1.31, 2.74) 1.46 (1.00, 2.11) 1.78 (1.21, 2.60) 0.08 
   Metastatic       
       Age-adjusted  1 2.81 (1.23, 6.41) 1.61 (0.78, 3.32) 2.26 (0.96, 5.31) 0.17 
       Multivariablec  1 3.63 (1.29, 10.23) 2.27 (0.86, 5.96) 2.09 (0.63, 6.97) 0.47 
aORs (95% CIs) of CRC were determined by conditional logistic regression.  
bMedians for each quartile used in trend test: quartile 1 = 2.0 µmol/L, quartile 2 = 3.1 µmol/L, quartile 3 = 4.5 µmol/L, and quartile 4 = 8.1 µmol/L.  
cMultivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of 
postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.  
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Associations of choline metabolites with colorectal cancer risk according to plasma B-vitamin 
concentrations 
To further explore whether B vitamins (folate, PLP, and vitamin B12) modified the 
associations between choline metabolites and colorectal cancer risk, we stratified into high/low 
plasma concentrations of B vitamins and assessed the interaction. After controlling for 
covariates, vitamin B12 status modified the association between plasma TMAO and colorectal 
cancer risk (P interaction = 0.003; Table 2.6). Specifically, higher colorectal cancer risk was 
observed with higher TMAO quartiles among women with low plasma vitamin B12 (i.e., <505 
pg/mL; P trend = 0.001), but not among those with high B12 levels. Other than this finding, no 
effect modifications by B vitamins were observed on the associations of plasma choline 
metabolites and their ratios with colorectal cancer risk (data not shown). 
 
Associations of choline metabolites with colorectal cancer risk according to FA fortification 
period 
We next explored the possible effect modification by FA fortification. The association of 
plasma choline, DMG, TMAO, and the ratios of choline metabolites with colorectal cancer risk 
did not differ by fortification periods (data not shown). However, after controlling for covariates, 
plasma betaine tended to interact with FA fortification period in association with colorectal 
cancer risk (P interaction = 0.08; Table 2.7). Specifically, lower colorectal cancer risk was 
observed with higher plasma betaine during the pre-(P trend = 0.02) and peri-(P trend = 0.02) 
fortification periods, but not during the postfortification period. 
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Table 2.6. ORs (95% CIs) of CRC associated with quartiles of plasma TMAO by vitamin B12 statusa 
 
 
Quartiles of TMAO (µmol/L)b 
P-interactionc 1 (≤ 2.6) 2 (>2.6-3.7) 3 (>3.7-5.6) 4 (>5.6) 
Vitamin B12 status       
Age-adjusted     0.0007 
Multivariabled     0.003 
Low B12 (≤505 pg/mL)      
no. of cases 77 107 122 153  
Age-adjusted  1 1.74 (1.17, 2.58) 2.01 (1.35, 2.98) 2.49 (1.68, 3.67)  
Multivariabled  1 2.00 (1.30, 3.06) 2.06 (1.34, 3.17) 2.44 (1.59, 3.75)  
High B12 (>505 pg/mL)      
no. of cases 71 122 95 86  
Age-adjusted  1 1.45 (0.97, 2.18) 1.11 (0.73, 1.69) 1.00 (0.66, 1.53)  
Multivariabled  1 1.49 (0.96, 2.32) 0.98 (0.63, 1.55) 0.92 (0.58, 1.47)  
aORs (95% CIs) of CRC were determined by unconditional logistic regression due to case-control matching being broken in these subset analyses. 
Models were additionally adjusted for ethnicity and time to diagnosis.  
bMedians for each quartile: quartile 1 = 2.0 µmol/L, quartile 2 = 3.1 µmol/L, quartile 3 = 4.5 µmol/L, and quartile 4 = 8.1 µmol/L.  
cP value for test of interaction between TMAO (as an ordinal variable) and plasma B-vitamin status. 
dMultivariable analyses were adjusted for days to CRC diagnosis, ethnicity, age, baseline BMI, pack-years of smoking, moderate or strenuous 
physical activity (min/wk), use of postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, and plasma homocysteine.  
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Table 2.7. ORs (95% CIs) of CRC associated with quartiles of plasma betaine by FA fortification periodsa 
 
Quartiles of betaine (µmol/L)b 
P-interactionc 1(≤18.8) 2 (>18.8-26.6) 3 (>26.6-34.0) 4 (>34.0) 
Fortification period      
Age-adjusted     0.04 
Multivariabled     0.08 
Pre-fortification       
       no. of cases 50 65 49 38  
       Age-adjusted  1 1.45 (0.84, 2.51) 0.85 (0.49, 1.48) 0.73 (0.41, 1.29)  
       Multivariabled  1 1.06 (0.55, 2.01) 0.65 (0.32, 1.31) 0.46 (0.22, 0.98)  
Peri-fortification       
       no. of cases 107 147 116 89  
       Age-adjusted  1 1.43 (0.99, 2.07) 0.98 (0.67, 1.42) 0.78 (0.53, 1.15)  
       Multivariabled  1 1.10 (0.72, 1.67) 0.74 (0.47, 1.15) 0.64 (0.39, 1.04)  
Post-fortification       
       no. of cases 44 48 38 44  
       Age-adjusted  1 1.09 (0.62, 1.92) 1.39 (0.74, 2.60) 1.58 (0.85, 2.91)  
       Multivariabled  1 0.88 (0.46, 1.69) 0.87 (0.41, 1.86) 0.97 (0.45, 2.06)  
aORs (95% CIs) of CRC were determined by unconditional logistic regression due to case-control matching being broken in these subset analyses. 
Models were additionally adjusted for ethnicity and time to diagnosis.  
bMedians for each quartile: quartile 1 = 14.4 µmol/L, quartile 2 = 22.8 µmol/L, quartile 3 = 29.9 µmol/L, and quartile 4 = 39.1 µmol/L.  
cP value for test of interaction between betaine (as an ordinal variable) and FA fortification periods. 
dMultivariable analyses were adjusted for days to CRC diagnosis, ethnicity, age, baseline BMI, pack-years of smoking, moderate or strenuous 
physical activity (min/wk), use of postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and 
plasma homocysteine.  
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Discussion 
To the best of our knowledge, this is the first study to assess associations between plasma 
biomarkers of choline metabolism and colorectal cancer risk among postmenopausal women in 
the United States. The following main findings emerged: (i) plasma choline (modest positive) 
and betaine (inverse) were divergently associated with colorectal cancer risk; (ii) the plasma 
betaine:choline ratio was more strongly associated with colorectal cancer risk than was either 
metabolite alone; and (iii) higher plasma TMAO concentrations were associated with higher risk 
of colorectal cancer especially among women with low plasma vitamin B12. 
The divergent associations of plasma choline and betaine with colorectal cancer risk are 
unexpected given that betaine is derived from choline and increases in response to a higher 
choline intake (24). Thus, the divergent associations may arise from the disease process itself, 
which could alter choline metabolism before diagnosis (29, 30). For example, postmenopausal 
women harboring undiagnosed, precancerous lesions may have a higher demand for choline due 
to its greater use for membrane biosynthesis by abnormally dividing cells (31, 32). This in turn 
may upregulate de novo choline production through the hepatic phosphatidylethanolamine N-
methyltransferase (PEMT) pathway. Enhanced hepatic PEMT activity would be expected to 
elevate choline, a product of the PEMT reaction, while depleting betaine, a source of methyl 
groups for the PEMT reaction. This metabolic scenario is observed during pregnancy (33), which 
like cancer is a state of rapidly dividing cells and exhibits several of the same molecular 
characteristics (34). However, unlike pregnancy where providing substrate for the PEMT 
reaction may beneficially influence fetal growth and development, betaine supplementation for 
the purposes of colorectal cancer reduction among postmenopausal women appears unwise 
because the prevalence of colonic neoplasia increases with age (35) and extra betaine may 
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accelerate tumor progression. 
The divergent associations of plasma choline and betaine with colorectal cancer risk 
observed in our study cohort differ from findings of a recent case–control study nested within the 
EPIC cohort, where, in the subgroup analyses of women, plasma choline (but not plasma 
betaine) was inversely associated with colorectal cancer risk (13). One major difference between 
the study cohorts that could explain these discordant findings is folate status. Specifically, 
median plasma folate concentrations were approximately 3.5 times higher in the WHI (vs. EPIC) 
cohort. Other contributing factors may include age of participants, follow-up period, blood 
sample collection (fasting vs. nonfasting), use of different cutpoints for categories of choline 
metabolites, and the status of other nutrients involved in one-carbon metabolism. 
 In the present study, the plasma betaine:choline ratio was more strongly associated with 
colorectal cancer risk than either metabolite alone. After adjusting for potential confounders, 
women in the highest (vs. lowest) betaine:choline quartile were at 44% lower colorectal cancer 
risk overall, 34% lower proximal tumors, 50% lower local/regional tumors, and 73% lower rectal 
tumors. The association between the betaine:choline ratio and colorectal cancer risk did not 
appear to differ according to B-vitamin status or FA fortification period. In contrast, FA 
exposure appeared to modify the association between plasma betaine and colorectal cancer risk 
with an inverse association observed in the preand perifortification periods, but not in the 
postfortification period. As such, the association between plasma betaine and colorectal cancer 
risk appears to be dependent on folate availability and may be more evident when folate 
availability is low (i.e., before FA fortification). Overall, these data support the utility of the 
plasma betaine:choline ratio as a potential biomarker for excess risk of colorectal cancer in 
postmenopausal women. 
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 In humans, choline can undergo catabolism by anaerobic intestinal bacteria to produce 
TMA, which is further converted to TMAO by the hepatic enzyme FMO (14, 15). Similarly, 
L-carnitine also serves as a precursor of TMAO through a gut microbiota–dependent metabolism 
(i.e., choline/carnitine → gut microbiota → TMA/TMAO; refs. 36, 37). This metabolic pathway 
mediated by intestinal microbiota has been linked to several diseases (37–41), suggesting the 
potential role of gut-microbial metabolism and their metabolic products in carcinogenesis among 
humans. The present study, for the first time to our knowledge, examined an association between 
circulating concentrations of TMAO and colorectal cancer risk. We found that women in the 
highest (vs. lowest) TMAO quartile had an approximately 3.4 times greater risk of rectal cancer. 
Although no statistically significant linear trend was observed, increased risk was also detected 
from the second quartile of TMAO with 1.9 times greater risk for colorectal cancer overall and 
for local/regional tumors, approximately 2.4 times greater risk for proximal tumors, and 
approximately 3.6 times greater risk for metastatic tumors. These findings collectively suggest 
that plasma TMAO may serve as a potential predictor of increased colorectal cancer risk. 
 Alterations in the intestinal microbiota may predispose to the development and 
progression of colorectal cancer through affecting multiple processes, including colonic 
epithelial cell proliferation, immune system, and chronic inflammation (16, 18). For example, 
compared with healthy individuals, increased number and diversity as well as the decreased 
stability of a colonic bacterial group, Clostridium, have been characterized in patients with 
colorectal cancer (16, 42). Indeed, Clostridium is also suggested to play a role in the conversion 
of choline (41, 43) and carnitine (37, 44) to TMA, thereby contributing to TMAO production. 
Thus, it is possible that the positive association between plasma TMAO and colorectal cancer 
risk may arise from abnormal changes in particular colonic bacteria, which could occur early in 
 58 
disease development before diagnosis. Given that TMAO is a gut bacteria–derived metabolite, it 
may also represent evidence for an etiologic correlation between intestinal microbiota and 
colorectal cancer and could potentially serve as a novel biomarker of colorectal cancer risk. 
 Notably, the association between plasma TMAO and colorectal cancer risk appeared to 
be modified by vitamin B12 status. Specifically, the risk of colorectal cancer increased across 
increasing TMAO quartiles in the low B12 group, but not in the high B12 group. These data 
suggest that postmenopausal women with higher TMAO and lower vitamin B12 may be more 
susceptible to developing colorectal cancer. Certain groups of intestinal bacteria can synthesize 
(45, 46) and consume (47, 48) vitamin B12, which may affect the vitamin B12 
requirement/status of the host. Indeed, overgrowth of intestinal bacteria that take up vitamin B12 
has been implicated in B12 malabsorption (47–50). In human intestine, overgrowth of a specific 
bacterial group can also block colonization of other bacterial groups (16), yielding an imbalance 
between their metabolic production and consumption. Therefore, elevated colorectal cancer risk 
among women with high TMAO and low vitamin B12 may in part be associated with the 
disturbances in colonic bacterial populations. Additional studies are required to confirm these 
findings, and potential biologic mechanisms need further elucidation. 
 Key strengths of the present study include: (i) the prospective design; (ii) the large 
sample size, which allowed for stratified analyses by tumor site/stage as well as by B vitamins 
and FA fortification periods; and (iii) assessment of choline metabolite ratios (especially 
betaine:choline ratio), which provided more robust colorectal cancer risk estimates. Several 
limitations should also be noted: (i) although we attempted to control confounding, there is a 
potential for residual confounding by factors that were either not collected in the WHI-OS or 
not measured with sufficient precision; (ii) although the concentrations of plasma choline and its 
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metabolites are stable through time in healthy women (24), single measures of these metabolites 
may not fully reflect long-term associations with colorectal cancer risk; and (iii) although 
baseline hysterectomy status was used as a matching factor based on the evidence that female 
sex hormones (e.g., estrogen) are associated with colorectal cancer risk (51–53), it may not 
comprehensively account for estrogen status. However, this would not be expected to have an 
influence on the results, as the analyses were adjusted for the use of postmenopausal hormone 
therapy (which would more comprehensively account for estrogen status). 
 In conclusion, the results of this study indicate that alterations in choline metabolism, 
which may arise early in disease development, associate with higher risk of colorectal cancer in 
postmenopausal women. Our data also indicate that the plasma betaine:choline ratio may be a 
potential indicator of colorectal cancer risk, which, if confirmed, could have clinical implications 
for colorectal cancer screening. This study also provides new evidence that plasma TMAO, an 
oxidative derivative of choline produced by intestinal bacteria, may serve as a potential 
biomarker for increased risk of colorectal cancer especially among those with low plasma 
vitamin B12 concentrations. Although further investigations are needed to delineate the 
underlying mechanisms, these novel findings may advance understanding of an etiologic 
correlation between intestinal bacteria and colorectal cancer pathogenesis. 
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Supplementary Table S2.1. ORs (95% CIs) of CRC by quartile of plasma DMGa 
 Quartiles of DMG (µmol/L) 
P-trendb 1 (≤1.9) 2 (>1.9-2.4) 3 (>2.4-2.9) 4 (>2.9) 
n 427 424 396 422  
All participants       
       Age-adjusted  1 0.99 (0.74, 1.31) 0.98 (0.72, 1.32) 1.03 (0.77, 1.40) 0.79 
       Multivariablec  1 0.85 (0.61, 1.18) 0.79 (0.55, 1.11) 0.75 (0.53, 1.07) 0.13 
By tumor site      
Proximal       
       Age-adjusted  1 0.90 (0.62, 1.32) 0.93 (0.62, 1.39) 0.88 (0.60, 1.31) 0.59 
       Multivariablec  1 0.75 (0.49, 1.17) 0.71 (0.44, 1.13) 0.67 (0.42, 1.06) 0.13 
Distal       
       Age-adjusted  1 0.77 (0.42, 1.39) 0.99 (0.51, 1.90) 0.86 (0.45, 1.65) 0.78 
       Multivariablec  1 0.53 (0.25, 1.12) 1.04 (0.47, 2.32) 0.51 (0.22, 1.17) 0.24 
Rectal       
       Age-adjusted  1 1.63 (0.81, 3.28) 1.10 (0.57, 2.12) 2.22 (1.06, 4.69) 0.08 
       Multivariablec  1 2.17 (0.84, 5.62) 1.23 (0.51, 2.99) 2.46 (0.90, 6.77) 0.19 
By stage      
Local/regional       
       Age-adjusted  1 0.96 (0.70, 1.32) 1.01 (0.73, 1.41) 1.03 (0.74, 1.43) 0.78 
       Multivariablec  1 0.87 (0.60, 1.25) 0.84 (0.57, 1.24) 0.77 (0.52, 1.14) 0.21 
   Metastatic       
       Age-adjusted  1 1.30 (0.59, 2.86) 0.86 (0.39, 1.88) 1.01 (0.44, 2.32) 0.88 
       Multivariablec  1 0.96 (0.38, 2.43) 0.71 (0.26, 1.93) 0.89 (0.29, 2.73) 0.78 
aORs (95% CIs) of CRC were determined by conditional logistic regression.  
bMedians for each quartile used in trend test: quartile 1 = 1.6 µmol/L, quartile 2 = 2.1 µmol/L, quartile 3 = 2.6 µmol/L, and quartile 4 = 3.4 µmol/L.  
cMultivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of 
postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.  
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Supplementary Table S2.2. ORs (95% CIs) of CRC by quartile of plasma DMG:choline ratioa 
 Quartiles of DMG:choline ratio 
P-trendb 1 (≤0.20) 2 (>0.20-0.25) 3 (>0.25-0.32) 4 (>0.32) 
n 431 403 433 402  
All participants       
       Age-adjusted  1 0.86 (0.65, 1.14) 0.97 (0.73, 1.30) 0.83 (0.61, 1.14) 0.36 
       Multivariablec  1 0.82 (0.60, 1.13) 0.93 (0.66, 1.30) 0.69 (0.48, 0.98) 0.06 
By tumor site      
Proximal       
       Age-adjusted  1 0.69 (0.47, 1.01) 0.80 (0.54, 1.18) 0.65 (0.43, 0.98) 0.10 
       Multivariablec  1 0.64 (0.42, 0.99) 0.79 (0.50, 1.24) 0.57 (0.36, 0.93) 0.07 
Distal       
       Age-adjusted  1 1.93 (1.02, 3.67) 1.18 (0.65, 2.14) 1.39 (0.70, 2.78) 0.54 
       Multivariablec  1 2.13 (1.02, 4.45) 1.15 (0.57, 2.33) 1.04 (0.47, 2.30) 0.75 
Rectal      
       Age-adjusted  1 0.61 (0.33, 1.13) 1.04 (0.52, 2.07) 0.86 (0.40, 1.87) 0.96 
       Multivariablec  1 0.62 (0.28, 1.37) 1.20 (0.50, 2.90) 0.98 (0.38, 2.56) 0.86 
By stage      
Local/regional       
       Age-adjusted  1 0.78 (0.58, 1.06) 0.87 (0.64, 1.19) 0.75 (0.53, 1.05) 0.17 
       Multivariablec  1 0.70 (0.49, 0.99) 0.81 (0.56, 1.16) 0.62 (0.42, 0.91) 0.04 
   Metastatic       
       Age-adjusted  1 1.74 (0.75, 4.02) 2.54 (0.98, 6.59) 2.13 (0.74, 6.15) 0.21 
       Multivariablec  1 2.57 (0.85, 7.84) 2.96 (0.84, 10.38) 1.96 (0.46, 8.33) 0.50 
aORs (95% CIs) of CRC were determined by conditional logistic regression. 
bMedians for each quartile used in trend test: quartile 1 = 0.17, quartile 2 = 0.23, quartile 3 = 0.28 and quartile 4 = 0.39.  
cMultivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of 
postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.  
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Supplementary Table S2.3. ORs (95% CIs) of CRC by quartile of plasma DMG:betaine ratioa 
 Quartiles of DMG:betaine ratio 
P-trendb 1 (≤0.07) 2 (>0.07-0.09) 3 (>0.09-0.12) 4 (>0.12) 
n 403 430 402 433  
All participants       
       Age-adjusted  1 1.10 (0.84, 1.45) 0.96 (0.72, 1.28) 1.13 (0.85, 1.50) 0.54 
       Multivariablec  1 1.07 (0.77, 1.47) 0.89 (0.64, 1.25) 1.08 (0.76, 1.55) 0.78 
By tumor site      
Proximal       
       Age-adjusted  1 1.08 (0.75, 1.54) 0.87 (0.60, 1.27) 1.04 (0.72, 1.51) 0.98 
       Multivariablec  1 1.04 (0.68, 1.59) 0.90 (0.58, 1.38) 0.94 (0.59, 1.48) 0.67 
Distal       
       Age-adjusted  1 0.85 (0.45, 1.58) 1.02 (0.52, 1.98) 1.08 (0.57, 2.04) 0.64 
       Multivariablec  1 0.77 (0.37, 1.61) 0.78 (0.34, 1.82) 1.06 (0.45, 2.51) 0.73 
Rectal      
       Age-adjusted  1 1.38 (0.73, 2.63) 1.23 (0.65, 2.31) 1.53 (0.79, 2.94) 0.25 
       Multivariablec  1 2.01 (0.85, 4.73) 1.32 (0.56, 3.11) 2.56 (0.98, 6.64) 0.09 
By stage      
Local/regional       
       Age-adjusted  1 0.99 (0.73, 1.34) 0.94 (0.69, 1.29) 1.06 (0.78, 1.45) 0.67 
       Multivariablec  1 0.95 (0.66, 1.36) 0.88 (0.61, 1.27) 1.07 (0.72, 1.58) 0.69 
   Metastatic       
       Age-adjusted  1 1.70 (0.84, 3.42) 0.96 (0.45, 2.05) 1.78 (0.82, 3.91) 0.28 
       Multivariablec  1 1.55 (0.63, 3.82) 0.79 (0.26, 2.39) 1.48 (0.49, 4.48) 0.66 
aORs (95% CIs) of CRC were determined by conditional logistic regression.  
bMedians for each quartile used in trend test: quartile 1 = 0.06, quartile 2 = 0.08, quartile 3 = 0.10 and quartile 4 = 0.15.  
cMultivariable analyses were adjusted for age, baseline BMI, pack-years of smoking, moderate or strenuous physical activity (min/wk), use of 
postmenopausal-hormone-therapy, history of colonoscopy, RBC folate, plasma PLP, plasma vitamin B12, and plasma homocysteine.
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CHAPTER 3 
Vitamin B-12 status differs among pregnant, lactating, and control women with equivalent 
nutrient intakes* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Bae S, West AA, Yan J, Jiang X, Perry CA, Malysheva O, Stabler SP, Allen RH, Caudill MA. 
Vitamin B-12 status differs among pregnant, lactating, and control women with equivalent 
nutrient intakes. J Nutr 2015;145(7):1507-14.  
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ABSTRACT 
Background: Limited data are available from controlled studies on biomarkers of maternal 
vitamin B-12 status. 
Objective: We sought to quantify the effects of pregnancy and lactation on the vitamin B-12 
status response to a known and highly controlled vitamin B-12 intake. 
Methods: As part of a 10–12 wk feeding trial, pregnant (26–29 wk gestation; n = 26), lactating 
(5 wk postpartum; n = 28), and control (nonpregnant, nonlactating; n = 21) women consumed 
vitamin B-12 amounts of ~8.6 µg/d [mixed diet (~6 µg/d) plus a prenatalmultivitamin 
supplement (2.6 µg/d)]. Serumvitamin B-12, holotranscobalamin (bioactive form of vitamin B-
12), methylmalonic acid (MMA), and homocysteine were measured at baseline and study-end. 
Results: All participants achieved adequate vitamin B-12 status in response to the study dose. 
Compared with control women, pregnant women had lower serum vitamin B-12 (221%; P = 
0.02) at study-end, whereas lactating women had higher (P = 0.04) serum vitamin B-12 
throughout the study (+26% at study-end). Consumption of the study vitamin B-12 dose 
increased serum holotranscobalamin in all reproductive groups (+16–42%; P < 0.009). At study-
end, pregnant (vs. control) women had a higher holotranscobalamin–to–vitamin B-12 ratio (P = 
0.04) with ~30% (vs. 20%) of total vitamin B-12 in the bioactive form. Serum MMA increased 
during pregnancy (+50%; P < 0.001) but did not differ by reproductive state at study-end. 
Serum homocysteine increased in pregnant women (+15%; P = 0.009) but decreased in control 
and lactating women (-16–17%; P < 0.001). Despite these changes, pregnant women had ~20% 
lower serum homocysteine than the other 2 groups at study-end (P < 0.02). 
Conclusion: Pregnancy and lactation alter vitamin B-12 status in a manner consistent with 
enhanced vitamin B-12 supply to the child. Consumption of the study vitamin B-12 dose (~3 
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times the RDA) increased the bioactive form of vitamin B-12, suggesting that women in these 
reproductive states may benefit from vitamin B-12 intakes exceeding current recommendations. 
This trial was registered at clinicaltrials.gov as NCT01127022. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73 
 
INTRODUCTION 
Vitamin B-12, a water-soluble micronutrient, is essential for hematologic and neurologic 
processes. It serves as a cofactor in the remethylation of homocysteine to methionine and in the 
conversion of L-methylmalonyl-CoA to succinyl-CoA. The current RDA of vitamin B-12 is 2.4 
µg/d for US adults with upward adjustments to 2.6 and 2.8 µg/d during pregnancy and lactation, 
respectively (1). However, previous studies conducted in healthy adults have suggested that 
vitamin B-12 intakes greater than the current recommendations may be required to ensure 
optimal vitamin B-12 status (2–5).  
Maternal vitamin B-12 deficiency has been associated with the increased risk of adverse 
pregnancy outcomes (e.g., neural tube defects, preterm delivery, and intrauterine growth 
retardation) (6–9), indicating the importance of sufficient vitamin B-12 intake/status during 
pregnancy for optimal fetal development and growth. Maternal serum vitamin B-12 
concentrations gradually decline throughout normal pregnancy with the lowest concentration 
reached in late gestation (10–13). Although a few studies have estimated dietary and/or 
supplemental vitamin B-12 intakes during this reproductive state (11, 13), to the best of our 
knowledge, no studies have assessed vitamin B-12 status of pregnant women under controlled 
feeding conditions. 
Maternal vitamin B-12 intake/status during lactation may influence the vitamin B-12 
concentration of her milk and possibly the vitamin B-12 status of breastfed infants (14). 
However, it has also been suggested that even high doses of maternal vitamin B-12 
supplementation during lactation may not yield a significant increase in milk vitamin B-12 
concentrations, thus not affecting infant vitamin B-12 status (15). Infantile vitamin B-12 
deficiency can lead to neurologic impairments including irritability, apathy, and developmental 
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regression (16–18). Although a few studies have examined longitudinal changes in maternal 
vitamin B-12 biomarkers during lactation (14, 19–21), less is known about the impact of this 
reproductive state (compared to the nonlactating state) on vitamin B-12 status and requirement. 
The objective of the present study was to quantify the effects of pregnancy and lactation 
on vitamin B-12 status biomarkers under controlled feeding conditions. To the best of our 
knowledge, this was the first study to assess and compare vitamin B-12 status response among 
pregnant, lactating, and control (nonpregnant, nonlactating) women with equivalent vitamin B-
12 intakes. We also assessed breast milk vitamin B-12 concentration in response to a known 
vitamin B-12 dose and its associations with maternal vitamin B-12 biomarkers. 
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METHODS 
Participants and study design  
The present study was an extension of a 10–12 wk controlled feeding trial (22, 23) in 
which healthy pregnant (26–29 wk gestation; n = 26), lactating (5 wk postpartum; n = 28), and 
control (nonpregnant, nonlactating; n = 21) women, aged 21–40 y, were randomly assigned to 
choline intakes of either 480 or 930 mg/d (380-mg choline/d from diet; 100 or 550 mg/d from 
supplemental choline chloride). The study participants were recruited from Ithaca, New York, 
and surrounding areas between January 2009 and October 2010 as previously described (22, 23). 
During the screening stage, interested women completed a questionnaire on their age, 
ethnicity/race, prepregnancy weight (for pregnant and lactating women), multivitamin 
supplement use, medication use, health history, education, work status, physical activity, and 
tobacco/drug/alcohol use. Inclusion criteria for study enrollment were the following: 1) general 
healthy status as assessed by the questionnaire, blood chemistry profile, and complete blood 
count; 2) normal kidney and liver function; and 3) willingness to comply with the study protocol 
(i.e., agreement to eat >3 meals/wk at the onsite location and only consume food and beverages 
provided by the study). An additional inclusion criterion for lactating women was the intention to 
exclusively breastfeed for the duration of the study. Women were excluded if they were taking 
prescription medications known to affect liver function; if they used tobacco, recreational drugs, 
or alcohol (for pregnant and lactating women); or if they had a history of chronic disease. 
Additional exclusion criteria for pregnant women were nonsingleton pregnancy and pregnancy-
associated complications (e.g., preeclampsia or gestational diabetes) (22, 23). The study protocol 
was reviewed and approved by the Institutional Review Board for Human Study Participant Use 
at Cornell University and at Cayuga Medical Center where pregnant participants delivered their 
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babies. Written informed consent was obtained from all participants before study entry. 
 
Study diet and supplements 
Throughout the study period of 10–12 wk, all participants consumed equivalent vitamin 
B-12 amounts of ~8.6 µg/d, which is ~3–3.5 times the RDA of vitamin B-12 for adult females 
(2.4 µg/d), pregnant women (2.6 µg/d), and lactating women (2.8 µg/d) (1). The sources of 
vitamin B-12 intake were the study diet containing ~6-mg vitamin B-12/d and a daily over-the-
counter prenatal multivitamin supplement (Pregnancy Plus; Fairhaven Health LLC) labeled to 
contain 2.6-µg vitamin B-12. The vitamin B-12 content of food and beverage items in the 7-d 
rotational study menu was calculated on the basis of the USDA National Nutrient Database for 
Standard Reference (24) (Supplemental Table S3.1). 
As previously described (22, 23), the study meal provided ~2000 kcal/d and was prepared 
by study personnel in the Human Metabolic Research Unit at Cornell University. The caloric 
intake could be modified by participants with addition or subtraction of the following food items 
that did not contain vitamin B-12: unenriched white rice, snack items (i.e., chips, popcorn, rice 
cake, and apple), and beverages (i.e., soda, lemonade, and apple juice). In addition, all 
participants consumed a 200-mg DHA supplement on a daily basis (Neuromins; Nature’s Way 
Products) and a thrice-weekly potassium and magnesium supplement (General Nutrition Corp) to 
achieve nutrient intake recommendations (25, 26). Under the supervision of study personnel in 
the Human Metabolic Research Unit, pregnant and control women consumed at least one meal 
(and supplements) per day (Monday through Friday), whereas lactating women consumed one 
meal (and supplements) every other day. All other food, beverages, and supplements were 
provided as takeaways. To enhance study compliance, all participants completed a daily 
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checklist indicating that they received and consumed all menu items and supplements. In 
addition, study personnel had near-daily contact with participants throughout the study period to 
maintain positive rapport and monitor compliance. 
 
Sample collection and analytic measurements 
Blood samples were drawn at study baseline (week 0) and study-end (week 12 for 
pregnant and control participants; week 10 for lactating participants) after 10 h of fasting. The 
plasma and serum were separated and stored at -80°C until analysis as previously described (22, 
23). Twenty-four-hour urine samples were also collected at baseline and study-end and stored at 
-80°C. For each collection, the total volume of urine was recorded. Lactating women were fasted 
(10 h) for milk sample collection, which occurred on the same day as the corresponding week’s 
blood draw and consisted of the full expression of one breast 2 h after the first feed of the day. 
Upon collection, samples were processed and stored at -80°C as previously described (23). 
Serum vitamin B-12 was measured by automated chemiluminescence immunoassay with 
use of the Immulite 2000 (Siemens Medical Solutions Diagnostics); serum holotranscobalamin 
(bioactive form of vitamin B-12) was measured by the Axis-Shield Active-B12 EIA (Axis-Shield 
Diagnostics); and serum and urinary homocysteine as well as serum methylmalonic acid 
(MMA), functional indicators of vitamin B-12 status that increase upon intracellular depletion of 
vitamin B-12, were quantified by GC-MS (27, 28). Breast milk vitamin B-12 concentration was 
determined by a recently published competitive protein binding immunoassay with use of the 
Immulite 1000 (Siemens Medical Solutions Diagnostics) (29). This method yielded a small SD 
among the samples but a relatively low recovery rate (29), which may possibly underestimate 
breast milk vitamin B-12 concentrations. However, our own recovery experiments yielded a 
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mean recovery rate of ~105%, suggesting that breast milk vitamin B-12 was not underestimated 
in this study. Urinary creatinine was measured with use of the Dimension Xpand Clinical 
chemistry system (Siemens Healthcare Diagnostics) and used to normalize urinary homocysteine 
concentrations; and transcobalamin II (TCN2) C776G genotype (rs1801198), a common 
polymorphism known to influence vitamin B-12 status biomarkers (30, 31), was determined with 
use of a florescent TaqMan probe commercially available kit (Applied Biosystems). The mean 
interassay CVs of the internal laboratory control samples for each of the assays were as follows: 
serum vitamin B-12, 5%; serum holotranscobalamin, 4%; serum/urinary homocysteine, 3%; 
serum MMA, 7%; breast milk vitamin B-12, 4%; and urinary creatinine, 5%. 
 
Statistical analysis 
Baseline characteristics of the reproductive groups (i.e., pregnant, lactating, and control 
women) were compared with use of 1) one-factor ANOVA for normally distributed continuous 
variables; 2) nonparametric Kruskal-Wallis tests for non-normally distributed continuous 
variables; or 3) chi-square tests for categorical variables. When significant differences were 
observed, Bonferroni corrections were made for post hoc comparisons 
To test the effect of reproductive states on vitamin B-12 status biomarkers and to assess 
vitamin B-12 status response through time, linear mixed models were used. Data that deviated 
from the normal distribution or homogeneity of variance (i.e., all serum/urinary vitamin B-12 
biomarkers and breast milk vitamin B-12) were natural log transformed and used in the models. 
In addition to serum vitamin B-12 and holotranscobalamin, their ratio (i.e., holotranscobalamin–
to–vitamin B-12) was included in the models (after log transformation) as an additional vitamin 
B-12 status indicator because this ratio (vs. individual metabolite alone) is suggested to better 
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reflect the tissue availability of circulating vitamin B-12 (32). Reproductive states (pregnant, 
lactating, or control), time (baseline or study-end), and the interaction of reproductive state and 
time (reproductive state x time) were entered as fixed factors, and participant identification was 
entered as a random factor. In the initial models, choline intake (480 or 930 mg/d) and potential 
confounding factors including age, ethnicity/race, baseline BMI (or prepregnant BMI for 
pregnant and lactating women), multivitamin supplement use before entering the study, and 
TCN2 C776G genotype were included; nonsignificant variables (P > 0.10) were then removed in 
a stepwise manner until final models were derived. Specifically, BMI (P < 0.001), multivitamin 
supplement use (P = 0.04), choline intake (P = 0.04), and TCN2 C776G genotype (P = 0.09) 
were retained in the final models of serum vitamin B-12, serum holotranscobalamin, serum 
MMA, and urinary homocysteine (normalized to urinary creatinine), respectively. Ethnicity/race 
(P = 0.09) and TCN2 C776G genotype (P = 0.10) were also retained in the analysis of breast 
milk vitamin B-12. For other vitamin B-12 biomarkers (i.e., the holotranscobalamin–to–vitamin 
B-12 ratio and serum homocysteine), none of the covariates were included in final models. The 
analyses were then followed by post hoc contrasts (Bonferroni correction) to 1) compare vitamin 
B-12 status among reproductive groups at study-end, and 2) assess vitamin B-12 status changes 
from baseline to study-end within each reproductive group. Correlations between breast milk 
vitamin B-12 and circulating biomarkers of vitamin B-12 were also examined among the 
lactating women with use of Pearson’s correlation analysis (with log-transformed variables). 
Finally, to assess vitamin B-12 deficiency among study participants, the following cutoff values 
were used (33–36): serum vitamin B-12 <148 pmol/L; serum holotranscobalamin <35 pmol/L; 
serum MMA >271 nmol/L; and serum homocysteine >12 mmol/L. All statistical tests were two-
sided, and significance was defined as P < 0.05. Analyses were performed with IBM SPSS 
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Statistics (version 20). 
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RESULTS 
Characteristics of study participants 
Baseline demographic and biochemical characteristics of pregnant, lactating, and control 
participants are shown in Table 3.1. No statistically significant differences were detected in age, 
ethnicity/race, BMI, and the distribution of TCN2 C776G genotype among reproductive groups. 
However, the percentage of multivitamin supplement use before study enrollment differed (P = 
0.001) among reproductive groups with a higher percentage in pregnant and lactating women 
compared with control women.  
 At baseline, serum vitamin B-12 differed among reproductive groups (P < 0.001) with 
higher serum vitamin B-12 in lactating women than in control (+40%; P < 0.001) and pregnant 
(+45%; P < 0.001) women (Table 3.1). Serum holotranscobalamin concentrations also differed 
among reproductive groups (P = 0.001) with higher holotranscobalamin in lactating women than 
in control women (+57%; P = 0.001). In addition, serum MMA and homocysteine differed 
among reproductive groups (P < 0.001) with lower MMA and homocysteine concentrations in 
pregnant women than in control women (-25% and -44%, respectively; P < 0.02) and lactating 
women (-32% and -40%, respectively; P < 0.001). Lastly, urinary homocysteine differed among 
reproductive groups (P < 0.001) with higher excretion in pregnant women than in control (+33%; 
P = 0.04) and lactating (+94%; P < 0.001) women. Compared with control women, lactating 
women had lower urinary homocysteine (-31%; P = 0.006). 
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Table 3.1. Baseline characteristics of pregnant, lactating and control participants1 
 Pregnant (n=26) Lactating (n=28) Control (n=21) P-value 
Age, y 28 ± 3 29 ± 5 29 ± 5 0.82 
Ethnicity/race, %    0.74 
   Non-Hispanic White 61.5 71 67  
   Other2 38.5 29 33  
Baseline or prepregnancy BMI, kg/m2 23 [21-26] 25 [21-31] 24 [21-25] 0.46 
TCN2 C776G genotype (rs1801198), %     
   CC/CG/GG 57/38/5 35/46/19 26/52/22 0.20 
Multivitamin supplement use before study entry, % yes 85a 75a 33b 0.001 
Serum vitamin B-12, pmol/L 320 (288-356)b 463 (419-511)a 330 (290-376)b <0.001 
Serum holotranscobalamin, pmol/L 76 (66-89)a,b 96 (82-111)a 61 (50-73)b 0.001 
Holotranscobalamin-to-vitamin B-12 ratio 0.24 (0.21-0.27) 0.21 (0.18-0.24) 0.19 (0.16-0.22) 0.10 
Serum MMA, nmol/L 134 (116-154)b 198 (173-227)a 179 (153-209)a <0.001 
Serum homocysteine, µmol/L 3.7 (3.4-4.0)b 6.2 (5.8-6.7)a 6.6 (6.0-7.1)a <0.001 
Urinary homocysteine, µg/mg creatinine 0.60 (0.52-0.70)a 0.31 (0.27-0.36)c 0.45 (0.38-0.53)b <0.001 
1Values are means ± SDs, medians [IQRs], or geometric means (95% CIs), unless otherwise indicated. Differences between reproductive groups 
were analyzed by one-way ANOVA for normally distributed continuous variables (i.e., age and natural log-transformed vitamin B-12 biomarkers); 
Kruskal-Wallis tests for non-normally distributed continuous variable (i.e., BMI); and chi-square tests for categorical variables (i.e., ethnicity, 
multivitamin supplement use and TCN2 C776G genotype). Labeled values in a row without a common letter differ, P<0.05. Because of limited 
sample volume, serum vitamin B-12 was only measured in 24 pregnant, 27 lactating and 16 control women, and serum holotranscobalamin in all 
pregnant, 27 lactating and 18 control women. MMA, methylmalonic acid; TCN2, transcobalamin II. 
2African American, Hispanic, Asian or other. 
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Vitamin B-12 status by reproductive state and its response through time 
Serum vitamin B-12 concentration. Throughout the study, all participants had serumvitamin B-
12 concentrations >148 pmol/L, indicating vitamin B-12 sufficiency of our study cohort. After 
covariate adjustment, reproductive state interacted with time (P = 0.02) to influence serum 
vitamin B-12 concentrations. Specifically, the concentration of serum vitamin B-12 did not 
change from baseline to study-end among pregnant and lactating women (P = 1.0), whereas it 
increased (P = 0.009) by ~23% among control women (Figure 3.1A). At study-end, lactating 
women had 26% higher serum vitamin B-12 than control women (P = 0.04) and 60% higher 
serum vitamin B-12 than pregnant women (P < 0.001). Although baseline serum vitamin B-12 
did not differ between pregnant and control women, its concentration at study-end was 21% 
lower in pregnant (vs. control) women (P = 0.02). 
Serum holotranscobalamin concentration. At baseline, serum holotranscobalamin concentrations 
of 1 pregnant woman and 2 control women were <35 pmol/L (range: 31.5–33.6 pmol/L). 
However, at study-end, serum holotranscobalamin concentrations among all participants were 
greater than this cutoff value. In covariate-adjusted analysis, reproductive state interacted with 
time (P = 0.004) to influence serum holotranscobalamin concentrations. Specifically, serum 
holotranscobalamin increased from baseline to study-end by ~19% among pregnant women (P < 
0.001), 16% among lactating women (P = 0.009), and 42% among control women (P < 0.001) 
(Figure 3.1B). Although the baseline serum holotranscobalamin was greater in lactating than in 
control women (P = 0.04), its concentration at study-end did not differ by reproductive state (P > 
0.44). 
Ratio of serum holotranscobalamin to vitamin B-12. Reproductive state and time did not interact 
(P = 0.51) to influence the holotranscobalamin–to–vitamin B-12 ratio. Although the baseline 
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holotranscobalamin–to–vitamin B-12 ratio did not differ by reproductive state, its ratio at study-
end was significantly higher in pregnant women than in control women (+33%; P = 0.04) 
(Figure 3.1C). No differences were observed between lactating and control women nor between 
lactating and pregnant women (P > 0.26).  
Serum MMA concentration. At baseline, serum MMA concentrations of 1 pregnant, 6 lactating, 
and 2 control women were >271 nmol/L (range: 277–451 nmol/L), whereas at study-end, those 
of 1 pregnant and 2 control women exceeded this cutoff value (range: 281–347 nmol/L). After 
covariate adjustment, we observed a significant interaction (P < 0.001) between reproductive 
state and time to influence serum MMA concentrations. Specifically, serum MMA increased 
from baseline to study-end by ~50% among pregnant women (P < 0.001), but no changes were 
observed among control and lactating women (P > 0.13) (Figure 3.1D). Although the baseline 
serum MMA was lower in pregnant women than in control and lactating women (P < 0.001), its 
concentration at study-end did not differ by reproductive state (P = 1.0). 
Serum homocysteine concentration. Throughout the study, serum homocysteine concentrations 
among all participants were <12 µmol/L, indicating vitamin B-12 sufficiency of our study 
cohort. Similar to serum MMA, there was a significant interaction (P < 0.001) between 
reproductive state and time in relation to serum homocysteine concentrations. Specifically, 
serum homocysteine increased from baseline to study-end by ~15% among pregnant women (P 
= 0.009), but decreased by 16% among control women (P < 0.001) and 17% among lactating 
women (P < 0.001) (Figure 3.1E). Despite these changes, pregnant women had lower serum 
homocysteine than control (-22%; P < 0.001) and lactating (-17%; P = 0.02) women at study-
end. No differences were observed between lactating and control women (P = 1.0). 
Urinary homocysteine concentration. After covariate adjustment, reproductive state tended to 
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interact (P = 0.08) with time to influence urinary homocysteine excretion. Specifically, urinary 
homocysteine increased from baseline to study-end by ~29% among pregnant women (P = 
0.045), whereas no changes were observed among lactating and control women (P = 1.0) 
(Figure 3.1F). At study-end, pregnant women excreted 75% more homocysteine than control 
women (P < 0.001) and 124% more homocysteine than lactating women (P < 0.001). Although 
the baseline urinary homocysteine excretion was lower in lactating women than in control 
women (P = 0.009), its excretion at study-end did not differ between the 2 groups (P = 0.39). 
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Figure 3.1. Biomarkers of vitamin B-12 status in pregnant, lactating, and control women with 
equivalent vitamin B-12 intakes under controlled feeding conditions. All analyses were 
performed with use of linear mixed models; values are geometric means and 95% CIs. (A) 
Serum vitamin B-12; (B) serum holotranscobalamin; (C) the holotranscobalamin–to–vitamin B-
12 ratio; (D) serum MMA; (E) serum homocysteine; and (F) urinary homocysteine. The study-
end reflects week 12 for pregnant (n = 26) and control (n = 21) women and week 10 for lactating 
women (n = 28); because of limited sample volume, serum vitamin B-12 was only measured in 
24 pregnant, 27 lactating, and 16 control women, and serum holotranscobalamin in all pregnant, 
27 lactating, and 18 control women. Labeled endpoint means without a common letter differ, P < 
0.05. *Different from baseline, P < 0.05 within a designated reproductive group. holoTC, 
holotranscobalamin; MMA, methylmalonic acid. 
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Correlations between breast milk vitamin B-12 and maternal biomarkers of vitamin B-12 status 
The vitamin B-12 concentration of breast milk did not change (P = 0.46) from baseline 
[geometric mean (95% CI): 318 (227, 447) pmol/L] to study-end [298 (213, 419) pmol/L]. At 
baseline, there were significant, but modest, positive correlations of breast milk vitamin B-12 
with maternal serum vitamin B-12 (r = 0.48, P = 0.01; Figure 3.2A) and holotranscobalamin (r = 
0.42, P = 0.03; Figure 3.2B). Breast milk vitamin B-12 also tended to inversely correlate with 
maternal serum homocysteine (r = 20.34, P = 0.08; Figure 3.2C). Other than these findings, no 
statistically significant correlations were observed between maternal vitamin B-12 indicators 
(i.e., holotranscobalamin–to–vitamin B-12 ratio, serum MMA, and serum/urinary homocysteine) 
and breast milk vitamin B-12. At study-end, the positive correlation of breast milk vitamin B-12 
remained significant with serum holotranscobalamin (r = 0.40, P = 0.04; Figure 3.2D), but not 
with serum vitamin B-12 concentrations (r = 0.18, P = 0.36).  
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Figure 3.2. Correlations between women’s breast milk vitamin B-12 and serum vitamin B-12 
(A), holotranscobalamin (B), and homocysteine (C) at baseline and between breast milk vitamin 
B-12 and serum holotranscobalamin at endpoint (D). All data were natural log (ln) transformed 
and analyzed by Pearson’s correlation analysis (n = 28); because of limited sample volume, 
serum vitamin B-12 and holotranscobalamin were only measured in 27 lactating women. Hcy, 
homocysteine; holoTC, holotranscobalamin.  
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DISCUSSION 
To the best of our knowledge, this is the first controlled feeding study to assess the 
effects of reproductive status (i.e., pregnancy and lactation) on biomarkers of vitamin B-12. The 
following 2 main findings emerged: 1) reproductive state was associated with altered biomarkers 
of vitamin B-12 status, and 2) pregnant and lactating women may benefit from vitamin B-12 
intakes exceeding current recommendations. 
Third trimester pregnant women had significantly lower (~21%) serum vitamin B-12 than 
control women at study-end despite equivalent vitamin B-12 intakes. This reduction, as 
suggested by other studies (10, 13, 37, 38), may be attributable to normal physiologic 
consequences of pregnancy including hemodilution, hormonal changes, and/or vitamin B-12 
transfer from mother to fetus. For example, throughout pregnancy, maternal plasma volume 
expands an average of 45% to meet the increased circulatory needs of maternal and fetal organs 
(39). This in turn can dilute serum vitamin B-12 concentrations among pregnant women and 
contribute to their lower vitamin B-12 concentrations. Notably, the concentration of serum 
holotranscobalamin did not differ between pregnant and control women, suggesting that greater 
amounts of vitamin B-12 are partitioned toward the biologically active form (i.e., 
holotranscobalamin) in this reproductive state. Indeed, compared with control women, pregnant 
women had a significantly higher holotranscobalamin– to–vitamin B-12 ratio at study-end, with 
a greater proportion of serum vitamin B-12 (i.e., ~30% vs. 20%) bound to transcobalamin. This 
metabolic alteration would be expected to augment the supply of vitamin B-12 to the fetus (40). 
Alternatively, but less likely, higher maternal holotranscobalamin concentrations may suggest 
impaired or limited placental uptake of holotranscobalamin. 
Lactation was also found to alter vitamin B-12 status with significantly higher total serum 
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vitamin B-12 observed among lactating (vs. control) women throughout the study period. Given 
that serum holotranscobalamin did not differ between the 2 groups at study-end and that the 
vitamin B-12 bound to haptocorrin can be approximated by subtracting holotranscobalamin from 
vitamin B-12 concentrations (41), these data imply that lactating (vs. control) women maintain 
higher circulating vitamin B-12 in the form bound to haptocorrin. Although the physiologic role 
of vitamin B-12–haptocorrin complex is not fully understood, it may serve as a circulating 
storage form of vitamin B-12, which would be expected to attenuate loss of free vitamin B-12 
(42, 43). However, given that haptocorrin is not taken up by the mammary epithelium (44), 
redistribution of vitamin B-12 from haptocorrin to transcobalamin may occur in the circulation 
and/or liver (a major storage site for vitamin B-12) when holotranscobalamin supply is 
insufficient. Additional studies are required to confirm these findings by directly measuring 
concentrations of vitamin B-12 bound to haptocorrin and to provide mechanistic insights into 
this metabolic adaptation. 
Over the course of the study, serum MMA concentrations increased significantly in 
pregnant women but not in control and lactating women. Despite this pregnancy-induced 
increase, serum MMA did not differ among reproductive groups at study-end. Moreover, the 
increased serum MMA during pregnancy did not appear to indicate functional vitamin B-12 
depletion because the mean serum MMA concentration remained <271 nmol/L (34). Previous 
reports (45, 46) have also suggested that an increase in serum or urinary MMA may not reflect 
low vitamin B-12 status during normal pregnancy. As such, serum MMA may not be a reliable 
biomarker of vitamin B-12 status among pregnant women. 
In accordance with previous results (47–49), the concentration of serum homocysteine 
was lower among pregnant (vs. control) women throughout the study period. The present study 
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also reports, for the first time to our knowledge, that pregnant women excreted ~75% more 
urinary homocysteine than control women and ~124% more homocysteine than lactating women 
under equivalent vitamin B-12 intakes. Given that none of the reproductive groups were vitamin 
B-12 deficient, lower serum homocysteine and higher urinary homocysteine concentrations 
among pregnant women may arise in part from pregnancy-induced physiologic changes 
including hemodilution and higher glomerular filtration rate. Indeed, the concentrations of other 
relevant metabolites (e.g., cysteine and methionine) were lower in serum and higher in urine 
during pregnancy (data not shown), further supporting this hypothesis. 
 The mean daily consumption of ~8.6 µg vitamin B-12 (which was supplied through a 
mixed diet containing ~6 µg/d and a prenatal multivitamin supplement labeled to contain 2.6 
µg/d) provided a vitamin B-12 intake ~3 times the RDA for pregnant women (2.6 µg/d) and 
lactating women (2.8 µg/d) (1). This amount of vitamin B-12 intake achieved adequate vitamin 
B-12 status among all reproductive groups, as indicated by biomarker concentrations that were 
above (serum vitamin B-12 and holotranscobalamin) or below (serum MMA and homocysteine) 
cutoff values. However, the mean concentration of serum vitamin B-12 among pregnant women 
(i.e., ~311 pmol/L) fell within the low- to mid-range of normal (i.e., 148–664 pmol/L) (50), 
suggesting that vitamin B-12 intakes approximating the RDA of 2.6 µg/d may not ensure 
acceptable vitamin B-12 status throughout this reproductive state. 
Consumption of the study vitamin B-12 dose also yielded a significant increase in serum 
holotranscobalamin concentrations among all reproductive groups, which would enhance tissue 
access to this bioactive form. However, breast milk vitamin B-12 concentration did not change 
among lactating women in response to the study vitamin B-12 dose, despite a positive correlation 
between maternal serum holotranscobalamin (but not total serum vitamin B-12) and breast milk 
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vitamin B-12 both at baseline and study-end. Additional studies with multiple time points and 
methodology that enables measurements of the various forms of vitamin B-12 in breast milk are 
required to more fully understand the relation between maternal vitamin B-12 indicators and 
milk vitamin B-12 concentration. 
The present study has 2 main limitations. First, no comparable group with a lower 
vitamin B-12 intake (e.g., the vitamin B-12 RDAs) was included in this study. Thus, additional 
doseresponse studies are needed to further assess the adequacy of the vitamin B-12 RDA during 
pregnancy and lactation. Second, the small sample size of the reproductive groups in this feeding 
study could limit detection of subtle differences between groups and across time. 
In conclusion, metabolic adaptations that increase vitamin B-12 supply to the child occur 
during pregnancy and lactation. Consumption of the study vitamin B-12 dose (~3 times the RDA 
for pregnant and lactating women) improved circulating concentrations of the bioactive form of 
this essential nutrient, suggesting that women in these reproductive states may benefit from 
vitamin B-12 intakes exceeding current recommendations. 
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Supplemental Table S3.1. Estimated vitamin B-12 content of foods in seven-day rotational menu consumed by pregnant, lactating and 
control women for 10-12 weeks1-3 
Day 
Estimated daily 
vitamin B-12 
content, µg/d 
Breakfast Lunch Dinner 
Monday 7.8 2 eggs, scrambled (50g each) Pesto sandwich: Beef & Cheese tacos: 
  
 
2 slices whole wheat toast (28g 
each) 
   2 slices whole wheat bread    
   (28g each) 
   3 Corn tortillas (33g each) 
   1 peach fruit cup (133g)    Pesto (15g)    Ground beef (105g) 
   Juice    Swiss Cheese (42g)    Cheddar cheese (30g) 
       Romaine lettuce (20g)    Iceberg lettuce (20g) 
    Celery sticks (30g) Melon (112g) 
    Carrot sticks (30g) Milk (284g) 
Tuesday 9.0 Waffle (130g) Tuna sandwich: Spaghetti: 
  
 1 egg, hard-boiled (50g) 
   2 slices whole wheat bread    
   (28g each) 
   Cooked pasta (220g) 
   Juice    Tuna, canned (56g)    Tomato sauce (220g) 
       Cheddar Cheese (30g)    Mushrooms (30g) 
       Iceberg lettuce (30g)    Parmesan cheese (10g) 
       Mayonnaise (15g)    Mozzarella cheese (25g) 
    Grapes (100g) Milk (284g) 
Wednesday 4.8 Fitness crunch cereal (80g) Pastrami sandwich: Vegetarian pizza: 
  
 Milk (284g) 
   2 slices whole wheat bread    
   (28g each) 
   Dough (200g) 
   1 box of raisins (42g)    Pastrami (24g)    Tomato sauce (112g) 
   1 banana (118g)    Swiss cheese (23g)    Red peppers, jarred (60g) 
   Juice    Romaine lettuce (30g)    Mushrooms (30g) 
    Cucumber (80g)    Spinach (20g) 
        Mozzarella cheese (50g) 
     Apple sauce (28g) 
 
   Milk (284g) 
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Supplemental Table S3.1 (Continued)1-3 
Thursday 5.6 2 pancakes (100g each) Egg salad sandwich: Beef & broccoli stir-fry: 
 
 Blueberries, frozen (50g) 
   2 slices whole wheat bread  
   (28g each) 
   Beef (160g) 
   Juice    1 egg, hard-boiled (50g)    Broccoli, frozen (110g) 
       Mayonnaise (20g)    Rice (200g) 
       Romaine lettuce (45g)    Onions, frozen (13g) 
    Celery sticks (30g) Melon (112g) 
    Carrot sticks (30g) Milk (284g) 
Friday 4.9 1 whole wheat bagel (95g) Bean Burrito: Lasagna: 
  
 1 orange fruit cup (133g)    Black beans, canned (40g) 
   2 whole wheat lasagna  
   noodles, dry (23g each) 
   Juice    Cheddar cheese (30g)    Tomato sauce (150g) 
       Rice (30g)    Ground beef (60g) 
  
  
   1 large whole wheat tortilla  
   (59g) 
   Cottage cheese (40g) 
        Mozzarella cheese (10g) 
        Parmesan cheese (10g) 
        Summer squash (40g) 
       Zucchini (40g) 
     Milk (284g) 
Saturday 4.3 
2 raspberry muffins  
(60g each) 
Turkey Sandwich: Chicken Quesadilla: 
  
 1 banana (118g) 
   2 slices whole wheat bread    
   (28g each) 
   Chicken (65g) 
  
 Juice    Turkey (25g) 
   2 large whole wheat  
   tortillas(59g each) 
       Provolone cheese (23g)    Cheddar cheese (150g) 
       Iceberg lettuce (20g)    Corn, frozen (100g) 
    Cucumber (80g) Milk (284g) 
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Supplemental Table S3.1 (Continued)1-3 
Day 
Estimated daily 
vitamin B-12 
content, 
µg/d 
Breakfast Lunch Dinner 
Sunday 5.9 Oat granola cereal (80g) Vegetable soup (396 g) Goulash: 
   Milk (284g) Corn muffin (60g)    Cooked pasta (200g) 
  1 box of raisins (42g) Grapes (100g)    Beef (120g) 
   1 peach fruit cup (133g)     Onion, frozen (30g) 
   Juice     Red peppers, jarred (30g) 
        Tomatoes, canned (50g) 
        Tomato puree (100g) 
        Potatoes, canned (35g) 
 
   Pineapple, canned (70g) 
     Milk (284g) 
1The vitamin B-12 content of the foods and beverages were estimated based on the US Department of Agriculture National Nutrient Database for 
Standard Reference, Release 22. 
2Snacks including 170 g yogurt (vanilla, raspberry, or peach flavored) and 156 g V8 juice (Campbell Soup Company) were provided daily and 
contained 0.85 μg vitamin B-12 (which was added to the final vitamin B-12 content for each day).  
3Juice choices included apple, cranberry-grape, or cranberry juice which did not contain vitamin B-12. 
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CHAPTER 4 
Alcohol dehydrogenase 5 is a source of formate for de novo purine biosynthesis in HepG2 Cells* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Bae S, Chon J, Field MS, Stover PJ. Alcohol dehydrogenase 5 is a source of formate for de 
novo purine biosynthesis in HepG2 cells. J Nutr 2017;147:1-7.  
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ABSTRACT 
Background: Formate provides one-carbon units for de novo purine and thymidylate (dTMP) 
synthesis and is produced via both folate-dependent and folate-independent pathways. Folate-
independent pathways are mediated by cytosolic alcohol dehydrogenase 5 (ADH5) and 
mitochondrial aldehyde dehydrogenase 2 (ALDH2), which generate formate by oxidizing 
formaldehyde. Formate is a potential biomarker of B-vitamin–dependent one-carbon 
metabolism. 
Objective: This study investigated the contributions of ADH5 and ALDH2 to formate 
production and folate-dependent de novo purine and dTMP synthesis in HepG2 cells. 
Methods: ADH5 knockout and ALDH2 knockdown HepG2 cells were cultured in folate-
deficient [0 nM (6S) 5-formyltetrahydrofolate] or folate-sufficient [25 nM (6S) 5 
formyltetrahydrofolate] medium. Purine biosynthesis was quantified as the ratio of [14C]-formate 
to [3H]-hypoxanthine incorporated into genomic DNA, which indicates the contribution of the de 
novo purine synthesis pathway relative to salvage synthesis. dTMP synthesis was quantified as 
the ratio of [14C]-deoxyuridine to [3H]-thymidine incorporation into genomic DNA, which 
indicates the capacity of de novo dTMP synthesis relative to salvage synthesis. 
Results: The [14C]-formate-to-[3H]-hypoxanthine ratio was greater in ADH5 knockout than in 
wild-type HepG2 cells, under conditions of both folate deficiency (+30%; P < 0.001) and folate 
sufficiency (+22%; P = 0.02). These data indicate that ADH5 deficiency increases the use of 
exogenous formate for de novo purine biosynthesis. The [14C]-deoxyuridine-to-[3H]-thymidine 
ratio did not differ between ADH5 knockout and wild-type cells, indicating that ADH5 
deficiency does not affect de novo dTMP synthesis capacity relative to salvage synthesis. Under 
folate deficiency, ALDH2 knockdown cells exhibited a 37% lower ratio of [14C]-formate to [3H]-
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hypoxanthine (P < 0.001) compared with wild-type HepG2 cells, indicating decreased use of 
exogenous formate, or increased endogenous formate synthesis, for de novo purine biosynthesis. 
Conclusion: In HepG2 cells, ADH5 is a source of formate for de novo purine biosynthesis, 
especially during folate deficiency when folate-dependent formate production is limited. Formate 
is also shown to be limiting in the growth of HepG2 cells. 
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INTRODUCTION 
Folate, an essential B-vitamin, serves as a cofactor in the form of tetrahydrofolate (THF) 
polyglutamates to carry and activate one-carbon units for the de novo synthesis of purines and 
thymidylate (dTMP) and for the remethylation of homocysteine to methionine (Figure 4.1) (1). 
Disruptions in folate-mediated one-carbon metabolism (FOCM), which can arise from 
insufficient intake of folate and other nutrients (e.g., choline and vitamins B-12 and B-6) and/or 
genetic variants, have been linked to a higher risk of cancer, neurodegenerative diseases, and 
developmental anomalies (1).  
FOCM occurs in the cytosol, mitochondria, and nucleus, all of which are interrelated 
through the exchange of one-carbon units from formate, serine, and glycine (2). Mitochondrial 
one-carbon metabolism plays a role in the generation of formate from the catabolism of serine, 
glycine, dimethylglycine, and sarcosine (Figure 4.1). Mitochondria-derived formate then enters 
the cytosol or nucleus and is incorporated into 10-formylTHF, which provides the C2 and C8 
carbon for de novo purine biosynthesis. Alternatively, cytosolic 10-formylTHF may be reduced 
to 5,10-methyleneTHF, which can be used for de novo dTMP synthesis or irreversibly reduced to 
5-methylTHF for homocysteine remethylation to methionine (Figure 4.1). Therefore, formate is 
an intermediate metabolite essential for one-carbon metabolism, its utilization and mitochondrial 
production are linked to folate status, and hence formate concentrations in serum have the 
potential to serve as a biomarker of folate status (3). Folate is essential both for formate synthesis 
and to sequester formate within the cell, because previous studies have reported increased plasma 
and urinary formate and decreased rates of formate production in rats and mice fed a folate-
deficient diet compared with those fed a folate-replete diet (4–6). 
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Figure 4.1. Cytosolic and mitochondrial folate-mediated one-carbon metabolism and formate generation by ADH5 and ALDH2. ADH5, alcohol 
dehydrogenase 5; ALDH2, aldehyde dehydrogenase 2; DHF, dihydrofolate; DMG, dimethylglycine; dTMP, thymidylate; dUMP, deoxyuridine 
monophosphate; GSH, reduced glutathione; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate. 
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In addition to formate synthesis through the folate-dependent mitochondrial pathways, 
formate can be produced through folate-independent pathways, one of which involves the 
oxidation of formaldehyde to formate (3). This can occur via the reaction mediated by the 
cytosolic glutathione and NAD+-dependent enzyme alcohol dehydrogenase 5 [ADH5, class III 
(alternative abbreviation, ADH3); also known as formaldehyde dehydrogenase]. Specifically, 
ADH5 oxidizes S-hydroxymethylglutathione, a molecule formed spontaneously from 
formaldehyde and glutathione, to S-formylglutathionine, which is further converted to formate 
(Figure 4.1) (7). Formaldehyde can also be oxidized to formate by a mitochondrial NAD+-
dependent aldehyde dehydrogenase class II (ALDH2; Figure 4.1) (8). ALDH2 and ADH5 are 
ubiquitously expressed in various tissues, including liver, kidney, and brain, and are most 
abundant in the liver (9–12). 
Although there has been increasing interest in the role of mitochondria-derived formate in 
the functioning of FOCM and as a biomarker of nutrient status, very little is known about the 
contribution of folate-independent sources of formate to one-carbon metabolism. The objective 
of the current study was to investigate the effects of ADH5 and ALDH2 activity on de novo 
purine and dTMP biosynthesis by inhibiting ADH5 or ALDH2 expression in human 
hepatocarcinoma (HepG2) cells. 
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METHODS 
Cell culture. HepG2 cells were maintained in DMEM (Corning) with 10% (vol:vol) FBS 
(HyClone), 1% penicillin/streptomycin (Corning), and 4 mM L-glutamine (Corning) at 37°C and 
5% CO2. For all experiments, modified DMEM lacking glycine, serine, methionine, folate, 
choline, and all nucleosides/nucleotides was used with 10% dialyzed and charcoal-treated FBS, 
1% penicillin/streptomycin, and 4 mM L-glutamine. 
Generation of ADH5 knockout HepG2 cells by CRISPR/Cas9. The CRISPR single guide RNA 
(5’-TGAACATGGCGAACGAGGTA-3’) targeting exon 1 of human ADH5 (NM_000671) was 
cloned into the pSpCas9(BB)-2A-Puro CRISPR/Cas9 vector as previously described (13). Cells 
were transfected for 48 h by using the FuGene 6 transfection reagent (Promega) following the 
manufacturer’s instructions. The transfected cells were selected in the presence of 2 µg 
puromycin/mL (RPI). The efficiency of ADH5 knockout was verified by immunoblotting. 
Gene knockdown by small interfering RNA transfection. Cells were transfected with either 
negative control small interfering RNA (siRNA; Qiagen) or FlexiTube GeneSolution (GS217) 
siRNA for ALDH2 (Qiagen) by using Lipofectamine RNAiMAX (Life Technologies) according 
to the manufacturer’s instructions. Cells were harvested 72 h after transfection. The efficiency of 
ALDH2 knockdown was verified by immunoblotting. 
Cellular total folate measurement. Total folate concentrations in cells were quantified by using a 
Lactobacillus casei microbiological assay as previously described (14). 
Immunoblotting. Cellular proteins were extracted and quantified as previously described (15). 
Proteins were resolved on 4–15% (vol:vol) gradient SDS-PAGE gels (Bio-Rad) and transferred 
to Immobilon-P PVDF membrane (Millipore). The membrane was blocked for 1 h at room 
temperature in 5% BSA in PBS with 0.2% Tween. Primary antibodies were diluted in 5% BSA 
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in PBS with 0.2% Tween and incubated overnight at 4°C. Secondary antibodies were diluted in 
5% nonfat dry milk in PBS with 1% Nonidet P-40 (US Biologicals) and added to the membrane 
for 1 h at room temperature. ADH5 and ALDH2 were detected with a 1:1000 rabbit anti-ADH5 
antibody and a 1:2000 rabbit anti-ALDH2 antibody, respectively (Proteintech Group), followed 
by a 1:5000 dilution of HRP-conjugated donkey anti-rabbit secondary antibody (Pierce). As 
loading controls, 1:1000 mouse anti-α-Tubulin antibody (Active Motif) and a 1:3000 mouse anti-
α-Calpain antibody (Affinity BioReagents) were used followed by a 1:5000 dilution of HRP-
conjugated goat anti-mouse secondary antibody (Pierce). The membrane was visualized by 
autoradiography after the addition of SuperSignal West Pico Chemiluminescent Substrate 
(Pierce). 
Purine biosynthesis assay. Cells were seeded on 100-mm plates in modified DMEM lacking 
glycine, serine, and all nucleosides/nucleotides but supplemented with 200 µM methionine and 
30 µM choline, with 25 nM (6S) 5-formylTHF (folate sufficiency) or without (6S) 5-formylTHF 
(folate deficiency). After 2 doublings, cells were plated in triplicate on 6-well plates and allowed 
to grow for another doubling in the same media but supplemented with 10 µM [14C]-formate and 
1 nM [3H]-hypoxanthine (Moravek Biochemicals). Cells were harvested, and genomic DNA was 
isolated by using a High Pure PCR template preparation kit (Roche) with RNase A treatment 
according to the manufacturer’s instructions. Isotope incorporation into genomic DNA was 
quantified by using a Beckman LS6500 scintillation counter in dual disintegrations/minute mode 
(16). Data are shown as the ratio of [14C]-formate to [3H]-hypoxanthine, which indicates the 
incorporation of formate into DNA via the folate-dependent de novo purine synthesis pathway 
relative to the incorporation of hypoxanthine into DNAvia the folate-independent purine salvage 
pathway. 
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dTMP biosynthesis assay. Cells were plated and grown in modified DMEM lacking glycine, 
serine, and all nucleosides/nucleotides but supplemented with 200 µM methionine and 30 µM 
choline, with 25 nM (6S) 5-formylTHF (folate sufficiency) or without (6S) 5-formylTHF (folate 
deficiency). After 2 doublings, cells were plated in triplicate on 6-well plates and allowed to 
grow for another doubling in the same media but supplemented with 2 µM [14C]-deoxyuridine 
and 25 nM [3H]-thymidine (American Radiolabeled Chemicals). [14C]-Deoxyuridine is 
incorporated into DNA via the folate-dependent de novo pathway, whereas [3H]-thymidine is 
incorporated into DNA via the salvage pathway. Total genomic DNA was isolated from the 
harvested cells, and the isotope incorporation was quantified as described above. Data are shown 
as the ratio of [14C]-deoxyuridine to [3H]-thymidine (17). 
Cell growth assay. Cell proliferation was determined by using a colorimetric MTT [3-(4,5)-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (18). Cells were plated in 96-well 
plates and grown in modified DMEM lacking glycine, serine, and all nucleosides/nucleotides but 
supplemented with 200 µM methionine, 30 µM choline, and 25 nM (6S) 5-formylTHF. The 
effect of formate supplementation on cell proliferation was determined by using the same media 
further supplemented with either 30 µM or 90 µM sodium formate. From 24 to <72 h, cell 
growth was measured by adding 20 µL of 2.5 g MTT reagent/L to each well followed by 4 h of 
incubation at 37°C in 5% CO2. The insoluble formazan product was resuspended in 100 µL 
DMSO, and A570 was measured on a microplate reader (Epoch; BioTek).  
Statistical analysis. Histograms and scatterplots of the residuals were used to assess normality 
and variance homogeneity. The effects of gene expression (wild-type compared with ADH5 
knockout or wild-type compared with ALDH2 knockdown) were assessed by using t tests. To 
examine the effects of gene expression and folate status as well as their interaction, a 2-factor 
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ANOVA was used with post hoc Bonferroni corrections. Linear mixed models with Bonferroni 
corrections were used to assess the effect of gene expression on cell growth over time. Data are 
shown as means ± SDs of 3–5 biological replicates per condition. All statistical tests were 
performed with IBM SPSS Statistics (version 20), and significance was defined as P < 0.05. 
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RESULTS 
ADH5 deficiency increases use of exogenous formate for de novo purine biosynthesis  
HepG2 cells lacking ADH5 were generated by using CRISPR/Cas9 genome editing (13). 
Ablation of ADH5 protein expression was confirmed by immunoblotting (Figure 4.2A). The 
wild-type and ADH5 knockout HepG2 cells were cultured in folate-deficient or folate-sufficient 
culture medium containing [14C]-formate and [3H]-hypoxanthine. The ratio of [14C]-formate to 
[3H]-hypoxanthine in DNA serves as a measure of de novo purine synthesis efficiency relative to 
salvage purine synthesis. 
Culturing cells in folate-deficient medium increased the ratio of [14C]-formate to [3H]-
hypoxanthine in both ADH5 knockout and wild-type HepG2 cells (P < 0.001; Figure 4.2B). This 
effect was driven by increased incorporation of [14C]-formate into DNA (Supplemental Figure 
S4.1). Given that folate is required for mitochondria-derived formate production, we 
hypothesized that loss of ADH5 protein expression may lead to greater incorporation of 
exogenous formate into DNA under folate-deficient culture conditions than under folate-
sufficient culture conditions. Notably, there was a significant interaction (P < 0.001) between the 
gene expression (comparing wild-type with ADH5 knockout) and folate in the culture medium 
(folate deficiency compared with folate sufficiency) on the ratio of [14C]-formate to [3H]-
hypoxanthine (Figure 4.2B). Specifically, the ratio of [14C]-formate to [3H]-hypoxanthine was 
significantly greater in ADH5 knockout than in wild-type HepG2 cells in both culture conditions, 
but with a greater increase under conditions of folate deficiency (+30%; P < 0.001) than with 
folate sufficiency (+22%; P = 0.02). In the folate-deficient condition, [14C]-formate 
incorporation normalized to DNA content was 30% greater in ADH5 knockout compared with 
wild-type HepG2 cells (P < 0.001), whereas the incorporation of [3H]-hypoxanthine into DNA 
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did not differ (P = 0.89) between the cell lines (Supplemental Figure S4.1). In folate sufficiency, 
the incorporation of [14C]-formate into DNA did not differ between ADH5 knockout and wild-
type HepG2 cells (P = 0.52), whereas [3H]-hypoxanthine incorporation into DNA decreased by 
12% in ADH5 knockout (compared with wild-type) HepG2 cells (P = 0.008). Overall, these data 
suggest that ADH5-mediated formate production contributes to de novo purine biosynthesis, 
especially during folate deficiency when mitochondrial formate production is limited. 
The effect of both ADH5 expression and exogenous folate availability on intracellular 
folate concentrations was determined. Intracellular folate concentrations were ~94% lower in 
folate-deficient compared with folate-sufficient medium in both ADH5 knockout and wild-type 
HepG2 cells (P < 0.004; Figure 4.2C). However, no effect of ADH5 gene expression was 
observed on intracellular folate concentrations (P = 0.43; P-interaction between gene expression 
and folate in culture medium = 0.54). 
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Figure 4.2. Purine biosynthesis in WT and ADH5 knockout HepG2 cells. (A) Silencing of ADH5 was 
confirmed by immunoblotting. (B) The ratio of [14C]-formate to [3H]-hypoxanthine indicates the 
incorporation of formate into DNA via the de novo purine synthesis pathway relative to the incorporation 
of hypoxanthine into DNA via the purine salvage pathway. Labeled means without a common letter 
differ, P < 0.05. (C) Total cellular folate concentrations. *Different from folate-sufficient cells, P < 0.05. 
Data were analyzed by using 2-factor ANOVA with Bonferroni corrections. Values are means ± SDs of 3 
biological replicates per condition. ADH5, alcohol dehydrogenase 5; DPM, decays per minute; KO, 
knockout; WT, wild-type. 
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ADH5 deficiency does not affect de novo dTMP synthesis 
The effects of ADH5 silencing on dTMP synthesis in folate-deficient and folate-sufficient 
conditions were investigated. The ratio of [14C]-deoxyuridine (an indicator of de novo Dtmp 
synthesis) to [3H]-thymidine (an indicator of salvage dTMP synthesis) in DNA did not differ 
between the wild-type and ADH5 knockout HepG2 cells (P = 0.14) independent of folate 
conditions (P-interaction = 0.85) (Figure 4.3). When grown under folate-deficient compared with 
folate-sufficient conditions, both wild-type and ADH5 knockout HepG2 cells had a significantly 
lower ratio of [14C]-deoxyuridine to [3H]-thymidine (P < 0.001), indicating that folate deficiency 
may upregulate the salvage pathway to meet cellular dTMP requirements. 
 
 
Figure 4.3. dTMP biosynthesis in WT and ADH5 knockout HepG2 cells. The ratio of [14C]-deoxyuridine 
to [3H]-thymidine indicates the relative contribution of the de novo pathway to the salvage pathway for 
dTMP synthesis. Data were analyzed by using 2-factor ANOVA with Bonferroni corrections. Values are 
means ± SDs of 3 biological replicates per condition. *Different from folate-sufficient cells, P < 0.05. 
ADH5, alcohol dehydrogenase 5; DPM, decays per minute; KO, knockout; WT, wild-type. 
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Reduced expression of ALDH2 decreases use of exogenous formate for de novo purine 
biosynthesis 
To determine the effect of ALDH2 on purine biosynthesis, ALDH2 expression was 
reduced by using ALDH2-targeting siRNA transfection and verified by immunoblotting (Figure 
4.4A). The wild-type and ALDH2 knockdown HepG2 cells were cultured in folate-deficient 
medium with [14C]-formate and [3H]-hypoxanthine. The ratio of [14C]-formate to [3H]-
hypoxanthine was 37% lower in ALDH2 knockdown HepG2 cells compared with wild-type cells 
(P < 0.001; Figure 4.4B). ALDH2 knockdown HepG2 cells exhibited decreases in the 
incorporation of both [14C]-formate (-82%; P < 0.001) and [3H]-hypoxanthine (-72%; P = 0.002) 
into DNA (Supplemental Figure S4.2). Overall, these data suggest that reduced ALDH2 
expression decreases the use of exogenous formate for de novo purine biosynthesis, indicating 
increased endogenous production of formate. 
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Figure 4.4. Purine biosynthesis in WT and ALDH2 knockdown HepG2 cells cultured in folate-deficient 
medium. (A) ALDH2 knockdown was confirmed by immunoblotting. (B) The ratio of [14C]-formate to 
[3H]-hypoxanthine indicates the incorporation of formate into DNA via the de novo purine synthesis 
pathway relative to the incorporation of hypoxanthine into DNA via the purine salvage pathway. Data 
were analyzed by using a t test. Values are means ± SDs of 3 biological replicates per condition. 
*Different from WT, P < 0.05. ADH5, alcohol dehydrogenase 5; ALDH2, aldehyde dehydrogenase 2; 
DPM, decays per minute; KD, knockdown; KO, knockout; WT, wild-type. 
 
Formate is limiting for HepG2 cell growth 
The growth of wild-type, ALDH2 knockdown, and ADH5 knockout HepG2 cells in the 
presence of exogenous formate was investigated by supplementing culture medium with sodium 
formate. No significant interaction between gene expression (wild-type compared with ADH5 
knockout) and time was detected (P = 0.3), indicating that the growth rate of ADH5 knockout 
HepG2 cells did not differ from the wild-type cells (Supplemental Figure S4.3). However, 
ALDH2 knockdown HepG2 cells exhibited significantly lower growth rates relative to wild-type 
cells over 72 h [P-interaction between gene expression (wild-type compared with ALDH2 
knockdown) and time < 0.001], indicating that reduced ALDH2 expression inhibits cell 
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proliferation. The ALDH2 knockdown HepG2 cells exhibited 23% and 31% lower cell viability 
at 48 and 72 h, respectively, compared with wild-type HepG2 cells (P < 0.001). 
There was a significant interaction between gene expression (wild-type HepG2 cells 
compared with ADH5 knockout or ALDH2 knockdown HepG2 cells) and formate 
supplementation on cell proliferation (P < 0.004; Table 4.1). Specifically, the addition of formate 
(30 or 90 µM) in culture medium increased the growth of wild-type HepG2 cells at 48 and 72 h 
(P < 0.001); at 72 h, the wild-type cells supplemented with 90 µM formate exhibited a 30% 
increase in their growth compared with those without formate supplementation. However, the 
addition of formate did not affect the proliferation of ALDH2 knockdown or ADH5 knockout 
HepG2 cells (P > 0.82). 
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Table 4.1. Effect of formate supplementation on the growth of WT, ALDH2 knockdown, and ADH5 knockout HepG2 cells1 
 
1 Values are means ± SDs of 5 biological replicates per condition. Values were normalized to the A570 value of WT HepG2 cells cultured in the 
medium without formate at 24 h. Data were analyzed by using a linear mixed model with Bonferroni corrections. Data from the formate 0-µM 
condition were presented in Supplemental Figure 4.3 to show the difference in the growth rates between the cell lines. Within each time point, 
labeled means in a row without a common letter differ, P < 0.05. ADH5, alcohol dehydrogenase 5; ALDH2, aldehyde dehydrogenase 2; WT, wild-
type. 
 
 
 
 
 
Formate, µM 
24h  48h  72h 
0  30 90 
 
0 30 90 
 
0 30 90 
WT 
1.00  
(± 0.02)   
1.03  
(± 0.02) 
1.04  
(± 0.04) 
 1.55a  
(± 0.02)   
1.67b  
(± 0.04) 
1.70b 
(± 0.03) 
 1.96a  
(± 0.01) 
2.09b  
(± 0.05) 
2.55c  
(± 0.06) 
ALDH2 knockdown 
0.85  
(± 0.02) 
0.81  
(± 0.00) 
0.83  
(± 0.03) 
 1.19  
(± 0.05) 
1.20  
(± 0.08) 
1.20  
(± 0.05) 
 1.35  
(± 0.23) 
1.31  
(± 0.19) 
1.23  
(± 0.28) 
ADH5 knockout 
1.43  
(± 0.04) 
1.51  
(± 0.02) 
1.51  
(± 0.03) 
 2.10 
(± 0.09) 
2.15 
(± 0.07) 
2.21  
(± 0.10) 
 2.54  
(± 0.22) 
2.41 
(± 0.32) 
2.22  
(± 0.45) 
 122 
 
DISCUSSION 
Formate provides one-carbon units for the de novo synthesis of purines and dTMP and 
for the remethylation of homocysteine to methionine. It also plays an important role in 
embryonic development, as reported by previous studies showing that formate has a protective 
effect on neural tube closure defects in a mouse model (3, 19, 20). Formate can be produced via 
both folate-dependent mitochondrial pathways and folate-independent pathways, but the relative 
contributions of these pathways to formate production and utilization are unknown (3). One of 
the folate-independent formate-generating pathways is mediated by NAD+-dependent cytosolic 
ADH5 and mitochondrial ALDH2, which function in the oxidation of formaldehyde to formate 
(Figure 4.1). The current study investigated whether ADH5 and ALDH2 enzymatic reactions 
contribute to the generation of endogenous formate for FOCM. 
This study provides evidence that ADH5 is a meaningful source of formate for de novo 
purine biosynthesis. We found a higher ratio of [14C]-formate to [3H]-hypoxanthine in ADH5 
knockout than in wild-type HepG2 cells, indicating that ADH5 knockout HepG2 cells 
incorporated higher amounts of exogenous formate into de novo purine biosynthesis than did 
wild-type cells. In addition, the use of exogenous formate for de novo purine synthesis in ADH5 
knockout HepG2 cells increased during folate deficiency, presumably due to decreased 
mitochondria-derived formate generation. These findings are consistent with a previous study 
that showed that rats fed a folate-deficient diet exhibited a 44% reduction in the rate of 
endogenous formate production compared with those fed a folate-replete diet (5). Moreover, in 
liver mitochondria isolated from folate-deficient rats, formate production from choline 
metabolites (dimethylglycine and sarcosine) increased, which may be attributable to 
formaldehyde production, as suggested by the authors (5). Specifically, in folate deficiency, 
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dimethylglycine and sarcosine are sources of one-carbon units through the reactions mediated by 
dimethylglycine dehydrogenase and sarcosine dehydrogenase, thereby generating formaldehyde 
(21). However, HepG2 cells do not metabolize sarcosine or dimethylglycine (data not shown). 
Alternatively, endogenous formaldehyde can be generated as a byproduct of the enzymatic 
demethylation reactions, including histone, RNA, and DNA demethylation (22–24). These 
findings, as well as the results of our study, support a role for ADH5 in formate production 
through the oxidation of formaldehyde during folate deficiency. ADH5 also makes contributions 
to the formate pool in states of folate sufficiency. In this study, the ratio of [14C]-formate to [3H]-
hypoxanthine was higher in the ADH5 knockout than in the wild-type HepG2 cells when they 
were cultured in the presence of 25 nM (6S) 5-formylTHF. Overall, our findings show a role for 
the folate-dependent and folate-independent production of formate for de novo purine 
biosynthesis. 
Notably, the effect of ADH5 deficiency was different between de novo purine and dTMP 
synthesis. The ratio of [14C]-deoxyuridine to [3H]-thymidine in DNA did not differ between 
ADH5 knockout and wild-type HepG2 cells, indicating that dTMP synthesis is not compromised 
by ADH5 deficiency. De novo dTMP synthesis occurs at the sites of DNA synthesis in the 
nucleus (25), whereas de novo purine biosynthesis occurs in the cytoplasm, where it requires the 
formation of a multienzyme complex referred to as a purinosome (26). Although the underlying 
mechanisms need further elucidation, the differences in the effect of ADH5 deficiency between 
purine and dTMP synthesis suggest that the source of the nuclear formate pool may be different 
from that of the cytoplasmic formate pool. Given that ADH5 is localized in the cytosol, it may 
contribute to the formate pool in the cytosol, but not in the nucleus, for de novo purine 
biosynthesis. 
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ALDH2 knockdown HepG2 cells exhibited a 37% reduction in the ratio of [14C]-formate 
to [3H]-hypoxanthine compared with wild-type cells, indicating that reduced ALDH2 expression 
decreases the use of exogenous formate for de novo purine biosynthesis. These results indicate 
that ALDH2 knockdown HepG2 cells may upregulate endogenous formate production from the 
other sources as a compensatory response to ALDH2 deficiency. Alternatively, ALDH2 
deficiency may enhance the conversion of formaldehyde to formate. However, given that the 
mitochondrial ratio of NAD+ to NAD(H) ranges between 7 and 8 (27), the latter scenario that 
ALDH2 reduces formate seems unlikely. Overall, the differential effects on de novo purine 
biosynthesis between ADH5 knockout (increased exogenous formate use) and ALDH2 
knockdown (decreased exogenous formate use) cells suggest that cytosolic ADH5 and 
mitochondrial ALDH2 may have distinct roles in providing formate for de novo purine 
biosynthesis. 
ALDH2 knockdown HepG2 cells exhibited significantly slower growth rates relative to 
wild-type cells, indicating that reduced ALDH2 expression inhibits cell proliferation. 
Supplementation with formate in culture medium did not rescue the growth of these cells, 
suggesting that the observed growth inhibition is unlikely to be associated with formate 
production and/or utilization. As evidenced by a previous study (28), decreased proliferation of 
ALDH2 knockdown cells may be due to cell cycle arrest and enhanced apoptosis caused by 
elevated concentrations of reactive oxygen species and toxic aldehyde due to reduced ALDH2 
activity. Interestingly, formate supplementation stimulated the growth of wild-type HepG2 cells, 
indicating that formate is limiting for the growth of these cells. This finding is consistent with a 
previous study that showed that methyleneTHF dehydrogenase 1 is essential for cell growth (29). 
Taken together, the results suggest that formate availability may be limiting for cell growth in 
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some cells. In conclusion, this study shows that endogenous formate produced by ADH5 is used 
in de novo purine biosynthesis and its contribution to the formate pool is enhanced in folate 
deficiency. 
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Supplemental Figure S4.1. Purine biosynthesis in wild-type and ADH5 KO HepG2 cells. (A) The 
incorporation of [14C]-formate into DNA were normalized to DNA content. (B) The incorporation of 
[3H]-hypoxanthine into DNA were normalized to DNA content. Data were analyzed using a 2-way 
ANOVA with Bonferroni corrections. Values are shown as means ± SDs of three biological replicates per 
condition. Labeled means without a common letter differ, P < 0.05. ADH5, alcohol dehydrogenase 5; 
DPM, decays per minute; KO, knockout; WT, wild-type.  
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Supplemental Figure S4.2. Purine biosynthesis in wild-type and ALDH2 KD HepG2 cells cultured in 
folate-deficient medium. The incorporation of [3H]-hypoxanthine and [14C]-formate into DNA was 
normalized to DNA content. Data were analyzed using t-test. Values are shown as means ± SDs of three 
biological replicates per condition. *Different from WT, P < 0.05. ALDH2, aldehyde dehydrogenase 2; 
DPM, decays per minute; KD, knockdown; WT, wild-type. 
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Supplemental Figure S4.3. Effect of ALDH2 KD and ADH5 KO on cell growth. Cell viability was 
determined in WT, ALDH2 KD, and ADH5 KO HepG2 cells. Data were analyzed using a linear mixed 
model with Bonferroni corrections. Values were normalized to the A570 of WT HepG2 cells at 24h and are 
shown as means ± SDs of five biological replicates per condition. Labeled means without a common 
letter differ, P < 0.05. ADH5, alcohol dehydrogenase 5; ALDH2, aldehyde dehydrogenase 2; KD, 
knockdown; KO, knockout; WT, wild-type.  
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AFTERWORD 
This dissertation research aims to advance understanding of the impacts of folate, choline 
and vitamin B12 on the functioning of one-carbon metabolism and their relationship with 
colorectal cancer risk and reproductive state. This was achieved through a combination of human 
participant studies, laboratory-based molecular studies and a systematic review that integrate the 
areas of nutrition, epidemiology, molecular biology and public health. The major findings and 
potential implications are discussed below. 
 
Relationship between folate status and DNA methylation is different before and after the U.S. 
folic acid fortification 
This study investigated the association between folate status and DNA methylation in samples 
from postmenopausal women of the WHI-OS cohort collected before and after mandatory folic 
acid fortification. The results of this study indicate that the relationship between folate and DNA 
methylation differs across fortification periods with a positive relationship in the pre-fortification 
period but an inverse relationship in the post-fortification period. This suggests that the overall 
association between folate status and DNA methylation may follow an inverted U-shaped curve, 
and additional studies are warranted to clarify the potential health outcomes. If there are adverse 
health outcomes related to the inverse relationship observed in the era of folic acid fortification, 
folic acid supplement use may not be advisable among postmenopausal women in the U.S. or 
other countries with mandated folic acid fortification programs.  
 
Alterations in choline metabolism are associated with higher risk of colorectal cancer 
This was the first study to examine associations between plasma biomarkers of choline 
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metabolism and colorectal cancer risk among postmenopausal women in the U.S. The major 
findings indicate a positive association between plasma TMAO and rectal cancer risk, suggesting 
plasma TMAO as a potential biomarker for rectal cancer risk. Given that TMAO is a gut 
bacteria-derived metabolite, the positive association may be related to abnormal changes in 
colonic bacteria, which could occur in disease development. Interestingly, the association 
between TMAO and colorectal cancer risk was modified by vitamin B12 status with a positive 
association observed in women with lower plasma vitamin B12 but not in those with higher 
plasma vitamin B12. Overall, these findings represent evidence for correlations between 
nutrients, gut microbiome and colorectal cancer pathogenesis. 
 
Vitamin B12 status differs among pregnant, lactating and control women with equivalent 
nutrient intakes 
This study compared vitamin B12 status response among pregnant, lactating and control 
(nonpregnant, nonlactating) women who consumed equivalent vitamin B12 intakes. The findings 
of this study indicate that pregnancy is associated with altered biomarkers of vitamin B12 status 
with enhanced bioavailability of vitamin B12, which may augment the supply of vitamin B12 to 
the fetus. Specifically, a higher ratio of holotranscobalamin (bioactive form of vitamin B12) to 
total vitamin B12 was observed in pregnant (vs. control) women, suggesting that greater amounts 
of vitamin B12 are partitioned toward the biologically active form during pregnancy. This study 
also found that consumption of the study vitamin B12 dose (~3 times the RDA) yielded a 
significant increase in serum holotranscobalamin among all reproductive groups, warranting 
further investigation of clinical benefit, if any, of vitamin B12 intakes exceeding current 
recommendations.  
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Alcohol dehydrogenase 5 is a source of formate for de novo purine biosynthesis in HepG2 cells 
The objective of this study was to investigate the effect of folate-independent formate-generating 
pathways mediated by alcohol dehydrogenase 5 (ADH5) and aldehyde dehydrogenase 2 
(ALDH2) on one-carbon metabolism. This study demonstrates for the first time that ADH5 is a 
source of formate for de novo purine biosynthesis, especially during folate deficiency when 
folate-dependent formate production is limited. This study advances current understanding of a 
role for the folate-independent formate synthesis in the functioning of one-carbon metabolism, 
and further investigation is warranted to determine its impacts in different tissues and in whole 
animals.  
 
A systematic review: Provision of folic acid for reducing arsenic toxicity in arsenic-exposed 
children and adults 
This ongoing systematic review using the Cochrane methodology aims to summarize and 
evaluate the evidence on the effects of folic acid provision on arsenic-related health outcomes 
and biomarkers of arsenic and folate status in arsenic-exposed populations. Given that chronic 
arsenic exposure is a public health burden and that folate functions in detoxifying arsenic 
through arsenic methylation, this review will help determine whether folic acid interventions are 
efficacious in reducing arsenic toxicity and address their public health implications. The results 
of this review will also serve to highlight the direction and need for future research.  
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APPENDIX A 
Provision of folic acid for reducing arsenic toxicity in arsenic-exposed children and adults:  
a systematic review* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Bae S, Kamynina E, Farinola AF, Caudill M, Stover PJ, Cassano PA, Berry R, Peña-Rosas JP. 
Provision of folic acid for reducing arsenic toxicity in arsenic-exposed children and adults. 
Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.:CD012649. DOI: 
10.1002/14651858.CD012649. 
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BACKGROUND 
Description of the condition  
Burden of chronic arsenic exposure 
Arsenic is a common environmental toxin and exists in both organic and inorganic forms. 
In general, organic arsenic is considered to be less harmful than inorganic arsenic; however, 
depending on the chemical form, some organic compounds are toxic (ATSDR 2007) and also 
may undergo degradation giving rise to bioavailable inorganic arsenic species (Chávez-Capilla 
2016). Acute poisoning by arsenic is rare, but low-level chronic exposure in humans through 
contaminated drinking water is common throughout the world. The World Health Organization 
(WHO) estimates that more than 140 million persons from more than 70 countries, including 
Bangladesh, China, India, Chile, Nepal and areas of the US, are chronically exposed to arsenic-
contaminated water at levels exceeding the recommended safe concentration of 10 μg/L (Ahmed 
2006; Chiou 2001; Ghosh 2013; Mazumder 2010; Naujokas 2013; Nielsen 2010; Rodíguez-Lado 
2013; Sanders 2012; Smith 2000; Smith 2002; WHO 2008; Yu 2007). The primary source of 
contaminated drinking water is groundwater exposed to naturally occurring arsenic-rich 
geological formations (IARC 2012; Kim 2011). Rice, a staple food for half of the world’s 
population, can contain high levels of arsenic, which is derived from the soil of paddy fields 
(Gilbert-Diamond 2011;Ma 2008;Melkonian 2013; Sohn 2014; Stone 2008; Zavala 2008a; 
Zavala 2008b).Water contamination remains an issue despite mitigation efforts, and food grown 
or produced (or both) in arsenic-rich environments contributes to human arsenic exposure 
(Banerjee 2013; Carignan 2016; Davis 2012; Karagas 2016; Kippler 2016; Rose 2007). A high 
amount of arsenic, in both organic and inorganic forms, may also be present in some species of 
seaweed (Almela 2002; Brandon 2014; Khan 2015; Rose 2007), and in fish, shellfish and other 
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types of seafood (Choi 2010; Seo 2016). The average daily intake of total arsenic (including both 
organic and inorganic forms) from food and beverages in US and European populations has been 
estimated to be in the range of 20 to 300 μg/day (deCastro 2014; EFSA 2009; EFSA 2014; IARC 
2012; IPCS 2001; Kurzius-Spencer 2014; Lynch 2014). 
Health consequences associated with arsenic exposure in adults and children 
Arsenic exposure affects almost every organ systemin the body, including the brain. 
Chronic exposure to arsenic has been associated with neurotoxicity in adults as well as increased 
risk of cancer, diabetes, cardiovascular disease, kidney disease, anaemia and skin disease 
(ATSDR 2007; Axelson 1980; Cohen 2013; Ettinger 2009; Farzan 2013; IARC 1980; IARC 
2012; Moon 2013; National Toxicology Program 2014; Naujokas 2013; Navas-Acien 2008; 
Prakash 2016; Sidhu 2015; Vahidnia 2007). Arsenic exposure through drinking water has also 
been linked to excess adult mortality (Argos 2010; Sohel 2009;Wu 1989; Yuan 2007; Yuan 
2010) and adverse pregnancy outcomes, including preterm delivery, stillbirth, spontaneous 
abortion and low birth weight (Ahmad 2001; Hopenhayn-Rich 2000; Huyck 2007; Kile 2016; 
Laine 2015; Milton 2005; Rahman 2007). There is limited evidence from human studies 
suggesting a link between arsenic exposure and risk of neural tube defects (DeSesso 2001; Kwok 
2006; Mazumdar 2015a;Wu 2011); furthermore, animal studies have demonstrated that a high 
dose of arsenic induces embryotoxicity, including neural tube defects and other congenital 
anomalies (Chaineau 1990; Han 2011; Hill 2008; Hill 2009; Morrissey 1983; Wlodarczyk 2001). 
Exposure to arsenic in drinking water during early childhood or in utero is reported to 
increase subsequent mortality in young adults from lung cancer and other lung diseases (Smith 
2006). Children have a higher metabolic rate than adults to support growth and development, 
which leads to a greater exposure to arsenic and a greater sensitivity to the adverse effects of 
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arsenic exposure (Bearer 1995). In the first six months of life, children drink seven times more 
water per kilogram of body weight than adults. Children aged between one and five years 
consume three to four times more food per kilogram of body weight than adults (Bearer 1995). 
Because of these metabolically-driven differences, exposure to arsenic in children younger than 
three years of age is estimated to be two to three-fold higher than adults (EFSA 2009; EFSA 
2014; Hojsak 2015; Ljung 2011; Meharg 2008; Rintala 2014; Signes-Pastor 2016).Higher 
exposure to arsenic in drinking water and/or higher blood and urinary arsenic concentrations 
have been inversely associated with intellectual function and neuropsychological development 
in children (Dong 2009; Rodríguez-Barranco 2016; Tolins 2014; Tsuji 2015; von Ehrenstein 
2007) and adolescents (Tsai 2003). 
Biomarkers of arsenic exposure 
Arsenic levels measured in blood and urine are reliable biomarkers of arsenic exposure 
and status (ATSDR 2007; Hall 2006). In general, blood arsenic and urinary arsenic levels greater 
than (>) 1 μg/L and 100 μg/L respectively are considered abnormal (ATSDR 2007), while some 
studies suggest that health risks of arsenic exposure may be associated with total urinary levels > 
50 μg/L (Tseng 2005; Valenzuela 2005; WHO 2001). Given that blood and urinary arsenic levels 
reflect short-term exposure (i.e. hours to days) to arsenic, these are considered as biomarkers 
amenable to modifications driven by interventions (e.g. dietary change) (Hall 2006). Arsenic 
levels measured in hair and nails reflect more prolonged exposure to arsenic because arsenic 
accumulates in these slow growing tissues (Hall 2006). 
The toxicity of arsenic is influenced by its chemical form. Inorganic arsenic species 
found in ground water are mainly arsenites (iAsIII) and arsenates (iAsV). Inorganic arsenic can be 
modified by the addition of one, two or three methyl (CH -) groups in a process known as 
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methylation, which leads to the organic forms known as monomethyl-, dimethyl-, or trimethyl-
arsenicals, respectively. These forms are also referred to as monomethylarsonic acid (MMAV), 
monomethylarsonous acid (MMAIII), dimethylarsonous acid (DMAIII), dimethylarsonic acid 
(DMAV) and tri-methyl-arsine oxide. The most toxic arsenicals are iAsIII, MMAIII and DMAIII, 
followed by iAsV, MMAV and DMAV (ATSDR 2007; Styblo 2000). 
Population groups exposed to arsenic mainly via drinking water typically excrete 10% to 
30% as inorganic arsenicals (iAsIII and iAsV), 10% to 20% as monomethylated arsenicals 
(MMAIII and MMAV), and 60% to 70% as dimethylated arsenicals (DMAIII and DMAV) (Vahter 
2000). Because methylated arsenicals are more easily excreted through urine, decreased 
methylation of arsenic is associated with its increased retention in the body, which leads to 
increased toxicity. For example, compared to women, men show higher urinary monomethyl 
arsenicals, which indicate incomplete methylation of arsenic, and men also show more frequent 
skin lesions (Lindberg 2008). In arsenic-exposed population studies, participants with skin 
lesions (versus those without skin lesions) had a higher proportion of monomethyl arsenicals in 
urine, which is consistent with a lower arsenic methylation capacity (Li 2011; Valenzuela 2005; 
Zhang 2014). Arsenic methylation patterns in children differ from those in adults (Concha 1998; 
Fängström 2009; Skröder Löveborn 2016). In preschool children, urinary total arsenic and 
monomethyl-AsV (MMAV) percentage were shown to be positively associated with the risk of 
developmental delay (Hsieh 2014). 
Several factors affect the extent of arsenic methylation in the body. Dietary factors that 
function in cellular methylation pathways can affect methylation of arsenic and therefore its 
excretion. Among these, folate, a B vitamin, has been suggested as an important dietary source 
for facilitating arsenic methylation and excretion (Carlin 2016). Thus, dietary interventions to 
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increase folate are a potential means to reduce arsenic toxicity and prevent arsenic associated 
diseases. Other physiological factors that may affect excretion of arsenic include gut microbiome 
(Pinyayev 2011; Rubin 2014), gender (Jansen 2016; Lindberg 2008), pregnancy (Gardner 2011; 
Gardner 2012), and body mass index (Gribble 2013). 
 
Description of the intervention  
Folate is a general term for the water-soluble vitamin B₉ naturally present in foods, which 
humans are not able to synthesize in vivo and which therefore has to be obtained from dietary 
sources. Folate serves as a carrier for methyl groups required for biochemical reactions within 
cells, including methylation of arsenic. Naturally occurring folates exist in many chemical forms 
and are unstable, while folic acid is the stable, synthetic, oxidized form used in supplements and 
fortified food (Fox 2008). When used as a dietary supplement or fortificant, folic acid is mostly 
metabolized to the metabolically active, natural forms of folate, including 5-
methyltetrahydrofolate, which is the form found in blood (Pfeiffer 2015; Stover 2004). Blood 
folate concentration can be reported as red blood cell (RBC) folate or serum/plasma folate. 
Serum blood folate levels are the earliest indicators of recent exposure and reflect recent dietary 
intake (short-term status). RBC folate is a sensitive indicator of folate status in the preceding 120 
days (Bailey 2015). Elevated serum/plasma homocysteine is a sensitive biomarker of folate 
deficiency; however, elevations in homocysteine are not specific given that they increase in other 
B-vitamin deficiencies, such as B12 deficiency, and can be affected by other factors such as 
renal insufficiency and drug treatments (Bailey 2015). Nonetheless, plasma homocysteine is 
highly responsive to intervention with folate, either alone or in combination with the other 
methyl donors involved in one-carbon metabolism such as betaine, choline, and vitamins B₂, B₆, 
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and B₁₂. 
Folate is critical for supporting rapid fetal growth and development and thus is especially 
important for women who may become pregnant. Failure of the neural tube to close during early 
embryonic development results in serious congenital anomalies collectively referred to as neural 
tube defects (Beaudin 2009; Botto 1999; Greene 2014). A Cochrane systematic review has 
showed that folic acid supplementation in women planning to become pregnant decreased the 
incidence and recurrence of neural tube defects in the fetus (De-Regil 2015). Currently, the US 
Preventive Services Task Force recommends that all women planning, or capable of, pregnancy 
take a daily supplement containing 400 to 800 µg of folic acid (USPSTF 2009) with a goal to 
reduce the occurrence of neural tube defects. To help achieve these recommended folate intake 
levels, the U.S. Food and Drug Administration (FDA) mandated fortification of the food supply 
through enriched cereal grain products (e.g., bread, pasta, rice fortified with 140 μg folic acid per 
100 g grain). Population-wide folic acid fortification has been introduced in 84 countries and has 
been effective in reducing the rates of live-born infants with spina bifida (Atta 2016; Cordero 
2015; FFI 2016; Grosse 2016, Rader 2006). 
Folic acid supplementation in women of child-bearing age, and population-wide 
fortification of staple foods are currently used as public health interventions to reduce the rate of 
neural tube defects. Given the function of folate to detoxify arsenic through arsenic methylation, 
this review evaluates and summarizes the evidence on whether similar folic acid interventions 
are efficacious in reducing the public health burden of arsenic-associated health outcomes in 
arsenic-exposed adults and children, including all ages and gender groups. 
 
How the intervention might work  
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An important folate-dependent reaction is the conversion of homocysteine to methionine 
(Caspi 2016). In this reaction, the enzyme methionine synthase converts the substrate 
homocysteine to methionine through transfer of a methyl group from the co-substrate 5-
methyltetrahydrofolate, while using vitamin B₁₂ as a cofactor (Doi 1989; Green 2011; Sauer 
1977). Methionine is then used in the synthesis of S-adenosylmethionine (SAM), a major cellular 
methyl-donor in over 100 methylation reactions, including the methylation of arsenic. Arsenic 
excretion in humans involves methylation reactions, whereby methyl groups are transferred from 
SAM to inorganic arsenic by the enzyme Arsenic(III)-SAM-methyltransferase (Dheeman 2014; 
Schlebusch 2015). Given the critical role of folate in methylation reactions, low folate status, 
through inadequate intake of folates or through genetic variation affecting folate-metabolizing 
enzymes, may impede arsenic methylation and excretion and thereby exacerbate arsenic toxicity. 
In contrast, folic acid supplementation has been shown to improve symptoms of chronic arsenic 
exposure, including arsenical skin lesion (Ghose 2014) and oxidative DNA damage (Guo 2015). 
Previous randomised controlled clinical trials in the adult population in Bangladesh (Gamble 
2007; Peters 2015) demonstrated that supplementation with folic acid lowers blood arsenic 
concentrations and increases urinary excretion of arsenic in a dimethylated form, suggesting folic 
acid supplementation as a preventive and/or therapeutic strategy for arsenic toxicity and arsenic-
induced illnesses. Furthermore, an ongoing randomised controlled trial examines the arsenic-
lowering effect of folic acid supplementation in arsenic-exposed Chinese populations (Xiao 
2014). Despite the evidence from observational studies and clinical trials, no systematic reviews 
have been conducted to estimate the effects of folic acid supplementation on arsenic toxicity in 
children and in adult men and women. 
Arsenic exposure may also affect folate metabolism. A metabolomic study in an animal 
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model reported a 9.9-fold decrease in urinary 5-methyltetrahydrofolate after four weeks exposure 
to arsenic (Lu 2014), suggesting that arsenic exhausts folate supply. A case-control study 
conducted in an arsenic-exposed population in rural Bangladesh also showed that arsenic 
exposure may reduce the effect of folic acid in the prevention of a specific form of neural tube 
defects, myelomeningocoele (Mazumdar 2015a). 
Inter-individual differences caused by genetic variations can affect the capacity to 
methylate arsenic (Gribble 2015; Schlebusch 2015). Genetic variants in folate-metabolizing 
enzymes have been shown to affect arsenic metabolism and retention in human and animal 
studies (Mazumdar 2015b; Schlawicke-Engstrom 2009; Wlodarczyk 2012; Wlodarczyk 2014). 
For example, a common genetic variant in the folate-metabolizing enzyme 
methylenetetrahydrofolate reductase (MTHFR), MTHFR C677T (i.e., C to T substitution at 
nucleotide position 677), has been associated with lower blood folate concentrations (Bailey 
1999; Stover 2011; Tsang 2015) and increased sensitivity to arsenic exposure in a mouse model 
(Wlodarczyk 2012; Wlodarczyk 2014). 
 
Why it is important to do this review  
Inorganic arsenic is a common environmental toxin (ATSDR 2007; National Toxicology 
Program 2014), and an important public health burden given that there are 140 million people 
world-wide who are exposed through contaminated drinking water and food. Chronic arsenic 
exposure has been associated with neurotoxicity as well as an increased risk of cancer, 
congenital anomalies and skin diseases. Observational epidemiological studies support an 
adverse effect of arsenic on neurodevelopment in children (Parvez 2011; Tolins 2014; 
Wasserman 2007; Wasserman 2014; Wasserman 2016; Yorifuji 2016). Folate, which plays an 
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essential role in methylation reactions, may lower blood arsenic concentrations in arsenic-
exposed populations, thereby contributing to the prevention of arsenic-associated illnesses, 
including neurotoxicity in children (Hall 2009). The provision of folic acid through 
supplementation or fortification, or both, to reduce neural tube defects may have the added 
benefit of facilitating arsenic methylation and excretion to decrease arsenic toxicity, particularly 
in populations with folate deficiency (Dubey 2007; Gamble 2005; Gamble 2006; Gamble 2007; 
Pilsner 2009). This review is important because it will be the first to evaluate and summarize the 
evidence on folic acid supplementation or fortification, or both, for reducing arsenic toxicity and 
arsenic-related health outcomes in children and in adult men and women. The findings of this 
review will help inform future research and public policy, especially in arsenic-exposed 
populations. 
 
OBJECTIVES  
To assess the effects of provision of folic acid (through folic acid fortified foods or supplements), 
alone or in combination with other nutrients, on arsenic toxicity and arsenic-related health 
outcomes (i.e. neurocognitive function, skin lesions, congenital disorder and cancer) in arsenic-
exposed populations. 
 
METHODS 
Criteria for considering studies for this review  
Types of studies  
We will only include the following study designs: 
• randomised controlled trials (RCTs), with randomisation at either the individual- or 
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cluster-level; and 
• quasi-RCTs (where allocation of treatment has been made, for example, by alternate 
allocation, date of birth or alphabetical order). 
 
Types of participants  
Arsenic-exposed populations of all ages and gender groups (including pregnant women) from 
any country. 
We will define arsenic exposure through exposure to drinking-water arsenic levels above the 
WHO guideline value (i.e. 10 µg arsenic per litre water (WHO 2008)) or above the national 
permissible limits, or through exposure to arsenic levels in food (e.g., rice) that may results in 
measurable blood and urine arsenic exposure, based on the values defined by trial authors. 
 
Types of interventions  
Provision of folic acid (through fortified foods or supplements) alone or in combination with 
other nutrients. 
Interventions may be given at any dose and for any duration, regardless of frequency of 
administration. A supplement may be in a tablet or capsule. Any form of folic acid fortification 
may be included. We will include studies with co-interventions (e.g., provision of arsenic water 
filtration systems, education, etc.), but only if the co-interventions were the same across study 
arms. 
We plan to assess the following comparisons: 
• folic acid supplements alone versus no intervention/placebo; 
• folic acid supplements in combination with other nutrient supplements versus only other 
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nutrient supplements without folic acid (exact same formulation of other nutrients in both 
arms); 
• food fortified with folic acid alone versus unfortified food; and 
• food fortified with folic acid in combination with other nutrients versus food fortified 
with the exact same formulation of other nutrients (but no folic acid). 
 
Types of outcome measures  
We will consider both statistically and clinically significant minimal differences for each 
outcome listed below. We will collect outcomes measured at any time point post-intervention. 
Primary outcomes  
The primary outcomes to be considered across populations include: 
• Any type of cancer (as defined by trial authors). 
• All-cause mortality (as defined by trial authors). 
• Neurocognitive function (as defined by trial authors, for example, including, but not 
limited to, the assessments of memory, attention, intelligence and other cognitive 
domains) (only in children). 
• Any congenital anomalies (as defined by trial authors, including, but not limited to, 
neural tube defects, cleft lip and cleft palate, and detected, for example, by 
periconception and neonatal screenings) (only in pregnant women) 
Secondary outcomes  
• Blood or urinary arsenic concentration (μg/L)* (as measured by trial authors, for 
example, including, but not limited to, the measurements using the atomic absorption 
spectrometry and ICP-mass spectrometry; various forms of arsenic, for example, 
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monomethyl-, dimethyl-, or trimethyl-arsenic forms, will be considered). 
• Blood folate concentration (nmol/L)* (as measured by trial authors, for example, 
including, but not limited to, the measurements using the mass spectrometry, competitive 
protein binding assays and microbiological assays). 
• Serum/plasma homocysteine concentration (μmol/L)* (as measured by trial authors, for 
example, including, but not limited to, the measurements using high-performance liquid 
chromatography, gas chromatography-mass spectrometry and immunoassays). 
• Skin lesions (as defined by trial authors, for example, including, but not limited to, the 
assessments of hyper- or hypo-pigmentation, keratosis and exfoliative dermatitis). 
 
Search methods for identification of studies  
We will search the electronic databases listed below for all available years without language 
restrictions. We will seek translations of documents, where needed. If we are unable to secure a 
translation, we will contact the editorial office of the Cochrane Developmental, Psychosocial and 
Learning Problems Group for support. 
Electronic searches  
We will search the following international and regional sources. 
International databases 
• Cochrane Central Register of Controlled Trials (CENTRAL; current issue) in the 
Cochrane Library, which includes the Cochrane Developmental, Psychosocial and 
Learning Problems Specialised Register. 
• MEDLINE Ovid (1946 to current). 
• MEDLINE In-Process & Other Non-Indexed Citations Ovid (current issue). 
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• MEDLINE Epub Ahead of Print Ovid (current issue). 
• Embase Ovid (1980 to current). 
• Social Science Citation Index Web of Science (1970 to current).  
• Social Sciences Citation Index Web of Science (1970 to current). 
• Conference Proceedings Citation Index - Science Web of Science (1990 to current). 
• Conference Proceedings Citation Index - Social Science & Humanities Web of Science 
(1990 to current). 
• Cochrane Database of Systematic Reviews (CDSR; current issue) part of the Cochrane 
Library. 
• Database of Abstracts of Reviews of Effects (DARE; current issue) part of the Cochrane 
Library. 
• CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature; 1982 
to current). 
• POPLINE (www.popline.org). 
• ClinicalTrials.gov (clinicaltrials.gov). 
• WHO International Clinical Trials Registry Platform (ICTRP; apps.who.int/trialsearch). 
Regional databases 
1. African Index Medicus (AIM, www.globalhealthlibrary.net/php/index.php?lang=en). 
2. Index Medicus for the Eastern Mediterranean Region (IMEMR, 
www.globalhealthlibrary.net/php/index.php?lang=en). 
3. Index Medicus for the South-East Asia Region (IMSEAR, imsear.hellis.org). 
4. PAHO (Pan American Health Library; 
http://www1.paho.org/english/DD/IKM/LI/library.htm). 
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5. WHOLIS (WHO Library, http://dosei.who.int/). 
6. WPRO (Western Pacific Region Index Medicus, http://www.wprim.org/). 
7. LILACS (Latin American and Caribbean Health Sciences Literature; 
lilacs.bvsalud.org/en). 
8. SciELO (The Scientific Electronic Library Online; www.scielo.br). 
9. IndMED, Indian medical journals (http://indmed.nic.in/). 
We will search MEDLINE using the search strategy in Appendix 1, which we will adapt for 
other databases, as appropriate. We will not limit the search by date or language. 
Searching other resources  
We will scan the reference lists of the included studies and relevant reviews to identify additional 
eligible studies. We will contact relevant study authors and experts in the field to identify any 
ongoing or unpublished studies. 
 
Data collection and analysis  
Selection of studies  
After retrieving all articles from the searches, we will remove duplicate records. Two review 
authors (SB and EK) will independently screen the titles and abstracts of articles to assess 
eligibility based on the aforementioned criteria (see Criteria for considering studies for this 
review). When a title or abstract cannot be rejected with certainty, SB and EK will obtain the 
full-text report and independently screen it for a final assessment of inclusion. If we are unable to 
obtain full-text reports, we will request a copy from the trial authors. Disagreements that occur at 
any stage of the eligibility assessment process will be resolved through discussion with other 
authors, who, if necessary, will independently check the included and excluded studies. 
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Data extraction and management  
Two review authors (SB and EK) will independently extract data from the included studies and 
record them on a piloted data extraction form designed for this review. The data extraction form 
will include the following information, and will be modified, if necessary. 
• General information: title, authors, publication type (e.g., journal article, abstract, book 
chapter, etc.), country of study, funding source of study, year of study, and authors’ 
conflicts of interest. 
• Details of study: study aim, design, inclusion/exclusion criteria, unit and method of 
randomisation, study location and duration, sample size, characteristics of participants, 
procedures for recruiting/selecting participants, method of allocation, and participant 
attrition. 
• Intervention and control (comparison group): method used for implementation of 
intervention, duration/dose/frequency of intervention and control, type of intervention 
and control, co-intervention, number of participants allocated to intervention and control 
groups, and compliance. 
• Outcomes: any measures of primary and secondary outcomes, time-points and method of 
outcome assessments, and blinding of outcome assessment. 
Any disagreements between SB and EK during the data extraction process will be resolved 
through discussion with other authors. We will enter all extracted data into the latest version of 
Cochrane Review Manager software (Review Manager 2014), and we will check the data for 
accuracy. When the information regarding any of the above is insufficient or unclear, we will 
contact the trial authors to request further details of the study. 
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Assessment of risk of bias in included studies  
Two review authors (SB and EK) will independently assess the risk of bias for each included 
study, based on the standard Cochrane ‘Risk of bias’ tool (Higgins 2011a). The authors will 
assign one of three ratings (low risk of bias; high risk of bias; or unclear risk of bias) to each of 
the domains listed below, with justifications for their judgements. Any disagreements will be 
resolved through discussion with other authors. When study information is insufficient or 
unclear, we will contact the trial authors to request further details. Examples of domain specific 
criteria for judgements of low, high or unclear risk of bias are shown in Table SA.1. More 
detailed criteria are provided in the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins 2011a, Table 8.5d). 
Random sequence generation (checking for selection bias) 
We will describe the method used to generate the allocation sequence and assess whether the 
sequence generation was suitable to minimize selection bias. 
Allocation concealment (checking for selection bias) 
We will describe the method used to conceal the allocation sequence and assess whether 
intervention allocation could have been foreseen in advance of, or during, enrolment. 
Blinding of participants and personnel (checking for performance bias) 
 
We will assess whether the study participants and personnel were blinded from knowledge of 
which intervention a participant received. 
Blinding of outcome assessment (checking for detection bias) 
We will assess whether the outcome assessors were blinded from knowledge of which 
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intervention a participant received. 
Incomplete outcome data (checking for attrition bias) 
We will assess whether the participants’ outcome data are missing due to attrition during the 
study or exclusions from the analysis. We will examine the reasons for attrition and exclusions, 
if reported, and whether the participants included in the analysis are exactly those who were 
randomised to the intervention and control groups. 
Selective reporting (checking for reporting bias) 
We will assess whether the included study reports only a subset of outcomes or only selective 
data for an outcome. 
Other sources of bias (checking for bias due to problems not covered by the domains above) 
We will assess other possible sources of bias, if any. For example, we will assess: whether the 
study has been claimed to be fraudulent; whether the study has contamination bias, which occurs 
when participants of the 'control' group inadvertently receive the treatment or are exposed to the 
intervention; and whether there are any other sources of bias not addressed in the other domains. 
 
 
 
 
 
TABLES SA.1. Examples of domain specific criteria for judgments of low, high or unclear risk 
of bias  
Random sequence generation 
Low risk 
of bias 
The study used an appropriate randomisation method (e.g., computer random 
number generator, random number table) in the sequence generation process. 
High risk 
of bias 
The study used a non-randomised method (e.g., birth date, case number) in the 
sequence generation process. 
Unclear There is no or insufficient information specifying the randomisation method. For 
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risk of 
bias 
example, if a study used blocked randomisation but did not specify the process of 
selecting the blocks, then we will classify the study as unclear risk of bias. 
Allocation concealment 
Low risk 
of bias 
The study used an adequate method to conceal the allocation sequence from 
participants and investigators (e.g., telephone or central randomisation, sealed 
opaque envelopes). 
High risk 
of bias 
The study used an inadequate method such that participants and investigators may 
have been able to foresee the assignment to intervention groups (e.g., open 
random allocation, unsealed or non-opaque envelopes). 
Unclear 
risk of 
bias 
There is no or insufficient information specifying the method of allocation 
concealment. 
Blinding of participants and personnel 
Low risk 
of bias 
The study participants and personnel were blinded and the blinding was unlikely 
to have been broken; or the lack of blinding was likely to have introduced bias. 
High risk 
of bias 
There was no, or incomplete, blinding of study participants and personnel and the 
lack of blinding was likely to have introduced bias; or blinding was attempted, but 
it was likely to have been unsuccessful. 
Unclear 
risk of 
bias 
There is no or insufficient information on blinding to permit a judgement of high 
or low risk of bias. 
Blinding of outcome assessment 
Low risk 
of bias 
The outcome assessors were blinded and the blinding was unlikely to have been 
broken; or the lack of blinding was likely to have introduced bias. 
High risk 
of bias 
There was no, or incomplete, blinding of outcome assessments and the lack of 
blinding was likely to have introduced bias; or blinding was attempted, but it was 
likely to have been unsuccessful. 
Unclear 
risk of 
bias 
There is no or insufficient information on blinding of outcome assessments to 
permit a judgement of high or low risk of bias. 
Incomplete outcome data 
Low risk 
of bias 
There are no missing outcome data (i.e. all participants randomised to the trial are 
included in the analysis); or missing data are balanced across groups and the 
reasons for missing data are unlikely to introduce bias. 
High risk 
of bias 
There are missing data; missing data are imbalanced across groups; the reasons 
for missing data are likely to introduce bias; or ‘as-treated (per protocol)’ analysis 
was performed with substantial differences between the intervention allocated at 
randomisation and the intervention actually received. 
Unclear 
risk of 
bias 
There is no or insufficient information to permit a judgement of high or low risk 
of bias. 
Selective reporting 
Low risk 
of bias 
It is clear, either by the study protocol or otherwise, that all of the pre-specified 
and expected outcomes have been reported. 
High risk 
of bias 
Not all pre-specified and expected outcomes have been reported; reported 
outcomes were not pre-specified (unless the reason for reporting is justified); or 
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outcomes were reported incompletely and cannot be used. 
Unclear 
risk of 
bias 
There is no or insufficient information to permit a judgement of high or low risk 
of bias. 
Other sources of bias 
Low risk 
of bias 
Baseline characteristics (related to outcome measures) or baseline outcome 
measures are similar across groups; an appropriate adjusted analysis was 
performed to account for differences in baseline measures across groups; or there 
are no other sources of bias. 
High risk 
of bias 
Baseline characteristics (related to outcome measures) or baseline outcome 
measures are not similar across groups and no, or an inappropriate, adjusted 
analysis was performed; there is a contamination issue, whereby the experimental 
and control interventions get mixed; the study has been claimed to be fraudulent; 
or there are any other sources of bias. 
Unclear 
risk of 
bias 
There is no or insufficient information to permit a judgement of high or low risk 
of bias. 
 
 
Measures of treatment effect  
We will report treatment effects separately based on the types of outcome data (dichotomous or 
continuous). If there are too few trials (< two) or we are unable to combine trials, we will provide 
a narrative description of the results. 
Dichotomous outcomes 
We will present dichotomous outcome data as risk ratios (RR) with 95% confidence intervals 
(CIs). We will also show absolute measures of effect. 
Continuous outcomes 
We will use mean differences (MDs) with 95% CIs if continuous outcomes are measured on the 
same scale between trials. We will use standardized mean differences (SMD) with 95% CIs to 
combine trials that measure the same outcome but using different measurement methods. Where 
some studies have reported endpoint data and others have reported changes from baseline data 
(with errors), we will first divide them in subgroups; the subgroup with studies that used the 
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same scale but have reported a mixture of endpoint data and changes from baseline data will be 
combined in the meta-analysis. On the other hand, the subgroup with studies that used different 
scale but have reported a mixture of endpoint data and changes from baseline will not be 
combined, and they will make two more subgroups: the studies with only endpoint data and the 
studies with only changes from baseline data. 
 
Unit of analysis issues  
Cluster-randomised trials 
We will consider combining the results from cluster- and individually-randomised trials if there 
is little heterogeneity between the studies, and if there is unlikely to be an interaction between 
the intervention effect and the choice of randomisation unit. We will conduct a sensitivity 
analysis to examine the impact of the randomisation unit (Sensitivity analysis). For cluster-
randomised trials, we will examine whether the authors’ accounted for clustering in their 
analyses. If not, we will attempt to calculate effective sample sizes by using the intra cluster 
correlation coefficient (ICC), according to the formula provided in the Cochrane Handbook for 
Systematic Reviews of Interventions (Higgins 2011b). If neither the ICC nor the design effect is 
available from the study publication, we will contact the authors for further details or obtain 
external estimates of the ICC from similar studies. We will conduct a sensitivity analysis to 
examine the effect of variation in the ICC, where appropriate (Sensitivity analysis). 
Studies with multiple treatment groups 
For trials with more than two intervention groups, we will follow the approaches to avoid double 
counting of participants, as recommended by the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins 2011b). We will present all intervention groups of a multi-arm study in 
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the ‘Characteristics of included studies’ tables. For the meta-analysis, we will assess which 
intervention group(s) of a multi-arm study is (are) relevant to the review based on the 
aforementioned criteria (see Criteria for considering studies for this review), and only include 
data from the directly relevant group(s). If a single study has more than one relevant intervention 
group or more than one control group, or both, we will create a single pair-wise comparison, 
where appropriate, by combining all relevant intervention groups into a single intervention group 
and all control groups into a single control group. For dichotomous outcomes, we will sum both 
the sample sizes and the number of people with events across groups. For continuous outcomes, 
we will combine means and standard deviations using the formula provided in the Cochrane 
Handbook for Systematic Reviews of Interventions (Higgins 2011b). In subgroup analyses, 
where the control group is shared by multiple intervention arms, we will divide the control group 
over the number of subgroup categories and include each pair-wise comparison separately 
(Subgroup analysis and investigation of heterogeneity). For dichotomous outcomes, we will 
divide the number of events and total participants. For continuous outcomes, we will divide the 
number of total participants only; the means and standard deviations will remain unchanged. 
Cross-over trials 
If we identify randomised trials with a cross-over design, we will consider using the data from 
the first period of the trial only, to avoid any potential risks of a carry-over effect. 
 
Dealing with missing data  
We will record attrition and missing outcome data for each included study on the data extraction 
form and report them in the ‘Risk of bias’ tables. When summary data for an outcome (e.g., 
standard deviations) are missing, we will base calculations on other reported measurements, if 
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possible. When pre-specified or expected outcome data are missing, we will contact the authors 
to request them. Where missing data are not supplied, we will report the available data alone 
without data imputation. For all relevant outcomes, we will attempt to conduct an intention-to-
treat (ITT) analysis by including all participants randomised to each group irrespective of 
whether they actually received the allocated intervention. If a study report provides the outcome 
data only for the participants who completed the trial, or who complied with their allocated 
intervention, we will contact the authors to request the additional information needed to perform 
an ITT analysis. If no further information is available, we will conduct an available case analysis 
using data from participants whose results are known. We will conduct a sensitivity analysis to 
examine the impact of studies with missing data in the overall assessment of intervention effect 
(Sensitivity analysis), and describe the extent to which the missing data might affect the results 
and conclusions of the review. 
 
Assessment of heterogeneity  
We will assess clinical and methodological heterogeneity among studies by examining the 
variability in study design, participants, intervention, outcomes, and risk of bias. We will also 
assess statistical heterogeneity, which is likely to be a consequence of clinical or methodological 
heterogeneity, or both, by using the Chi² and I² statistics included in the forest plots. We will 
consider a P value less than 0.10 in the Chi² test as evidence of heterogeneity of intervention 
effects. We will also use the I² statistic, which indicates the percentage of the variability due to 
heterogeneity rather than sampling error or chance, based on the thresholds listed below, as 
suggested in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011c). 
0% to 40%: might not be important.30% to 60%: may represent moderate heterogeneity.50% to 
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90%: may represent substantial heterogeneity.75% to 100%: considerable heterogeneity. 
In addition, as an estimate of the between-study variability, we will report Tau2 from the 
random-effects meta-analysis. If there is heterogeneity among studies, we will explore the 
potential reasons for heterogeneity by conducting pre-specified subgroup analyses (Subgroup 
analysis and investigation of heterogeneity), and we will take caution in the interpretation of 
those results with high levels of unexplained heterogeneity. 
 
Assessment of reporting biases  
We will attempt to minimize reporting biases by comprehensively searching for eligible studies 
(including ongoing and unpublished studies) using multiple sources and databases. If there are 
more than 10 studies reporting the same outcome of interest, we will generate funnel plots and 
examine asymmetry that indicates the possibility of publication bias. We will also consider 
reasons for asymmetry other than publication bias such as differences in methodological quality 
among studies (Higgins 2011d). For example, smaller trials tend to use less rigorous 
methodological approaches than larger trials, which may result in spuriously larger intervention 
effects. If there is evidence of publication bias and small study effects, we will take it into 
account in the overall assessment and interpretation of intervention effects. We will also assess 
selective outcome reporting bias within each included study as described in the Assessment of 
risk of bias in included studies section. Where relevant outcome data are missing, we will contact 
the authors to request them. We will conduct a sensitivity analysis to explore the impact of 
studies with high levels of missing data in the overall assessment of results (Sensitivity analysis). 
 
Data synthesis  
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We will conduct a meta-analysis to yield an overall (pooled) estimate of the intervention 
effect when more than one study can be appropriately combined (e.g., studies examining the 
same intervention and outcomes with comparable methods and approaches in similar 
populations). For example, we will assess the appropriateness of combining studies by 
considering whether they: 1) used comparable measurement tools or scales for outcome 
assessment; and 2) examined the same intervention and outcomes in similar populations (e.g., 
age (adults versus children) and reproductive status (pregnancy versus non-pregnancy)), and 
consider with the comparability of timing of the outcome measurement (i.e., scale comparable, 
timing comparable). To examine heterogeneity among studies, we will conduct subgroup 
analyses (See Subgroup analysis and investigation of heterogeneity) based on pre-specified 
factors (e.g., folic acid alone versus folic acid plus other nutrients). 
We will perform a random-effects analysis since we anticipate natural heterogeneity 
among studies in terms of study populations, comparisons and interventions (e.g., doses and 
durations of intervention). We will pool the outcome data using the inverse variance method. We 
will attempt to conduct an ITT analysis by including all participants randomised to each group, 
where appropriate. If we are unable to combine data using a meta-analysis, we will provide a 
narrative summary of the results from individual studies. 
Summary of findings 
For each individual outcome, two review authors (SB and EK) will independently assess the 
quality of evidence across studies using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) approach (Balshem 2011). Disagreements will be 
resolved through discussion with other authors, who, if necessary, will independently conduct 
the quality assessment. We will grade evidence as one of four levels of quality (high, moderate, 
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low, or very low), depending on the presence of the following five factors: 1) within-study risk 
of bias (e.g., limitations in study design and implementation such as a lack of allocation 
concealment or blinding and a large loss to follow-up); 2) indirectness of evidence (e.g., indirect 
comparisons between interventions and the use of surrogate outcomes instead of health 
outcomes); 3) unexplained heterogeneity or inconsistency of results; 4) imprecision of results as 
indicated by wide CIs of effect estimates; and 5) high probability of publication bias. We will 
use GRADEprofiler: Guideline Development Tool (GRADEpro GDT 2015), to create a 
‘Summary of findings’ table. The table will include all of the primary outcomes and the 
secondary outcomes indicated by an asterisk (*) (see the Types of outcome measures section) for 
each comparison listed in the Types of interventions. 
 
Subgroup analysis and investigation of heterogeneity  
Where sufficient data are available, we will conduct the subgroup analyses listed below, to 
investigate heterogeneity observed among studies. We will also examine whether the summary 
effects vary in relation to particular participant groups or types of intervention. 
• Baseline folate status: deficient (defined as RBC folate <340 nmol/L or plasma/serum 
folate <10 nmol/L) versus non-deficient versus mixed/unknown/unreported. 
• MTHFR C677T genotype: CC versus CT versus TT versus unknown/unreported, where 
power allows; or CC versus CT/TT versus unknown/unreported. 
• Sex: male versus female versus mixed/unknown/unreported. 
• Pregnancy: yes versus no versus mixed/unknown/unreported. 
• Daily dose: less or equal than 400 μg/d folic acid versus greater than 400 μg/d folic acid. 
• Nutrient composition: folic acid alone versus folic acid plus other nutrients. 
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• Duration: less than three months versus three months or more. 
We will conduct subgroup analyses using Review Manager 2014. We will assess the differences 
among subgroups by inspecting the CIs of the summary estimates. Non-overlap of the CIs 
indicates a statistically significant difference in a treatment effect among the subgroups. We will 
also report the I² statistic for the interaction tests. Given that subgroup analyses are exploratory 
by definition, we will apply caution in the interpretation of the results of pre-planned subgroup 
analyses. 
 
Sensitivity analysis  
We will assess the robustness of the results and conclusions of the review by conducting 
sensitivity analyses to examine: 
• the effect of excluding studies at high or unclear risk of bias in both the random sequence 
generation and allocation concealment domains and in one more of the other domains); 
• the effect of excluding cluster-randomised trials where appropriate adjustments for 
clustering have not been made; 
• the effect of different ICC values of cluster-randomised trials; and 
• the effect of excluding studies with high levels (>20%) of missing outcome data. 
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APPENDIX 1 
1 MEDLINE Search Strategy (Ovid)  
1 Metals, Heavy/  
2 Heavy Metal Poisoning, Nervous System/  
3 (metalloid$ or metal poison$ or heavy metal$).tw,kw.  
4 Arsenic/ 
5 Arsenic Poisoning/ 
6 exp Arsenicals/  
7 arsen$.mp.  
8 (arsenic$ or arsenite$ or arsenate$).mp.  
9 (monomethylarsonic or mono-methylarsonic).mp.  
10 (monomethylarsonous or mono-methylarsonous).mp.  
11 (dimethylarsinous or di-methylarsinous).mp.  
12 (trimethylarsine or tri-methylarsine).mp.  
13 or/1-12  
14 exp Folic Acid/  
15 Folic Acid Deficiency/  
16 folate$.mp.  
17 folic.mp.  
18 folinic$.mp.  
19 folacin$.mp.  
20 vitamin B9.mp. 
21 5-methyltetrahydrofolate.mp.  
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22 5-methylTHF.mp.  
23 metafolin.mp.  
24 leucovorin.mp.  
25 Micronutrients/  
26 Food, Fortified/  
27 Functional Food/  
28 (food$ adj3 (fortif$ or functional$ or supplement$1)).tw,kw.  
29 (micro-nutrient$ or micronutrient$).tw,kw.  
30 or/14-29  
31 13 and 30  
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